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Abstract 
Mitochondrial Damage-associated molecular patterns (mtDAMPs) are an emerging 
source of endogenous alarmins. N-formylated peptides bind members of the formyl-
peptide receptor (FPR) family. From its original role in chemotaxis of immune cells 
towards sites of infection the part that this G-protein coupled receptor (GPCR) plays in 
the human body is expanding with expression evident in cells of non-phagocyte origin 
as well as neutrophils and macrophage.  
To investigate how FPR1 affects the development of pulmonary fibrosis the bleomycin 
acute injury in vivo model was employed as its pathogenesis shares features with 
Idiopathic pulmonary fibrosis (IPF). Transgenic mice lacking functional fpr1 displayed 
a reduced inflammatory profile and fibrotic phenotype at acute and end-stage 
endpoints respectively post-bleomycin instillation. In vivo models of fibrosis in different 
organs such as the liver and kidney there was not the same protective effect with 
deletion of fpr1 as with acute bleomycin lung injury mechanism. This in turn brought 
the pathogenesis of the in vivo models into question particularly due to the abundance 
of fpr1 expression on neutrophils, the first line of defense of the immune system. By 
depleting neutrophils prior to the bleomycin injury the nature of these myeloid cells in 
this lung fibrosis model and through evaluation of the inflammatory and fibrotic phases 
post-instillation it is evident that these cells play a major role in how the disease 
develops. 
Translation to the human disease (IPF) was a vital step to elucidate the true role of 
FPR1 in chronic fibrosis mechanisms. Expression was demonstrated by 
immunofluorescence in CD45+ leukocytes as well as in isolated fibroblasts. This was 
corroborated by mRNA levels in primary cultured cells when FPR1 expression was 
‘primed’ by inflammatory stimuli such as lipopolysaccharide (LPS). With effects 
observed in a murine setting and also in primary tissue/cells the FPR1 effect may be 
microenvironment/neutrophil dependent.  
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1 Introduction 
 
1.1 Damage-associated molecular patterns (DAMPs) 
DAMPs are endogenous molecules released as a result of injury/damage that interact 
with cellular receptors. DAMPs are distinct from pathogen-associated molecular 
patterns (PAMPs) in that they are derived from damaged/dying cells within a host 
rather than an infectious agent. DAMPs share homology with exogenous PAMPs 
therefore initiating and controlling the immune response via affecting activation, 
maturation, cell trafficking, antigen presentation efficiency and function of neutrophils, 
macrophages, mast cells and eosinophils (Chen and Nuǹez, 2010).  
Since Matzinger’s postulation of the ‘danger theory’ concepts in immunology have had 
to drastically change and adapt on account of the inclusion of a vast array of new 
players in the innate immune response (Matzinger & Kamala., 2011). The ability of the 
body to recognise non-self and self-molecular determinants is another caveat of the 
immune system linked with evolution. These signals due to shared homology with 
exogenous PAMPs are recognised by pattern recognition receptors (PRRs) including 
toll like receptors (TLRs), nod like receptors (NLRs) and formyl peptide receptors (FPR) 
(Arnoult et al., 2011; Krysko et al., 2011). Initial studies demonstrated cytotoxic 
(CD8+ve) and T-helper (CD4+ve) mediated immune responses to DAMPs secreted by 
dead cells (Shi et al., 2003; Kono et al., 2014). 
The innate immune response (IL-1α-mediated) in so-called ‘sterile inflammation’ has 
been tied with these intracellular ‘alarmins’ since the early days of their conception 
(Matzinger, 1994). Interleukin 1α/1β release is triggered by inflammasome-mediated 
Caspase-1 cleavage which constitutes the response to non-pathogenic stimulus (Kono 
et al., 2014). Endogenous DAMP release is controlled by cellular death. Apoptosis and 
necrosis are fundamentally similar and distinct from one another simultaneously. The 
spontaneous nature of cellular content release into the extracellular environment by 
necrotic/dying cells generates a pro-inflammatory response leading to activation of 
immune cells stimulating phagocytosis and neutrophil trafficking. This contrasts with 
the passive apoptotic pathways (Kono et al., 2014).  
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Certainly, since their conception DAMPs have become heavily associated with trauma 
injuries. Although not entirely aseptic (sterile) endogenous danger signals have been 
implicated in exacerbations of injuries triggering systemic immune responses acting as 
a potential mechanism for secondary infections and sepsis (Hwang et al., 2011). 
DAMPs have previously been categorised as either extracellular matrix (ECM) 
components such as fibronectin, hyaluronan, heparin sulphate or cellular stress 
molecules including heat shock proteins (HSPs), nucleic acids, high-mobility group box 
1 (HMGB1) or immunomodulatory proteins comprising β-defensins and pulmonary 
surfactant proteins (Tolle and Standiford, 2013). All of which have a role in acute lung 
injury and other inflammatory diseases (Fairchild and Bromberg, 2012). Uric acid 
(monosodium urate) was the first intracellular danger signal to be shown to promote a 
T-cell immune response (Shi et al., 2003) and since then many more have been 
discovered such as CpG-rich DNA, RNA, ATP, Adenosine, actin and myosin filaments, 
peroxideroxin, IL-1α and IL-33 (Piccini and Midwood, 2010; Kono et al., 2014).  
Indeed in human disease elevated levels of endogenous alarmins have been 
demonstrated. Different inflammatory and autoimmune conditions such as rheumatoid 
arthritis (RA), inflammatory bowel disease, sarcoidosis, sclerosis, psoriasis, chronic 
renal disease, diabetes are all associated with increased DAMPs (Piccini and 
Midwood, 2010). In chronic, progressive pulmonary diseases DAMPs have been 
implicated in their pathogenesis. Ellson et al. (2014) indicate DAMP – receptor 
interactions in three main pathways: pro-inflammatory and apoptosis inhibition as part 
of the innate immune response and thirdly, the adaptive immune response. DAMPs 
are driving forces behind necrotic and apoptotic events in Idiopathic Pulmonary 
Fibrosis (IPF) with some instances of defective danger signalling have aberrant 
downstream effects. In Chronic obstructive pulmonary disease (COPD), a 
characteristically inflammatory disease there is progressive degeneration of airway 
tissue which is now linked to alarmin release due to elevated levels of S100 proteins, 
defensins and HMGB1 (Pouwels et al., 2014). Clearly, DAMPs are not just limited to 
acute injuries with as yet undefined exacerbating roles in long-term diseases. 
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1.2 Mitochondrial Damage-Associated Molecular Patterns  
 
Mitochondrial DAMPs (mtDAMPs) have emerged as a reservoir of signalling molecules 
with unknown potential in recent years. Mitochondria are the power-house of 
eukaryotic cells with demonstrable roles in the respiration, apoptosis and reactive 
oxygen species (ROS) production as well as a source of mtDAMPs. These organelles 
share many properties with prokaryotes due to their concurrent evolution as put 
forward by the theory of ‘endosymbiosis’ (Vargas-Parada, 2010; Krysko et al., 2011) 
in which ancestral eukaryotic cells assimilated aerobic prokaryotes (or a proto-
mitochondrion) to form a eukaryote capable of ATP production. Mitochondrial origin is 
logical especially when comparing mitochondrial deoxyribonucleic acid (mtDNA) and 
mitochondrial N-formyl-peptides with bacterial DNA and N-formylated-peptides such 
as fMLF respectively (Le et al., 2002). Some researchers have even postulated that 
mitochondria are a sub-species of bacteria due to distinct features shared between the 
organelle and prokaryotes. Indeed the outer and inner membranes and 
cytoplasm/mitochondrial matrix have similarities. β-barrel proteins and outer 
membrane protein (OMP) machinery are conserved but key features in bacterial 
plasma membranes are absent in the eukaryotic organelle such as LPS residues and 
flagella used for motility. Due to the intrinsic role of mitochondria in respiration and ATP 
production the arrangement of the mitochondrial inner membrane is distinctly unique 
by multiple folds forming cristae structures which house elements of the electron-
transport chain (ETC) (Pallen, 2011).  
Indeed mitochondrial N-formyl peptides, analogues of bacterial counterparts, were 
shown to promote interleukin-8 (IL-8) production from activated monocytes hence 
showing a role for the mitochondria in innate immunity (Crouser et al., 2009; Krysko et 
al., 2011). Mitochondrial DAMPs are frequently elevated in the serum of trauma 
patients due to release from damaged/dying cells during cellular and inflammatory 
changes. Disrupted mitochondria in damaged cells release material via the intrinsic 
apoptotic pathway. In this key paper mtDAMPs were determined to be immunogenic 
in circulation and across different organ systems potentially contributing to systemic 
inflammatory response syndrome (SIRS) (Raoof et al., 2010). 
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1.2.1 Mitochondrial DNA 
 
Key mitochondrial DAMPs characterised by recent papers include mitochondrial DNA 
(mtDNA) such as non-methylated cytosine-phosphate-guanosine, CpG, sites which 
encode N-formyl peptides. MtDNA has been documented in recent data in systemic 
inflammatory response syndrome (SIRS) associated with acute trauma in dramatic 
serum concentration elevations. Non-methylated CpG motifs such as these bind the 
intracellular endosome pattern recognition receptor (PRR) TLR9, a highly conserved 
Type I membrane protein (Zhang et al., 2010). MtDNA is distinct from nuclear DNA by 
a characteristic pre-sequence only present before nuclear translocation. Ligation of 
TLR9 by the pro-inflammatory mtDNA triggers p38 mitogen-activated kinase protein 
(MAPK) phosphorylation in neutrophils.  
 
1.2.2 N-Formyl peptides 
 
For many years now the degradation products of bacterial and mitochondrial proteins 
have been distinguished by their chemoattractive behaviour (Prossnitz & Ye, 1997; 
Hartt et al., 1999).  Mitochondrial DNA and their translated products are considered 
the major signatures of a new source of DAMPs, distinct from bacterial counterparts 
due to their endogenous nature (Zhang et al., 2010). Even thirty years ago Carp (1982) 
recognised that mitochondrial N-formylated proteins were important just by their 
similarity to bacterial products. Though defined as the original chemoattractant G-
protein coupled receptor with high expression on neutrophils and monocytes, Becker 
et al. (1998) characterised FPR expression by immunohistochemistry on a variety of 
different cell types including those of non-phagocytic origin. Staining has been noted 
for FPR particularly on endothelial cells and in thyroid, adrenal, liver and nervous 
system tissue. Human FPR was originally characterised as a high affinity binding site 
for the prototypic N-formyl peptide formyl-methionine-leucyl-phenylalanine (fMLF) (Le 
et al., 2002). Recent studies have demonstrated that mitochondrial peptides/lysates 
are capable of eliciting an immunogenic response on neutrophils in vitro and in vivo. 
This has implications for human disease by increasing susceptibility to organ 
dysfunction and systemic inflammation through mitochondrial alarmins affecting 
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neutrophil physiological behaviour after trauma. The effect of mitochondrial DAMPs 
feeds into the idea of ‘sterile inflammation’ which is of concern after trauma injuries 
where sepsis and uncontrolled inflammation is a major problem (Raoof et al., 2010; 
Wenceslau et al., 2013). 
 
1.2.3 N-formylation post-translational modification 
 
Delving into the evolutionary importance of N-formyl peptides highlights the principal 
reason behind the role of the FPR in host defense. Originally, N-formylation is a post-
translational modification of amino acids that marks the start site for peptide synthesis 
in bacteria (Gerack et al., 2014). In prokaryotes protein production begins with a 
methionine residue and the transfer of a formyl group from formyl tetrahydrofolic acid 
via formyl transferase activity. With activity restricted to bacteria the N-formyl peptides 
are firstly cleaved by methionine aminopeptidase after deformylation and then targeted 
by the human immune system as exogenous foreign material during bacterial 
infections (Mader et al., 2013). 
 
 
1.3 Formyl-peptide receptor molecular properties 
1.3.1 Genetic details of FPR gene 
 
The three human members of the formyl-peptide receptor family: FPR1, FPR2 (69% 
homology to FPR1), FPR3 (58% homology to FPR1) are clustered at the locus 19q13.3 
(Le et al., 2002; Ye et al., 2009). Positions on chromosome 19q13.3 are shown in 
Figure 1.1 perhaps alluding to the different expression and binding behaviours of these 
receptors. Several groups have cloned the fpr genes in an attempt to elucidate its 
molecular role in the cell (Boulay et al., 1990; Murphy et al., 1993; Rabiet et al., 2005). 
Early work concluded that the expression of the fpr1 receptor arises from two 
alternatively spliced mRNAs hence the presence of two transcript variants 
(NM_001193306.1 and NM_002029.3 respectively). The lower affinity receptors 
FPRL1 and FPRL2 like FPR1 were isolated by gene cloning techniques with the only 
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difference being the probes’ stringency threshold (Murphy et al., 1992; Prossnitz & Ye, 
1997). Key features shown in Figure 1.1 mark the fpr gene cluster apart from others 
are its 6kb single copy coding region and three Alu repeats (Le et al., 2000; Murphy et 
al., 1992 & 1993).  Luciferase assays also elucidated that there is no need for a CCAAT 
box in order for gene transcription (Miettinen, 2011) therefore the promoter consists of 
a non-consensus TATA element. 
Phylogenetic analysis has shown that humans and other members of the primate 
family display a high degree of sequence homology especially when compared to 
gorilla and chimpanzee counterparts. This can clearly be seen in Figure 1.2 (b) even 
more so with the divergent FPR genes of the other mammalian species. This is 
particularly evident in murine genetic makeup which consists of seven related 
sequences. Mouse FPR1 is essentially orthologous to human FPR but due to a 76% 
identity its ligand affinity is drastically reduced (Le et al., 2000). The other Fpr-related 
amino-acid sequences split even further with regards to their extracellular loops. 
Mouse fpr-rs1 and fpr-rs2 both equate to the multi-ligand receptor FPR2/LXA4 
receptor. The other Fpr-related amino-acid sequences have been deemed functional 
but are not orthologous to human receptors. Recently in fact another gene has been 
characterised despite previously classified as Fpr-rs2 pseudogene, fpr-rs8 (Tiffany et 
al., 2011). The divergence of this family is clearly evident when subject to sequence 
similarity analysis (Figure 1.2 (a)).  
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Figure 1.1: The loci of the three FPR genes as organised on chromosome 19q13.3. 
FPR1 is encoded by a 6kb copy gene with an intronless open-reading frame translating 
to a 350 amino acid (aa) product. Human FPR2 gene encodes a 351 aa 7 
transmembrane receptor with 68% sequence identity to FPR1. FPR3 gene translates 
to a 353 aa product with 58% homology to FPR1 (adapted from Ye et al., 2009). 
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Figure 1.2: Phylogenetic analysis of the FPR gene family between (a) the three human 
functional isoforms and murine functional/pseudogenes; (b) FPR1 sequences across 
the evolutionary scale from higher mammals to simple eukaryotes. Phylogram 
generated using ClustalW2 online sequence alignment software on 
http://www.ebi.ac.uk/Tools/msa/clustalw2/ .  
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With regards to the polymorphic nature of the FPR family, human FPR1 has many 
different single-nucleotide polymorphisms (SNPs) associated with its gene resulting 
multiple different isoforms (Le et al., 2002). In some cases this variability in sequence 
has been linked to certain diseases such as juvenile periodontis arising from defective 
immune responses (Sahagun-Ruiz et al., 2001). Differences in the activity of these 
FPR1/FPRL1 receptors may potentially trace back to their common evolutionary origin 
which was followed by a distinct heritage.  
FPR family genes have been investigated and characterised in mammals only to date 
(Panaro et al., 2007). Panaro et al. (2007) employed a conservation/mutation pattern-
based strategy and for conservation indexes it appears mutations are likely to occur 
from G to A and C to T. Evolutionary analysis of FPR gene sequences has revealed 
that certain bases are less susceptible to selective pressure. Conservation/mutation 
indexes of 1st/2nd nucleotides of codons share a strong, proportional linkage but the 
conservation index of the 2nd is significantly elevated compared to the first codon base. 
This chemokine receptor conservation/mutation trend is shared by the FPR family and 
Chemokine CXC Receptor 4 (Panaro et al., 2008). The divergent phylogeny observed 
in all mammals and the SNPs in human FPR1 present evidence for distinct 
evolutionary events directing its development (Sahagun-Ruiz et al., 2001). 
 
1.3.2  FPR ligands  
1.3.2.1 Agonists 
 
Due to its originally defined role as one of the first chemoattractant receptors a majority 
of the ligands which bind FPRs are bacterial (exogenous) but in recent years N-
formylated peptides encoded by the mitochondrial genome (endogenous antigens) 
have demonstrated the ability to bind in a similar fashion (Zhang et al., 2010).  
Studies investigating mitochondrial DAMPs and their effect on the cell typically involve 
the application of the subcellular fraction of disrupted organelles. Rabiet et al. (2005) 
have carried out such investigations revealing that members of the electron transport 
chain may indeed activate the FPR family (Raoof et al., 2010). The former group 
utilised N-formylated hexapeptides equivalent to the N-termini of NADH 
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dehydrogenase and cytochrome c oxidase subunits which trigger signalling through 
both FPR1and FPRL1.  
Human formyl-peptide receptor (FPR) is essentially a high affinity binding site on the 
surface of neutrophils for the bacterial formyl-methionine-leucyl-phenylalanine (fMLF). 
Human FPR constitutes a high affinity binding site on the surface of neutrophils for the 
formylated complex N-fMLF. In terms of kinetics fMLF is capable of activating FPR1 
with as little as picomolar concentrations. FPR2 bind various different ligands including 
bacterial formylated peptides, annexin 1, cathespin G and HIV gp41 peptides (Le et 
al., 2002). FPR1 stimulation is thought to trigger surface marker expression, reactive 
oxygen species (ROS) production, pro-inflammatory cytokine/chemokine production 
and degranulation (Migeotte et al., 2006). Emerging evidence suggests the importance 
of formyl peptide receptor (FPR) ligands in lung epithelium, with established 
expression of the receptors in monocytes and neutrophils. Particularly of note is its role 
in chemotaxis and migration of cells to sites of injury (Shao et al., 2011; Rescher et al., 
2002; Crouser et al., 2009).  
FPR2 stimulation is somewhat more complicated by the fact not only does it bind fMLF 
(at micromolar concentrations) but also non-formylated ligands, not unlike FPRL2 (Ye 
et al., 2009). Due to its wide and variable repertoire of ligands, complicated even further 
by the discovery of small-molecule agonists for FPR1 and FPR2 (Kirpotina et al., 2010; 
Khlebnikov et al., 2010), this inflammatory GPCR family is aptly described as 
‘promiscuous’ by the scientific community (Huet et al., 2007). Full determination of the 
FPR family's role can only come with elucidation of all the possible receptor-ligand 
interactions (Migeotte et al., 2006). 
 
 
1.3.2.2 Antagonists  
 
Certain inhibitory agents are capable of binding this GPCR family desensitising and 
preventing further interactions with the receptor. The promiscuous nature of the FPR 
family has only been elucidated by the use of antagonists such as cyclosporins, Boc-
MLF and Boc-FLFLF (Stenfeldt et al., 2007). For many years the cyclosporine family 
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of compounds have been characterised as inhibitors of FPR signalling, acting as 
selective antagonists (Loor et al., 2002). Cyclosporin H (CsH) are classified as high 
affinity ‘inverse agonists’ locking the receptor into an inactive conformation caused by 
an ion pair localised key residues in the seven putative transmembrane domains of 
FPR1 (Loor et al., 2002; Stenfeldt et al., 2007). The binding and efficacy of N-
formylmethionyl-leucyl-phenylalanine (fMLF) peptide depends upon residues in the 
human formyl peptide receptor structure. These include conserved and non-conserved 
amino acids Arg84, Lys85, Arg163, Arg205 and Asp284 situated on the extracellular 
loops of TM domains (Lala et al., 1999).  
The high affinity bacterial fMLF, the same peptide that has been utilised to assess FPR 
functionality in numerous cell types (Rabiet et al., 2005) was altered by the removal of 
the N-formyl group and replaced with a tert-butyloxycarbonyl (Boc) group creating a 
nonselective antagonist (Freer et al., 1980; Stenfeldt et al., 2007). Studies of different 
inhibitors have characterised CsH as the most potent. Asides from antagonists 
discovered more than thirty years ago not many inhibitors are available although recent 
high throughput screening (HTS) of compound libraries have pointed towards two 
novel, potent candidates: benzimidazole and diamide as small molecule FPR inhibitors 
(Unitt et al., 2011; Arterburn et al., 2009). Clearly these flow cytometry-based 
screening methods merit further investigation due to potential, highly selective binders 
for the different members of the FPR family as yet unidentified and uncharacterised. 
There was scope for use of FPR antagonists in vitro or in vivo but the specificity of 
cyclosporin H and small molecule inhibitors is not optimal therefore they were not 
utilised in my project. In recent months a human FPR1-specific antibody was optimised 
in-house by MedImmune (Cambridge, UK) with improved enzyme kinetics and binding 
affinities over other receptor inhibitory agents (Douthwaite et al., 2014). Since this 
antibody is specific for human immunogens it is ideal for evaluation of receptor 
expression at a protein level but not for mouse in vivo experiments. The crux of this is 
that a knockout mouse must be used for in vivo research as there is no specific mouse 
FPR1 antibody that could be used for blockage of FPR1. 
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1.3.3 Structure of the FPR1 GPCR  
 
Typically, this receptor family is characterised as a seven trans-membrane (TM) G-
protein coupled receptor as depicted in Figure 1.3 (adapted from Ye et al., 2009). The 
transmembrane segments are hydrophobic and connect to each other by hydrophilic 
components composed of 3 intracellular cytoplasmic and 3 extracellular loops. Two N-
glycosylation sites are present at the amino terminus and in the 2nd extracellular loop 
(Prossnitz and Ye, 1997). Different amino acid residues equate to a variety of functions 
within in this receptor’s structure as indicated in Figure 1.3. FPR1 is highly polymorphic 
as previously described with several substitutions as at number of positions including 
11 (Ile/Thr), 47 (Val/Ala), 101 (Leu/Val), 190 (Arg/Trp), 192 (Asn/Lys) and 346 
(Ala/Glu). Shaded circular residues Arg84, Lys85, and Asp284 are key for maximal 
binding of N-formylated ligands (Mills et al., 1998). Other residues play a role in generic 
G-protein interactions with Asp122, Arg123, and Cys124 forming this conserved motif. 
Also of note is the NPMLY sequence in the 7th TM segment required for receptor 
internalisation (He et al., 2001). 
 
At the Carboxy-terminus Ser/Thr phosphorylation occurs at 11 distinct sites which are 
functionally activated depending on FPR isoform in the cytoplasmic tail. These 
phosphopeptides were determined by mass spectrometry of tryptic digests (Maaty et 
al., 2013). Differential phosphorylation on neutrophil FPRs appears to correlate with 
the affinity of the receptors (FPR1 has high fMLF affinity as opposed to low affinity with 
FPRL1). Evaluation of this important receptor regulation process could be key in the 
development of a therapeutic approach for tailoring the innate immune response driven 
by neutrophils. 
 
1.3.4 GPCR signalling 
 
All three human FPR1, FPR2 and FPR3 receptors are intrinsically associated with the 
Gi protein subunit. FPR1 is specifically coupled to Gi1, Gi2 and Gi3. The heterotrimeric 
G protein breaks into alpha and beta-gamma subunits. This dissociation of this 
multicomponent complex triggers stimulation of downstream effectors such 
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phosphatidylinositol-3-kinase (PI3K), phospholipase C (PLC), protein kinase C (PKC) 
and a number of mitogen-activated protein kinases (MAPKs). PLC activation allows 
the generation of the second messenger IP3, ultimately causing a calcium flux and 
diacyglycerol (DAG) accumulation. (Amatruda et al., 1995; Le et al., 2002; Selvatici et 
al., 2006). 
GPCR activation is intrinsically linked to the control of vital cellular events such as 
growth, proliferation, differentiation and apoptosis (Roux and Blenis, 2004). Typically 
signalling through these heterotrimeric complexes triggers downstream cascades, 
most notably MAPK activation. Principal members of this important family of kinases 
include ERK1/2 (p44/p42), ATP and p38 which ultimately feed into the master 
transcription factor, NF-kB pathway (Caunt et al., 2006; Huet et al., 2007; Crouser et 
al., 2009; Zhang et al., 2010). As for the mechanisms of GPCR signalling with regards 
to receptor kinetics most of these seven transmembrane (TM) putative domain 
structures undergo desensitisation with repeated ligand exposure. In order to prevent 
saturation adaptor molecules called ‘arrestins’ are in place to sterically hinder G protein 
activation and even to trigger internalisation of chronically stimulated receptors (Caunt 
et al., 2006; Le et al., 2000).  
In terms of the formyl peptide receptor family only FPRL1 signalling requires the action 
of these beta-arrestins (Huet et al., 2007). The variety of ligands which bind FPR2 adds 
to the complexity of this receptor family's function and consequences of activation. 
Across the board in mammalian species the seven transmembrane coding regions is 
distinctive of GPCRs. Cross-talk of FPR with other signalling pathways seems to be a 
common trait as interactions with CCR5, EGFR and SUPAR pathways have been 
reported (Zein et al., 2010). 
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Figure 1.3: Human FPR1 G-protein coupled receptor amino acid (aa) arrangement 
across the transmembrane (predicted). 350 aa are encoded by the fpr1 gene. 
Throughout its structure are sites important for SNP formation (black squares), high-
affinity binding of potent ligands (fMLF), G-protein interaction, receptor internalisation, 
N-glycosylation sites and Ser/Thr phosphorylation sites (black circles). Asterisks 
indicate residue positions implicated in SNPs associated with juvenile periodontis 
(adapted from Ye et al., 2009).  
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Figure 1.4: Schematic representation of receptor-ligand (fMLF) interaction with FPR 
upon the plasma membrane detailing activation of different downstream processes by 
the GPCR-binding of a ligand (fMLF) (adapted from Selvatici et al., 2006). 
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1.3.5 FPR functionality in disease 
Originally characterised as one the first chemoattractant GPCRs in humans FPR 
function and physiological role has evolved over the years. The importance of this 
family in host defense has long been known but new tools in recent years have further 
elucidated its effects on this vital process. Fpr null -/- mice demonstrate ablated 
immune responses and this evident in different in vivo models. Susceptibility to 
bacterial infection and immunogenicity changed with loss of functional fpr1 expression 
due to altered infiltration and migration of leukocytes to sites of infections (Gao et al., 
1999). Due to lack of bacterial clearance by the innate immune response spleen and 
liver bacterial loads were dramatically elevated 2 days post infection correlating with 
impaired neutrophils in fpr1-deficient mice. In neutrophils FPR1 stimulation is 
responsible for a myriad of different processes such superoxide production, 
chemotaxis, CD11b, CD66b, CD62L surface marker expression changes, granule 
contents secretion including MMP-8, MMP-9, Cathepsins B, D, G, Myeloperoxidase, 
elastase activity and release of cytokine/chemokines (IL-8, MIP-1β, TNF-α). 
Decreased PMN function is demonstrated in FPR1 blocked mice similar to depleted 
migrating wildtype neutrophils in CsH treated cells (McDonald et al., 2010). 
 
With bacterial and mitochondrial products capable of catalysing identical signalling 
pathways the significance of the DAMPs should not be underplayed with regards to 
trauma (Hauser et al., 2010). As trauma is essentially a sterile inflammation event is 
not surprising that mtDAMPs have been readily associated with it. Increased mtDNA 
levels in serum was confirmed in patients following trauma injuries, potentially acting 
to promote migration of leukocytes to damage sites via binding of TLR9. Indeed Hauser 
et al. (2010) detected thousand fold increases in femur fracture reamings (FFx) where 
tissue was disrupted as a result of lung injury. MtDAMPs isolated from patients were 
found to phosphorylate p44/p42 MAPK kinases, promote IL-8 and MMP9 secretion as 
well inducing calcium (Ca2+) influx. Obviously trauma-induced alarmins are capable of 
activating neutrophil function. This is indeed a common theme due to role of the formyl-
peptide receptor family in host defense. Monocytes are activated in a similar manner 
to neutrophils by the necrosis/damage-induced release of mitochondrial peptides 
which bind FPRs (Crouser et al., 2009). Due to evolutionary similarities FPR1 is able 
17 
 
to detect formyl peptides from both gram negative bacteria and dysfunctional 
endogenous cells.  
Recent studies suggest the importance of FPR interactions promoting an innate 
immune response specifically by their expression in non-immune cells such as human 
fibroblasts of lung/skin origin (Van Compernolle et al., 2003).  As an endogenous 
source of inflammatory agents N-formyl-peptide activation of FPRs has been shown to 
be integral in the migration of neutrophils and monocytes to sites of sterile inflammation 
(McDonald et al., 2010). In effect FPR signalling is aiding the wound healing 
mechanism which has been further corroborated by Shao et al. (2011) in a linear 
scratch injury model using human lung epithelium. Interestingly, this paper has 
confirmed that FPR expression is integral to the wound healing response in non-
haemopoietic cells. Another function mediated by human FPR1 is the induction of 
mesenchymal stem cell differentiation to osteoblast lineages presenting this GPCR as 
having a role in dynamic bone remodelling (Shin et al., 2011; Viswanathan et al., 2007). 
Another factor to consider is that different ligands exert a variety of effects through the 
FPR receptor. Formyl-peptides are certainly immunogenic but not necessarily pro-
inflammmatory. Synthetic FPR agonists such as compound 43 (Cpd43) inhibit 
inflammation by downregulating interleukin 6 (IL-6) and dampening 
osteoclastogenesis (bone damage) in a murine rheumatoid arthritis (RA) K/BxN model 
as well as suppressing IL-6 release in translational human cells (Kao et al., 2014). 
 
FPRs are relatively uncharacterised in non-inflammatory diseases but recent staining 
in malignant tumours of the central nervous system may suggest a role in cancer status 
(Huang et al., 2008). Before that even FPR expression was confirmed in human glioma 
cell line (U-87) by reverse transcription-polymerase chain reaction (RT-PCR) (Zhou et 
al., 2005). Furthermore Huang et al. (2010) have determined that the chemotactic 
behaviour of FPR1 is not limited to immune cells but is present in glioblastoma tumours 
thus increasing the chances of malignancy distribution. This was demonstrated by 
reduced malignancy and its associated features through in vitro and in vivo 
experiments, Receptor-ligand interactions were found to induce proliferation, 
angiogenesis and migration of tumours. Interestingly, these effects are similar to those 
demonstrated by leukocytes upon fMLF challenge (Zhou et al., 2005; Ye et al., 2009; 
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McDonald et al., 2010). Recent findings by Snapkov et al. (2014) indicate that N-formyl-
peptides of mitochondrial origin are involved in the tumorigenesis of neuroblastoma 
cell lines at least in vitro. This correlates with its role in immune cells particularly 
neutrophils. 
Interestingly emerging research may indicate contrasting roles for FPR activity in 
cancer as FPR1 was determined to downregulate angiogenic processes in human 
gastric cancer opposite to its effect in glioblastoma (Prevete et al., 2014). With 
expression on gastric epithelia cells and confirmed roles in wound repair in this setting 
it appears that FPR1 ligation limits key tumorigenic processes by acting as a 
suppressor in this specific setting. Clearly in certain types of cancer the FPR family 
may present a novel therapeutic target for future therapy interventions. 
 
1.3.6 Neutrophil biology 
Regarded as the first line of defense against pathogenic attack and acting as a link 
between the innate and adaptive immune response mechanisms, the neutrophil has 
many unique features that gear it towards its multiple functions. Due to their short 
lifespan neutrophils (Farahi et al., 2012) are an obvious effectors to fight against 
opportunistic infections with the ability to secrete a myriad of cytokines and 
chemokines. These include CXC-chemokines, CC-chemokines, pro-inflammatory 
cytokines, anti-inflammatory cytokines, immunoregulatory cytokines, colony-
stimulating factors, fibrogenic factors, and TNF superfamily members (Mantovani et 
al., 2011). 
Neutrophils in the bloodstream are captured by the endothelium via selectin-mediated 
interactions. P-selectins and E-selectins bind P-selectin glycoprotein ligand-1 (PSGL-
1) and L-selectins. The movement of neutrophils along the endothelial wall is by a 
rolling mechanism along a chemoattractant gradient until firm adhesion is achieved. 
This next stage is facilitated by integrins (ICAM/VCAM) and is followed by diapedesis 
whereby the cell translocates across the barrier to migrate to the infection site (Amulic 
et al., 2012). 
After chemotaxis to the sites of inflammation and infection neutrophil elicit a myriad of 
different functions including release of pro-inflammatory cytokines, NET formation and 
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phagocytosis of microbes and infected cells. The latter is effected by NADPH 
(nicotinamide adenine dinucleotide phosphate-oxidase) oxidase activity which 
generates superoxide free radicals and triggers degranulation of intracellular 
organelles. Degranulation allows the release of anti-microbial proteins with enzymatic 
functions. Azurophilic granules contain stores of cathespin G, elastase, proteinase 3, 
defensins and myeloperoxidases with other granules containing lactoferrin, 
cathelicidin, collagenase and gelatinases. These granular effectors are the 
implementors of foreign cell/material breakdown in phagocytic activity (Witko-Sarsat, 
et al., 2000)  Immunodeficiency Chronic granulomatous disease (CGD) is caused by 
NADPH subunit mutations in which infections are prolonged and with poor phagocytic 
ability (Heyworth et al., 2003). Upon clearance of bacteria neutrophils are rapidly 
depleted by apoptosis in order to resolve the inflammation associated with infection 
(Mocsai, 2013).  
Neutrophil extracellular traps (NETs) are one of many methods that neutrophils 
mediate the removal of bacteria and compromised cells. NETs are a branched network 
of chromatin, granules and cytoplasm peptides. Only subpopulations of neutrophils 
manufacture NETs by a process called NETosis, a type of programmed cell death 
(Mantovani et al., 2011). The decondensation of chromatin fibres triggers the 
destruction of the nucleus. Another process, superoxide (reactive oxygen species, 
ROS) production is fundamental for NETs to be formed. Typically, NETs are released 
upon cell disintegration. These events are stimulated by bacteria recognition or 
stimulation with PMA which triggers remodelling of nuclear chromatin and dissolution 
of the nuclear membrane (Kobayashi, 2015). 
From the millennium onwards it has become clear that neutrophils have a myriad of 
different roles in modulating the immune response both innate and adaptive. Through 
interactions with other immune cells such as T-lymphocytes, B-cells, dendritic cells and 
Natural Killer (NK) cells, a fully-equipped anti-bacterial/fungal response is mounted. 
Neutrophils facilitate cell activation through antigen presentation and polarising, pro-
inflammatory cytokine production.  
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1.4 The heterogeneous environment of the lung 
The structure of the human respiratory system is designed to provide an efficient 
delivery mechanism for oxygen into the body. Air travels through the nasal cavity or 
mouth passing down through the trachea (windpipe) and ultimately through its 
respective branches or bronchi. The divisions in the airways continue forming a tree-
like structure until the bronchioles lead to their termini, gas-exchanging surfaces called 
alveoli. The alveolar airspaces present a large surface area for respiration numbering 
over ~300 million in healthy, non-diseased lungs (American Thoracic Society, 2014).  
Epithelial cells constitute a major cell type in the human lung but depending on the 
location functions may vary from large to small airways to alveolar airspaces. Large 
airways cell types are involved in host defense against infection with ciliated and 
secretory cells as well as undifferentiated basal types. Small airways, further into the 
lung architecture (26 branches), have significantly increased proportion of ciliated cells 
with Clara cells differentiating from secretory cells. At the terminal branches (223) of the 
lung, the alveolar structures, airway and alveolar epithelium combine with type I/II cells 
(Crystal et al., 2008). Depending on the amount of branching epithelium constituents 
are subject to changes with ciliated columnar cells giving way to cuboidal epithelium 
which then branch further to squamous epithelium (the alveolar airspaces). The 
heterogeneous nature of lung epithelium and its co-ordination with endothelial, 
mesenchymal and fibroblasts cells is a key factor in the pathogenesis of most of the 
chronic pulmonary diseases commonplace today.  
In a normal alveolus (air-sac) functionality is optimal with gas-exchange processes 
occurring due to close localisation with blood capillaries. Within this large surface area 
a resident population of alveolar macrophages represent the primary line of defense 
against opportunistic infection. Surfactant production by type II pneumocytes maintains 
the surface tension of the alveoli in a healthy pulmonary setting but with neutrophil 
recruitment and damage the alveolar membrane is compromised. The gas-exchange 
structures of the lung composed of type I pneumocyte cells are irrevocably altered with 
injury (acute and chronic) undergoing programmed and uncontrolled cell death (Figure 
1.5). 
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Upon injury granulocytes (neutrophils) transmigrate into the lung across the capillary 
and alveolar cell membranes. Bloodstream neutrophils move along a chemokine 
gradient secreted by activated platelets rolling on selectins. Following neutrophil 
infiltration of the lung injury/infection is resolved by action of the immune cells. 
Epithelium/endothelium layers drastically increase their permeability resulting in 
leakage of protein-rich oedema material into the interstitium. This in turn alters the 
stability of the alveolar wall and the oxygen/carbon dioxide exchanging capability of 
the lung (Grommes and Soehnlein, 2010).   
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Figure 1.5: Diagram of healthy normal alveolus (A) versus a similar structure following 
neutrophil recruitment and damage to the lung (B). Schematic altered from Grommes 
and Soehnlein (2010) in which acute lung injury was characterised.   
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1.5 Fibrosis: an overview of fibrogenesis and wound-healing 
 
Fibrosis is the result of unchecked wound-healing and fibrogenesis associated with the 
loss of functional tissue and the formation of dense scar tissue composed of 
collagenous depositions (Araya et al., 2010). Tissue fibrosis in different organs has 
many commonalities partly due to the similarity of the wound healing process. In the 
kidney, heart and liver particularly similar patterns are demonstrated with parenchymal 
injury, inflammatory response, vascular leakage and fibroblast proliferation (Zeisberg 
and Kalluri, 2012). Fibrosis occurs in many different organs such as the lung, liver, skin 
and kidney. Typically this involves an injury and damage which triggers a wound-
healing response. Fibrogenesis mediators act upon immune cells but unchecked this 
leads to fibrosis and the replacement of tissue with non-functional scars. Pathogenesis 
of fibrosis in different organs is not identical due to differing microenvironments and 
cell interactions but a common mechanistic pattern is evident.   
As is usually the case chronic insults impair the normal wound-healing response 
leading to progression from fibrogenesis to fibrosis such as cirrhosis – the end stage 
of chronic liver disease (CLD) (Hold et al., 2009). Disruption of the ECM production 
and turnover is a key feature of fibrosis in different organs. Type I collagen as well as 
other collagens (Type III and IV) are elevated with excessive deposition affecting tissue 
architecture and ultimately function. Tissue inhibitor of metalloproteinases (TIMP) and 
matrix metalloproteinases (MMP) work to maintain the equilibrium the ECM content. 
TIMP-1 and TIMP-2, the primary ECM regulatory elements bind MMP in an inhibitory 
fashion. The breakdown of this regulatory mechanism is an inherent part of the fibrotic 
process as production of collagen exceeds the rate of degradation (Friedman, 2008). 
Fibrogenic processes that drive organ fibrosis and subsequent degeneration have 
been extensively characterised. Several mediators have been shown to induce an 
activated phenotype at a molecular level with differential effects between organs. 
Transforming growth factor-βeta (TGF-β1), a pleiotropic growth factor is responsible 
for fibroblast activation to an activated myofibroblast phenotype. All isotypes of TGF-β 
(1/2/3) in mammals have similar ECM regulatory activity. In particular it stimulates ECM 
production/deposition. Traditionally, sequestered in its latent form as a disulphide-
bonded homodimer, by linkage to latency-associated protein (LAP) TGF-β undergoes 
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proteolytic cleavage to become activated triggering the Smad signalling pathway upon 
binding of its receptors. Phosphorylation of Smad and serine/threonine kinase 
activation results in stimulation of COL1A1 transcription (Wynn. 2008; Hold et al., 
2009). 
Transforming growth factor-Beta elicits a multitude of effects: inflammatory immune 
cell infiltration and secretion of different mediators which trigger hyperproliferation and 
deposition of collagen and other ECM components (Pohlers et al., 2009). TGF-β has 
long been associated with fibrogenesis and aberrant wound-healing responses. This 
cytokine is involved in maintenance of the extracellular matrix balance with increased 
secretion prior to tissue remodelling. In terms of tissue fibrosis TGF-β-mediated ECM 
production is demonstrated in chronic human diseases as well as experimental animal 
models in a variety of different organs including lung, liver, kidney, heart, skin and 
pancreas (Branton and Kopp, 1999). Key effects in wound-healing and fibrosis 
development are ECM accumulation, fibroblast proliferation, migration and 
myofibroblast differentiation (Pohlers et al., 2009).  
The different members of this cytokine superfamily: TGFβ1/2/3 are all processed in a 
similar manner from latent proteins forming a complex with latent binding proteins. 
Upon cleavage of the LTBP from the C-terminus the precursor is activated allowing 
binding by a heterodimeric receptor composed of TGF-ΒRI and TGF-βRII. 
Subsequently the Smad signalling pathway is activated, with Smad4 is translocated to 
the nucleus for transcriptional regulation of gene expression (Leask and Abraham, 
2004). As in human disease TGFβ is elevated with bleomycin-induced pulmonary 
fibrosis, with the selected duoset ELISA (R&D systems) detecting total cytokine level 
in bronchoalveolar lavage (BAL) fluid. 
Normal wound healing responses are required to maintain tissue homeostasis and 
repair damage. Injury to epithelial/endothelial layers of tissue in the different organs 
leads to apoptosis of dysfunctional cells. These dying cells signal the release of pro-
inflammatory mediators which in turn triggers coagulation. Platelet aggregates form 
and blood vessels undergo vasodilation with an increase in permeability. The effector 
cells of fibrogenesis, myofibroblasts are activated due to inflammatory events 
developing a collagen producing and α-smooth muscle actin (α-SMA) phenotype. 
These fibroblasts secrete MMPs as well as a variety of inflammatory mediators and 
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growth factors. Normal wound-healing processes are composed of 4 main stages: 
homeostasis, inflammation, proliferation (fibrogenesis) and remodelling. In 
homeostasis certain bio-physiologic events take place triggering vascular constriction 
as well as platelet aggregation, degranulation and the formation of fibrin. Inflammation 
consists of leukocyte infiltration via innate and adaptive immune responses localised 
to the injury site. Neutrophils, macrophages and lymphocytes migrate and secrete pro-
inflammatory and pro-fibrogenic mediators which interact with tissue architecture. The 
cascade of co-ordination events leads to the proliferative phase consisting of re-
epithelialisation, angiogenesis, collagen synthesis and ECM deposition. The resolution 
of the inflammatory phase is finished via tissue remodelling where the maintenance of 
the collagen synthesis/turnover balance and maturation of vascular architecture is 
effected (Guo and DiPietro, 2010; Wynn et al., 2008).  
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Figure 1.6: Schematic showing the stages of wound healing and cell types involved in 
the development of fibrogenesis and the fibrotic phase. Initial injury leads to triggering 
of haemostatic mechanisms causing accumulation of immune cells. During 
fibrogenesis proliferation of fibroblasts occurs to replace damaged tissue which if 
dysregulated will lead to the fibrotic phase (adapted from Wynn et al., 2010). 
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Neutrophils and macrophages the principle immune cells involved in the innate 
response to damage play a vital part in potentiating the fibrogenic response. They 
facilitate inflammatory mediator release, chemotactic signalling, activation of effector 
cells and ultimately tissue remodelling. Macrophages are potent producers of TGF-β 
promoting ECM production by myofibroblasts. TGF-β has also been found to directly 
affect cell populations in fibrosis by promotion of epithelial-mesenchymal 
transdifferentiation (EMT) leading to an increase in activated myofibroblasts (Wynn, 
2008). Depletion of TGF-β1 mRNA was a key effect with macrophage-deficient mice 
highlighting the centrality of growth factor production by wound macrophages in lung 
injury models (Brancato and Albina, 2011). Long established is the idea of differential 
responses by macrophages in response to stimuli. Distinct subsets have been 
characterised as ‘classically (M1) and alternatively activated (M2) macrophages’ 
resulting from LPS/IFN-γ or IL-4/IL-13 triggers respectively. A certain degree of 
controversy surrounds the concept of macrophage polarisation and whether or not 
subsets exist or is it down to spatial temporal differential regulatory mechanisms 
(Brancato and Albina, 2011). The plasticity of the macrophage allows it to have multiple 
roles in the development of fibrosis. In mouse models of wound healing wound 
macrophages have traits of both M1 and M2 phenotypes strengthening the idea of 
temporal regulation of activation status. Cytotoxic M1 cells are expressed by inducible 
nitric oxide synthase (iNOS), a phenotypic marker responsible for superoxide 
production. Wound-healing macrophages (alternatively activated) induce expression 
of arginase as well as key heparin-binding Ym1/Ym2 protein during well-characterised 
Th2 immune responses. The expression of arginase correlates directly with M2 
macrophage role in fibrosis due to their effect on collagen turnover. FIZZ-1 (found in 
inflammatory zone 1) is another marker of M2 macrophages found specifically in these 
differentiated cells (Brancato and Albina, 2011).  
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1.6 Chronic fibrotic conditions 
Human fibroproliferative disorders are a major health concern causing a massive drain 
on the economy. Major chronic diseases include interstitial lung disease (ILD), liver 
cirrhosis, chronic kidney disease (CKD), heart disease, eye macular degeneration. 
Research routinely uses different methods to replicate fibrosis in multiple organs 
relating to a variety of different insults such as trauma, toxic injury, impaired immune 
mechanisms, chronic infectivity and transgenic modelling (Wynn, 2004). 
 
1.6.1 Chronic pulmonary disease  
 
Pulmonary fibrosis is an umbrella term for interstitial lung diseases (ILDs) of which 
there are different grades and varying aetiologies despite similar clinical presentations. 
The classification of ILD depends on the causative factors such as exposure-related 
triggers, connective tissue disorder-related, genetic predisposition and its idiopathic 
nature.  
Three main examples of human lung disease are COPD, emphysema and Idiopathic 
Pulmonary Fibrosis (IPF). IPF is a common ILD but is arguably the most devastating; 
with a high mortality 3-5 years post diagnosis (Mura et al., 2005; Lee et al., 2014) and 
transplantation of a healthy lung is probably the best chance of surviving (Moeller et 
al., 2006). This progressive fibrotic ILD is the most distinguishable idiopathic interstitial 
pneumonias and is characterised by massive tissue damage, development of fibrotic 
foci with excessive fibroblast proliferation and collagen deposition resulting in a 
‘honeycombing pattern’ as pleural surface changes in a bosselated fashion (Devaraj, 
2014; Wolters, Collard and Jones., 2014). Definitions of honeycombing are not 
standardised but the Fleischner Society has worked to bring together a consensus. 
Cystic air spaces group to form clusters in severely damaged tissue in ILDs with 
disrupted architectural structures (Devaraj, 2014). A classical HRCT presentation of 
IPF consists of honeycombing, reticular opacities, basal and subpleural predominance 
which essentially is a typical usual interstitial pneumonia (UIP) pattern (Figure 1.7). 
Pathogenesis of IPF is quintessentially 3 main phases: (1) Damage/injury; (2) 
Inflammatory response; (3) Resolution/Repair that comprise an aberrant wound-
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healing response. Repeated injury leads to chronic inflammation disrupting 
cytokine/chemokine equilibrium. This perpetual pro-inflammatory response and pro-
fibrotic factors, IL-13 and TGF-β1 combine to generate a fibrotic phenotype. A 
multitude of different factors, known and unknown, coordinate in uncontrolled 
myofibroblast activity with increased proliferation and ECM production (Wilson and 
Wynn, 2009) resulting in this severe disease (Figure 1.8). 
 
Primary diagnosis of IPF is by exclusionary criteria and subsequent classification is 
basic compared to other lung diseases (Chakraborty et al., 2014). COPD, unlike IPF, 
has established guidelines and measures for prognosis purposes in the form of Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) system which increases 
therapeutic scope and patient surveillance (Kolb and Collard, 2014). The unknown 
nature of IPF in terms of pathogenesis, severity and heterogeneous classification 
presents a real challenge to developing a similar system. Its aggressive and 
complicated pathogenesis has made it difficult for clinicians to adequately treat this 
condition. Unlike other chronic lung diseases, generally characterised by progressive 
decline in lung function, IPF is irreversible with little treatment options while COPD is 
much more treatable, albeit dependent on whether or not exacerbations present and 
to what degree (Murray, 2011).  
Potential therapeutic intervention strategies for interstitial lung disease include anti-
inflammatory and anti-fibrotic drug regimens. Non-steroidal anti-inflammatory drugs 
(NSAIDs) comprise the analgesic/antipyretic group of medications. Key members of 
this non-steroidal group are paracetamol, aspirin and ibuprofen which act mainly by 
blockage of cyclooxygenase-1/-2 (COX-1/-2) activity and ultimately prostaglandin and 
thromboxane production (Vane and Botting, 1998).  
Corticosteroids are another class of steroid anti-inflammatory drugs, derived from 
cholesterol through cytochrome P450 enzymatic activity. There are 4 main groups: 
Hydrocortisone, Acetonides, Betamethasone and Esters. Two notable steroids are 
prednisolone, the IPF therapeutic agent and dexamethasone. Dexamethasone has 
anti-inflammatory and immunosuppressant properties when used in humans and mice 
(Weichhart et al., 2010) with significant depletion of LPS effects in C57Bl6 mice in an 
acute model. 
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The most successful option for combating IPF is Pirfenidone (anti-fibrotic agent) which 
inhibits growth factors and collagen deposition through reduced TGF-β production as 
well as anti-inflammatory effects including reduction of TNF-α, interferon-γ and IL-6 
(Nakazato et al., 2002). The actual benefit to the patient is only within a certain window 
dependent of stage of disease. Many researchers have questioned the validity of the 
use of this drug due to the prevailing opinion that IPF is not inflammatory driven (Oku 
et al., 2007; British Lung Foundation, 2014). Other drugs are being piloted such as 
anti-fibrotic agents Nintedanib and N-acetyl-cysteine (NAC) but the unknown 
pathogenesis and cause present problems development of therapeutic options 
(Chakraborty et al., 2014). Some evidence indicates IPF progression from non-specific 
interstitial pneumonia (NSIP) where chronic injury and inflammation at different stages 
trigger alveolitis, widespread damage and tissue remodelling. 
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Figure 1.7: High-resolution computed tomography (HCRT) is standard method of 
diagnosing IPF with basal and peripheral honeycombing distribution (adapted from 
Devaraj, 2014) comprising a typical UIP pattern. 
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In normal tissue this would be a normal wound-healing response but in IPF impaired 
regulation of the repair process leads to an aberrant, uncontrolled response. This leads 
to the formation of type II pneumocytes, epithelium dysfunction, fibroblast hyper-
proliferation, metaplasic squamous cells and honeycomb structure formation (Mura et 
al., 2005). 
Alternatively activated macrophages are commonly associated with fibrosis 
development. Fibrotic responses resolve inflammatory responses to tissue damage. 
Increased immunomodulatory TGFβ cytokine levels triggers fibrogenesis and in 
response fibroblast proliferate. The change in phenotype correlates with a switch to 
Th2 cell cytokine profile comprising of IL-4, IL-13 and IL-10. Heterogeneous alveolar 
macrophages are fibrotic mediators contrasting with ‘classically activated’ M1 
macrophages (Pechkovsky et al., 2010).  
As for potential targets for therapeutic intervention in IPF there are many avenues that 
are currently being pursued. The dysregulated wound-healing response, chronic injury 
and inflammation and fibrotic processes are a by-product of multiple signalling 
pathways occurring simultaneously in a synergic and non-synergic fashion. Pathways 
that have been investigated in the past have been determined to have no effect by 
themselves indicating a complicated micro-environment within an IPF lung with 
redundant/coordinated processes and variation in different phenotypic groups 
presenting with IPF (Chakraborty et al., 2014). Studies into IPF so far have determined 
that in the course of this progressive disease there are three main pathogenic stages: 
predisposition, initiation and uncontrolled progression (Wolters, Collard and Jones, 
2014). The initial stage consists of chronic dysfunctional epithelium due to SNPs and 
environmental factors predisposing a lung towards a fibrotic phenotype. Tissue 
remodelling is largely prevalent in the latter stages of IPF but exacerbations may flare 
in ILD-suffering individuals leading to an IPF presentation (Selman et al., 2001). 
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Figure 1.8: Schematic showing a simplified pathway for the development of pulmonary 
fibrosis from injury against normal tissue and the dysregulation of the haemostatic 
response to the progression to non-functional scar tissue (adapted from Drug 
Discovery Models:Today). 
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1.6.2 Chronic liver disease  
 
Chronic liver disease (CLD) is a serious health implication with over 800,000 people 
worldwide dying each year (WHO) from end stage liver cirrhosis. Cirrhosis is 
irreversible due to a loss of the majority of functional tissue. Therapeutic interventions 
are largely focussed on liver fibrosis before it reaches the cirrhotic stage as the organ’s 
regenerative capacity is able to be utilised in treatment (Marques et al., 2012). As with 
other organs CLD is associated with loss of parenchymal tissue leading to non-
functionality. Parenchyma obliteration pre-empts either reversible fibrosis or 
irreversible cirrhosis. Cirrhosis is a chronic condition resulting from multiple bouts of 
damage and apoptosis from consecutive acute episodes. The difference between the 
two conditions is the ability to resolve the damage triggering the wound-healing 
response (Liu et al., 2012). Tissue homeostasis is maintained by apoptotic pathways 
which if unbalanced leads to disease. Damage to healthy liver cells triggers 
programmed cell death and inflammation is induced.  
Liver fibrosis is preceded by injury or damage to tissue which initiates a pro-
inflammatory immune response. Fibrogenesis is triggered and the immune response 
is resolved, proliferation replaces defunct tissue and liver can function normally again. 
With chronic liver injury the damage is never fully resolved resulting in an uncontrolled, 
fibrogenic response (Friedman, 2008).  
Hepatocyte damage generally occurs in the form of membrane damage and lipid 
peroxidation. This generates reactive oxygen species (ROS) which perpetuate the 
injury phase. Apoptosis via the FAS-mediated TRAIL pathway has been shown to 
activate stellate cells. Essentially the initiation of an inflammatory response via 
hepatocyte destruction stimulates the liver microenvironment in a paracrine manner. 
Constant injury to hepatocytes drives hepatic stellate cell (HSC) activation from their 
quiescent form. Fibrogenesis leads to the proliferation, migration, contraction and ECM 
equilibrium shift within the stellate cell populations (Friedman, 2008). Trans-
differentiation causes matrix degradation via production of tissue inhibitors of 
metalloproteinases (TIMPs). In response to TIMP enzymatic function collagen 
accumulates from positive enforcement of the feedback loop promoting liver fibrosis 
and cell survival. Cell death is a key factor in the wound-healing response. Resolution 
of fibrotic scar tissue and isolated hepatocytes is facilitated by hepatic myofibroblast 
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apoptosis. Gliotoxin, an epipolythiodioxoperazine fungal toxin has pro-apoptotic effects 
via its inhibition of NFκB. This destabilises the membrane enabling release of 
cytochrome C. Experimental in vitro studies have demonstrated gliotoxin-induced HSC 
apoptosis which when applied in vivo in rats stimulates fibrosis reversion in CCl4 model 
(Wright et al., 2001). Activated stellate cell apoptosis alters the balance of MMP and 
TIMP action to favour matrix degradation ultimately leading to tissue remodelling and 
reversing of liver fibrosis (Elsharkawy et al., 2001). 
HSCs are normally located in the sub-endothelial space of Disse between hepatocytes 
and sinusoidal endothelium where they are the main reservoir of extracellular matrix 
(ECM). With liver damage HSCs undergo a hyper-proliferative response losing their 
retinoid (Vitamin A) stores in their differentiation to activated myofibroblasts, the drivers 
of the fibrotic responses (Friedman, 2003; Jang et al., 2008).  
Human liver disease is attributed to a variety of different causative agents with different 
aetiologies across conditions. These include viral infections such as hepatitis B and C 
(HBV & HCV), cholestasis, genetic susceptibility due to occurrence of single nucleotide 
polymorphisms (SNPs), portal hypertension, leptin accumulation (Non-alcoholic 
steatohepatitis; NASH), cancer (hepatocellular carcinoma, HCC), parasitic and 
opportunistic infections as well as drug abuse and alcoholism (Friedman, 2004; Liu et 
al., 2012; Liedtke et al., 2013).  
In humans the main read-outs for chronic liver damage/fibrosis are serum damage 
enzyme levels: Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), 
bilirubin and hyaluronan. ALT and AST are intracellular enzymes localised in the 
cytoplasm levels of which is able to be measured in plasma of patients due to cellular 
turnover. They are particularly indicative of hepatic liver damage and are used as a 
‘liver function test’ with individuals diagnosed with clinical features of CLD or those at 
risk of CLD (Nyblom et al., 2004). Typically liver biopsy samples are analysed by 
histological means allowing grading (depending on amount of bridging collagen 
deposition patterns). In recent years non-invasive imaging such as IVIS methodologies 
have been employed to gauge level of damage/fibrotic tissue. These techniques 
involve fluorescent probes which label cells, ideally this is the way to analyse patients 
as it allows a real-time study of CLD (Liedtke et al., 2013). 
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1.6.3 Chronic kidney disease 
 
Chronic kidney disease (CKD) encompasses a wide variety of conditions with 
complicated aetiologies which have damaged renal architecture and function. With 
CKD incidence on the rise, from a mere 7,000 patients in 1982 to over 50,000 reported 
cases in 2009, in the UK and rates increasing globally this is not a disease to be ignored 
(Zoccali et al., 2010; Caskey et al., 2011). Often involved with other diseases such as 
diabetes mellitus, hypertensions, and glomerulonephritis and also with aging (Levey et 
al., 2010; Zeisberg and Kalluri, 2013) there is demonstrable co-ordination in different 
aetiologies with increased cardiovascular and mortality risk with CKD.  
CKD is difficult to diagnose in early stages with detection often coming too late for 
successful therapeutic intervention. Typically renal functions proteinuria and 
haematuria are assessed by serum creatine levels to determine the estimated 
glomerular filtration rate (eGFR) which is subsequently used to rank patients in order 
of severity (Levey and Coresh, 2012). The National Kidney Foundation has set out 
KDOQI staging of CKD comprising five severity ranks ranging from normal – mildly 
reduced – moderately reduced – severely reduced – renal failure correspond to 
progressive structural/functional alterations which ultimately result in impaired 
functional capability (Stevens et al., 2007; Cirillo, 2010). 
End-stage renal disease (ESRD) is the last point for therapeutic treatment but at this 
stage renal replacement therapy (RRT) is involved in the form of either dialysis or 
transplantation. Increasing incidence of CKD has in turn raised numbers of patients 
requiring RRT according to UK Renal Registry 13th Annual Report (2010) which is a 
major cost equating to over £30,000/patient/year (Caskey et al., 2011). Tightly 
organised tubules in the cortical region located in the extracellular matrix (ECM) with 
basal deposition levels are subject to drastic changes in ESRD. An interstitial fibrotic 
phenotype is exhibited with ECM equilibrium dysregulation, myofibroblast activation, 
proliferation, nephron destruction, leukocyte infiltration and tubular atrophy (Zocalli et 
al., 2010).  
Key factors that distinguish renal fibrosis over other organs are its architecture and cell 
types in the microenvironment. Development of fibrosis and loss of functionality 
typically occurs in two main areas: glomeruli and tubular interstitium. Depending on 
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region in kidney fibroblasts have differing functions. Erythropoietin is exclusively 
produced by medulla region lipid-rich fibroblast unlike cortical counterparts. A major 
feature of chronic renal fibrosis is the nullified expression of this anaemia inhibitor in 
activated myofibroblasts. Indeed fibroblasts have a degree of heterogeneity within this 
setting but they also differ significantly with other organs. Proliferation and regenerative 
capability are severely compromised in CKD but unlike the liver it is largely irreversible 
(Zeisberg and Kalluri, 2013). The cortical region is largely tubulointerstitium (~90) as 
well as glomeruli (~10%). Other cell types include tubular epithelial cells, quiescent 
fibroblasts and immune cells (macrophages and lymphocytes). In terms of human CKD 
the key region affected by renal fibrosis is the cortical region (Harris and Nelson, 2006).  
The progressive nature of the disease is devastating in terms of function and kidney 
mass with little hope of therapeutic intervention. Regression has noted in cases of 
diabetic nephropathy with pancreas transplantation and with clinical drug trials of ACE 
inhibitors but research is still a significant way from making a difference in therapeutic 
treatment. Avoidance of renal failure (eGFR<15mL/min/1.73m2) by improvement of 
available tools available for early diagnosis is a priority of current research. 
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2 Hypothesis 
FPR activity through the ligation of its vast repertoire including mitochondrial DAMPs 
is important in the pathogenesis of fibrosis. As the microenvironment in different organs 
varies in terms of architecture and cellular infiltration particularly neutrophil recruitment 
the fibrotic mechanism will vary in turn.  
Neutrophil involvement will vary in different mechanisms of fibrosis in different organs 
which may be, due to an abundance of FPR expression, related to FPR activity. 
Pulmonary fibrosis mechanisms are neutrophil-dependent with regards to the 
bleomycin-injury in vivo model. In other settings, hepatic and renal FPR expression 
loss will have a marginal effect on the development of fibrosis. 
Aims (i) 
To elucidate FPR1’s role in the development of fibrosis in the pulmonary setting  
 
Objectives 
 Utilisation of bleomycin-induced injury in vivo model with evaluation 
inflammatory and fibrotic phases 
 
 Evaluation of the bleomycin model as a method of investigating pulmonary 
fibrosis with regards to its pathogenesis 
 
Aim (ii) 
 
To determine role of FPR1 in the pathogenesis of other in vivo organ fibrosis models 
such as the kidney, liver and skin  
 
Objectives 
 
 Utilisation of obstruction renal model (UUO) to determine effect of fpr deletion 
on kidney fibrosis 
 Utilisation of chronic toxic injury model (CCl4) to gauge effect on liver fibrosis 
and fibrogenesis 
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Aim (iii) 
 
Characterisation of FPR receptor family expression in in vitro cultured cells and primary 
human tissue 
 
Objectives 
 Utilisation of different methodologies to assess levels of receptor 
expression in terms of messenger RNA (mRNA) and translated protein in 
cultured cells, cell lines and primary human and murine cells. 
 Evaluation of FPR1 receptor in primary diseased human tissue combined 
with other cellular markers. This in turn will allow assessment of importance 
in architectural and/or immune cells. 
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3 Methods 
 
3.1 Cell culture  
3.1.1 Primary human tissue culture  
 
Primary bronchial epithelial cells (PBECs) were obtained from bronchial brushings of 
unused donor normal or explant IPF/COPD. Cells were grown in specialised small 
airway growth medium (SABM, Gibco) supplemented with Bovine Pituitary Extract 
(BPE), 2.0ml; Hydrocortisone, 0.5ml; human Epidermal Growth Factor (hEGF), 0.5ml; 
Epinephrine, 0.5ml; Transferrin, 0.5ml; Insulin, 0.5ml; Retinoic Acid, 0.5ml; 
Triiodothyronine, 0.5ml; GA, 0.5ml; Bovine Serum Albumin-Fatty Acid Free (BSA-
FAF), 5.0ml. All flasks and plates used for culture were coated with 0.5% Purecol 
(Invitrogen, UK) diluted in PBS prior to seeding. Primary lung fibroblasts were grown 
in minimal eagle medium (MEM, Sigma) supplemented with 10% Fetal Bovine Serum 
(FBS), 100μg/ml penicillin, 100U/ml streptomycin (P/S) and 1% L-glutamine (L-GLUT). 
Regardless of cell type consistent seeding densities were used, for RNA experiments 
200,000 cells per well of a 6-well plate with serum-starving upon attainment of ~70% 
confluence. Primary cells were utilised from passages 1-4 as with later generations of 
isolated populations cells begin to change their characteristics losing physiological 
relevance.  
 
3.1.2 Isolation of human immune cells 
3.1.2.1 Peripheral blood neutrophils 
 
All isolations performed by Simpson group at Newcastle University by Jonathan Scott 
or other members of the lab accordingly to a method described in Dransfield et al. 
(1994). Neutrophils were isolated from whole blood obtained from healthy, normal 
volunteers via dextran sedimentation and Percoll gradient fractionation steps. As part 
of the same protocol primary macrophages/monocytes were obtained from similar 
samples for use in gene expression investigations. 
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3.1.2.2 Peripheral T cell populations 
 
Primary T lymphocytes were obtained from healthy, normal volunteers in PBMC 
populations isolated from peripheral blood. Isolation of PBMCs and positive selection 
for CD3 expression using microbeads (Milteny Biotec) was undertaken by Monika 
Suwara. 
  
 
3.1.3 Cell line tissue culture 
 
Human embryonic kidney (HEK) cells were maintained in Dulbecco’s Modified Eagle 
Media (DMEM, Sigma) media supplemented with 10% FBS, 1mM glucose-pyruvate 
and 100μg/ml penicillin, 100U/ml streptomycin (P/S). HEK cells transfected with FPR1 
and FPR2 clonal constructs were grown also in 10% FBS DMEM but with supplement 
differences. Media supplements included 1mg/ml Geneticin (G418, Invitrogen), 
350μg/ml Zeocin (Invitrogen, UK) and x5 Non-essential amino acids (NEAA, 
Invitrogen) for FPR1-overexpressing HEK cells and 1mg/ml Geneticin (G418) only for 
FPR2-overexpressing HEK cells. These semi-adherent cell lines did not require 
trypsinisation for passage events instead washes with phosphate-buffered saline 
(PBS) were sufficient. With regards to assessing FPR expression either at a protein or 
transcript level these stably transfected cell lines acted as positive controls for formyl-
peptide receptors, FPR1 and FPRL1. Both transfected cell lines were obtained as part 
of the collaboration with MedImmune (Cambridge, UK) and were used in the 
optimisation of a human FPR1-specific antibody developed by Douthwaite et al. 
(2014).  
THP-1 monocytic cells (1x106 cells/ml) were activated to an adherent phenotype in 6 
well plates containing 2ml of RPMI 1640 medium (Sigma, UK) supplemented with 
5ng/ml phorbol 12-myristate 13-acetate (PMA) over 24 hours. Doses of PMA used to 
differentiate THP-1 cells among different groups range from 5-400ng/ml (Greenberger 
et al., 1980; Park et al. (2006) ascertained that THP-1 monocytes were converted to 
functional macrophages (CD14+ve) with an optimal dose of 5ng/ml. For differentiation 
to inflammatory (M1) and anti-inflammatory (M2) phenotypes PMA-activated cells were 
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treated with IFNγ or an IL-4/IL-13 mixture all 20ng/ml (R&D Systems, UK) for 18 hours 
respectively. Following RPMI media was replaced to remove any non-adherent cells 
and LPS (1µg/ml) was then added at various time points. 
16-HBE14o- (a gift of D. Grinert), a differentiated SV-40 transformed bronchial 
epithelial cell line were maintained in HyClone media supplemented with 10% FBS, 
1% L-GLUT and P/S. 
MRC5, a fibroblast cell line were cultured in 10% FBS MEM media with 1% L-GLUT 
and P/S.  
 
3.2 Polymerase chain reaction (PCR)  
3.2.1 RNA isolation and cDNA synthesis 
 
Total ribonucleic acid (RNA) was extracted from cultured cells aswell as tissue samples 
and neutrophil preparations using the RNeasy Kit (Qiagen) starting with lysis in RLT 
buffer-β-mercaptoethanol (10µL per 1ml RLT). Following RNA isolation in RNase-free 
water (Qiagen) a nanodrop 2000 machine was used to quantify RNA (ng/µl). Purity 
was ascertained by 260/280 ratio with samples <1.8 excluded. Subsequently, between 
0.25-1.0µg was used to prepare cDNA templates with Moloney murine leukemia virus 
reverse transcriptase (MMLV-RT). A suitable quantity of RNA was incubated at 37°C 
for 30mins along with 1µl DNAse and 1µl DNase buffer. Application of a DNase Stop 
solution consisting of 0.5M EGTA stopped DNAse activity and was followed by 0.5µl 
Random Hexamers (Primers) plus 2µl of nuclease water. After a 5 minute incubation 
at 70°C, samples were kept on ice till a reaction mixture of 0.5µl RNAsin, 1µl MMLV-
RT, 1µl dNTPs oligonucleotides and 4µl MMLV-RT buffer was added (all reagents 
Promega, UK). Sample templates were diluted to 10ng/µl following 60min incubation 
at 42°C.  
3.2.2 RT-PCR 
 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) was performed under 
the following thermocycling conditions: 3 minutes at 94°C, followed by 40 cycles of 20 
seconds at 94°C, annealing at 50-60°C for 30 seconds and elongation at 72°C for 
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30seconds followed by a final 7 minutes at 72°C. Reaction mixtures contained 
Dreamtaq master mix (Promega, UK), 20ng cDNA template 0.1umM of primers made 
up to 25µl final volume with RNase-free water. Following PCR run, products were run 
with 3µl of 10x OrangeG running buffer on a 2% agarose gel for one hour at 0.15A. 
Upon completion of gel electrophoresis PCR bands were visualised alongside a PCR 
marker DNA ladder under UV.  
 
3.2.3 Quantitative PCR (qPCR)  
 
Quantitative polymerase chain reaction (qPCR) was performed using a 7500 Fast 
System (Applied Biosciences). Standard reactions in each well of a 96-well plate 
consisted of 6.5µl SYBR Green Master Mix (Sigma-Aldrich, UK), 10ng of cDNA and 
0.1µM of primers made up to a total volume of 13µl. Reaction mixtures underwent 40 
cycles of denaturation for 10 seconds at 95°C, annealing at 50-60°C (depending on 
primer pair) for 30 seconds and elongation at 72°C for 30 seconds, followed by a final 
dissociation curve cycle of 95°C for 15 seconds, 60°C for 60 seconds and 95°C for 30 
seconds. All results were normalised to a control housekeeping gene (GAPDH). 
3.2.3.1 Primer design and optimisation 
 
All primers were designed using NCBI nucleotide sequences. The coding sequences 
were analysed with OLIGO ™ primer generator software to produce short 
oligonucleotide sequences for forward and reverse primers. Primer pairs capable of 
amplifying unique genetic sequences 150-250bp in length were then ordered from 
Sigma-Aldrich (UK). Using this approach primers were generated for human FPR1 
(hFPR1), human FPR2 (hFPR2), mouse FPR1 (mFPR1), mouse FPR2 (mFPR2) and 
the human TLRs (Table 1). These oligonucleotides were tested for specificity and 
efficiency via RT-PCR and qPCR respectively.  A dilution series for each primer’s 
control cDNA allows primer efficiency to be calculated by linear regression (Figure 3.1). 
The higher the efficiency percentage the better the affinity and PCR product yield. 
Another test of any primers designed with OLIGO software was qualitative assessment 
of qPCR melt curve at the end of the run. This enabled elimination of primers which 
formed excessive primer-dimer and mis-primed product signal. 
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3.2.3.2 Normalisation of gene expression 
 
All results were normalised to a housekeeping control gene: GAPDH (Human/Mouse) 
to assess accuracy. Gene expression was calculated relative to untreated controls by 
using the formula: (1/2A) x100.  
 
3.3 Protein isolation and Western blotting 
 
Following in vitro treatment cultured cells were harvested using Radio Immuno-
Precipitation Assay (RIPA) lysis buffer. Homogenization of samples was achieved by 
sonication for 6 minutes under ice conditions. Samples were then subjected to high-
speed centrifugation at 4°C for 15 mins at 13,000xg. The supernatant was decanted 
into another eppendorff, discarding the resulting pellet of cellular debris. Samples were 
then quantified using the Bradford DC Protein assay. Absorbance at 750nm 
measurement using a spectrophotometer enabled 50µg of protein sample to be 
aliquoted and stored at -80°C. Equal amounts of protein samples were added to 5x 
Laemmli buffer and denatured for 5 minutes at 95°C. 10% sodium dodecylsulfate 
(SDS)-polyacrylamide gels were run for approximately 2 hours at 100V followed by 
100V nitrocellulose membrane transfer. Membranes were then stained with Ponceau 
Red to confirm accurate sample loading and blocked with 5% milk in Tris-buffered 
Saline (TBS)/0.01% Tween 20 (TBS-T) to prevent non-specific binding.  
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Figure 3.1: Primer optimisation evaluated by (a) primer efficiency following doubling 
dilution of template cDNA (initial quantity: 20ng). Linear regression of line of best fit 
allows calculation of R2 value which should be above 0.95 for optimal results. (b) 
Optimal melt dissociation curve showing a single, clear peak with no secondary 
peaks (indicative of primer-dimer formation). 
 
Table 3.1: Oligonucleotide 5’-3’ sequences for functional primers of human and mouse 
genes 
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Milk contains casein, a phosphoprotein hence if looking at phosphorylated proteins 5% 
bovine serum-derived albumin (BSA) should be utilised to block membranes. Upon 1 
hour room temperature incubation primary antibodies in 5% milk or 5% BSA were 
applied to membranes which were then incubated overnight at 4°C. Membranes were 
washed in TBS-T solution for 5 minutes three times preceding 1/5000 diluted 
horseradish peroxidise (HRP) conjugated secondary antibody 1 hour incubation at 
room temperature. Blots were again washed with TBS-T before development using 
Pierce ECL kit. Antibody-substrate complexes ascertained via usage chemi-
luminescent detection reagents and X-ray film cassettes according to manufacturer’s 
instructions. 
ERK1/2 phosphorylation status was assessed via western blot analysis utilising FPR-
transfected HEK cells. ERK activation was measured using an anti-Pp44/p42 mAb 
(1:1000, Cell Signalling Technology) and equal loading with a total ERK (p44/p42) 
(1:1000. Cell Signalling Technology). 
 
3.4 Immunohistochemistry  
3.4.1 Haemotoxylin and Eosin (H&E) staining 
 
Formalin-fixed paraffin embedded sections were dewaxed in Xylene (10 minutes), and 
then 100% alcohol (2 minutes) followed by 95% alcohol. For staining sections were 
washed in running tap water before 4 minute incubation in Mayers Haemotoxylin. This 
was followed by tap water wash for 1 minute then 30 seconds in Scott’s Water for 
nuclei counterstain. Another 1 minute wash was performed succeeded by an Eosin 1 
minute incubation. A final thorough wash in running tap water was performed for 4 
minutes. This was followed by dehydration steps through graded alcohols: 50%, 75%, 
95%, 100% Ethanol (EtOH) 2 seconds each then 100% EtOH 2 minutes. Two Xylene 
treatments for 4 minutes were performed until clear. Sections were then mounted with 
coverslips using DPX. 
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3.4.2 Pico-Sirius Red (PSR) 
 
Formalin-fixed paraffin embedded sections (4μm thick) were dewaxed via 5 minute 
incubation in the following solutions: Clearene I, Clearene II, 100% Ethanol and 70% 
Ethanol (EtOH). Distilled water washes 3 minute/washes directly preceded incubation 
in phosphomolybdic acid (0.2% PMA) for five minutes. Distilled water washes were as 
described previously. Subsequently sections were incubated with 0.1% Sirius red F3B 
in saturated picric acid for 2 hours. This was followed by 0.01M HCl wash (2 minutes) 
and dehydration of sections through alcohols: 70%, 90%, 100% for 20 seconds each 
then 2 minutes in 100% EtOH and finally Clearene for 5 minutes prior to mounting in 
Pertex. 
 
3.4.3 Murine formalin-fixed tissue 
 
Formalin-fixed paraffin embedded (FFPE) sections (4μm thick) were dewaxed as 
previously described. Non-specific endogenous peroxidase activity was blocked by 
0.2% hydrogen peroxide (H2O2)/methanol incubation. Antigen retrieval varied 
depending on antibody methodology (see table 1). Subsequent blocking was achieved 
by Avidin/Biotin Blocking Kit (Vector Laboratories) followed by 20% porcine serum 
block in PBS. Sections were incubated with primary antibodies to alpha-SMA, PCNA, 
CD68, NIMP and CD3 overnight at 4°C. Sections were in turn applied with the 
appropriate secondary antibody for 2 hours, washed and incubated with ABC tertiary 
agent (Vector Laboratories) and visualised for positivity using 3,3′-diaminobenzidine 
tetrahydrochloride (DAB, Vector Laboratories). Sections were counterstained using 
Mayers-Haemotoxylin (for 10-30 seconds) and Scott’s water (30 seconds). All antigen 
retrieval methods and concentration of antibodies used (primary and secondary) are 
described in Table 3.2. 
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3.4.4 Human formalin-fixed tissue stained for FPR1 expression 
 
Human IPF paraffin-embedded formalin-fixed sections were pre-heated to 60°C for 1 
hour. Sections were then de-waxed in xylene for 10 minutes and re-hydrated through 
graded alcohols: 99%, 99% and 95% IMS for 1 minute. Endogenous peroxidases were 
blocked in 0.3% methanol/H2O2 for 30mins. Sections were then washed for 10 minutes 
in running tap water followed by rinsing in TBS buffer. Antigen retrieval was achieved 
by microwaving in boiling citrate buffer (pH= 6.0) for 15 minutes.  Subsequently 
sections were left to cool for 20 minutes and then rinsed in TBS prior to primary 
monoclonal antibody incubation. Human FPR1–HRP direct conjugated antibody was 
diluted in 3 % BSA to a concentration of 2μg/ml for staining the tissue. Antibody was 
linked to HRP conjugate as per manufacturer’s instructions (Innova Biosciences). 
100µl monoclonal antibody was added to sections and incubated at 4°C for 48 hours. 
After this primary incubation sections were washed three times in TBS buffer for 5 
minutes per wash. For the final immuno-reactivity step a working solution of DAB was 
applied for 5 minutes with positive areas turning brown. Following this incubation DAB 
was neutralised in a bleach/water solution and sections were washed for 5 minutes in 
running tap water. Haematoxylin counterstain was then applied for 1 minute and 
subsequently washed in tap water.  Stained sections were finally dehydrated through 
ethanol: 95%, 99% and 99% for 30 seconds, cleared in Xylene solution and mounted 
using DPX solvent. Staining protocol was developed extensively from the beginning by 
Kasim Jiwa (Biomedical Scientist, Freeman Hospital, Histopathology Department). 
 
3.4.5 Periodic Acid-Schiff (PAS) stain 
 
Specifically stains carbohydrate residues in proteoglycan components of the basement 
membranes. Paraffin-embedded formalin-fixed 2-4µm thick tissue sections were 
dewaxed in xylene (10 minutes) and rehydrated in EtOH (100% and 95% each 30 
seconds) then distilled water (5 minutes). Sections were then incubated in Periodic 
Acid (1%) for 6 minutes then washed in distilled water (3x 2 minutes). Sections were 
incubated in Schiff’s reagent for 10 minutes followed by 10 minutes under running 
distilled water. Tissue was then counterstained with haematoxylin for 1 minute and 
washed thoroughly for 5 minutes under the tap. Dehydration was performed in 
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increasing strengths of Ethanol (60% 80% 95% 100%), each for 30 seconds and then 
into xylene for 30 seconds. Finally sections were mounted with coverslips using DPX 
(Sigma, UK). 
 
3.4.6 Image analysis 
 
Bright-field image analysis was carried out using Nikon Eclipse Upright microscope 
proprietary Elements™ software. Cell counts were performed to give an average 
number of positive cells per field. Typically for counting cells 20 fields (at x20 
magnification) were taken and analysed. For densitometry of ECM components 
(collagens and α-smooth muscle actin) a threshold was defined and applied to images 
acquired of IHC stains at x10 magnification. From this a percentage area was 
calculated allowing treatment groups to be compared using GraphPad Prism 5.0 
software. 
Fluorescent image analysis was carried out using Zeiss Axio Observer Inverted and 
Laser Scanning Confocal Microscopy (LSCM) equipment. 
 
 
3.4.7 Histological scoring 
3.4.7.1 Liver  
 
Picro-Sirius Red (PSR) stained sections from chronic CCl4 / Olive oil 8 week model 
were scored on a scale of 0-4 by Dr Fiona Oakley (Fibrosis Research Group). Ranking 
was assigned according to the degree of fibrosis indicated by collagen staining and 
scar formation. Ranks are as follows: 0 – No fibrosis evident, 1- Mild, 2-Moderate, 3-
Severe (>2 vessels linked and multi-layered deposition), 4-Cirrhosis (multiple 
instances of bridging fibrosis and nodule formation). 
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3.4.7.2 Kidney 
 
Histological scoring of UUO model was determined by examination of sections stained 
according Periodic Acid Schiff’s (PAS) protocol by bright field microscopy using the 
aforementioned Nikon Eclipse Upright microscope. For each contralateral and 
obstructed kidney section, 20 fields in the cortical region were acquired at x20 
magnification. Using Photoshop software, a 10 x 10 grid was superimposed onto each 
image and the number of grid intersections overlaying interstitial areas and tubular 
luminae were counted and expressed as a percentage of the total 81 grid intersections 
(excluding glomeruli), for each image (Figure 3.2). All counts were performed in a 
blinded manner. Depending on where in the particular field intersections were 
observed the percentage interstitial expansion (A) or tubular dilatation (B) was 
calculated. 
 
 
Figure 3.2: Manual scoring of periodic acid Schiff’s stained renal tissues for tubular 
dilatation and interstitial expansion. Counting of grid intersections over areas of 
interest to measure tubular dilatation (A), and interstitial expansion (B). Scores 
calculated by converting counts to percentages of the total number of grid 
intersections (81) per high powered field minus intersections located on glomeruli 
structures. (B). Magnification of acquired images is x20. 
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Table 3.2: Immunohistochemistry antibodies used on murine FFPE-sections for 
different cellular markers. Commercial supplier, antigen retrieval and secondary 
antibody for each antibody detailed. 
Antigen  Supplier Cellular target  Antigen 
retrieval  
Secondary 
antibody  
NIMP, Rat 
monoclonal 
Abcam, UK/ 
ab2557-50/ 
NIMP-R14 
Neutrophils 0.01% 
Pronase, 
humidified 
atmosphere 
37°C 
Goat anti-rat biotin 
conjugated Ac 
(STAR80B Serotec, 
1/200 dilution) 
CD3, Rat anti-
human  
AbDSerotec, 
UK/ MCA1477/ 
CD3-12 
Lymphocytes EDTA pH 
8.0, 
microwave 
Goat anti-rat biotin 
conjugated Ac 
(STAR80B Serotec, 
1/200 dilution) 
CD68, Rabbit 
polyclonal 
Aviva 
Biosystems, 
UK/ 
OABB00472 
Macrophages Sodium 
citrate buffer 
(H3300, 
Vector),  
microwave 
Swine anti-rabbit 
biotinylated  
antibody (E0353 
Dako, 1/200 
dilution) 
PCNA, Rabbit 
polyclonal 
Abcam, UK/ 
ab2426 
Proliferation Trypsin, 
waterbath 
37°C 
Swine Anti-Rabbit 
Immunoglobulins/Bi
otinylated (E0353 
Dako, UK) 
α-SMA, 
Monoclonal 
anti-FITC  
Sigma, UK/ 
F3777 
α-Smooth 
Muscle Actin, 
ECM 
Sodium 
citrate buffer 
(H3300, 
Vector),  
microwave 
Goat Biotinylated 
anti-fluorescein 
(BA-0601 Vector, 
1:3000 dilution) 1% 
piggy serum 
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3.5 Immunofluorescence  
3.5.1 Fixation and staining of cultured cells 
 
Cultured cells were grown to confluence in chamber slides (4 well) and subsequently 
fixed with 4% Paraformaldehyde (PFA) in a 10 minute incubation. Fixative was then 
quenched using 100mM Glycine solution and permeabilised with 0.1% Trition-X-100 
following a 30 minute incubation. Cells were blocked with 5% BSA 0.01% Tween 
Phosphate Buffered Saline (PBST) for 1 hour. IgG APC control antibody and FPR1 
APC direct conjugate were incubated in the dark at room temperature for 2 hours at 
1:100 concentration. Coverslips were mounted in DAPI-containing fluorescent 
mounting medium (VectaShield) for at least 2 hours in the dark at 4◦C. 
 
3.5.2 Human FPR1 staining of fixed cells/paraffin-embedded tissue (FFPE) 
 
Formalin-fixed paraffin embedded tissue was dewaxed and rehydrated in Clearene 
and decreasing concentrations of ethanol. Endogenous peroxidase was blocked to 
eliminate non-specific binding prior to antigen retrieval in 1mM EDTA (pH=8.0) solution 
(15 minutes full power microwave incubation). Elimination of non-specific binding 
achieved by 1 hour block at room temperature with 5% BSA PBST. E-Cadherin 
(epithelial marker), alpha-smooth muscle actin (alpha-SMA), CD45 and CD68 primary 
antibodies were incubated overnight at 4◦C at 1:100 concentration diluted in blocking 
solution. All washes were performed in PBST. FITC, TRITC, IgG APC control antibody 
and FPR1 APC direct conjugate were incubated in the dark at room temperature for 2 
hours at 1:100 dilution. Coverslips were mounted in DAPI-containing fluorescent 
mounting medium (VectaShield) for at least 2 hours in the dark at 4◦C. 
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Table 3.3: Immunofluorescence antibodies used on human FFPE-sections for different 
cellular markers. Commercial supplier, antigen retrieval and secondary antibody for 
each antibody detailed.  
Antigen  Supplier Cellular target  Secondary antibody  
CD45 
 
Abcam Ab10558, UK Leukocytes Goat anti-rabbit TRITC conjugated, 
Sigma T6778 (UK) 
E-CADHERIN BD Biosciences 61081, 
UK 
Epithelium Goat anti-mouse FITC conjugated, 
Sigma F2012 (UK) 
VIMENTIN Abcam, Ab92547 UK Fibroblasts Goat anti-rabbit TRITC conjugated, 
Sigma T6778 (UK) 
CD68 Abcam Ab955, UK Macrophages/ 
Moncytes 
Goat anti-mouse FITC conjugated, 
Sigma F2012 (UK) 
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3.6 Flow cytometry 
3.6.1 Principle of assay 
Flow cytometry is a process by which dyes and fluorochromes absorb light and emit a 
higher wavelength. Dichroic mirrors are responsible for the reflection of light at specific 
wavelengths. These emissions are detected and converted to an electrical current with 
a proportional voltage relative to the amount of light resulting in a digital signal in the 
form of median fluorescence intensity (MFI). 
Side and forward scatter equate to the two main measurements of the physicality of 
the cells being analysed. Forward scatter is the diffracted light from the laser is 
proportional to size. Side scatter is the refracted (plus reflected) light from the different 
lasers allowing intracellular complexity to be gauged.  
In the event of multi-parameter analysis when multiple antibodies are used to stain the 
same sample a variety of different channels are required. In the case of multiple 
fluorophore utilisation spectral overlap is a concern as conjugates with emission 
ranges that are close together may result in false positive signals. Electronic 
compensation is required to correct signal ‘bleeding’ between different channels. 
Ideally fluorophores should be chosen with separate emission ranges such as FITC 
and PerCp.  
Each experiment will have several different controls such as unstained cells, 
compensation controls and isotype controls. The latter control will define the non-
specific background. A threshold can be generated by defining a cut-off for negative 
and positive staining when using a multi-parameter panel. 
 
3.6.2 Human FPR1-based flow cytometry of cultured cells: fibroblasts, epithelial 
cells and neutrophils 
 
Cultured cells were grown to confluence in 12-well tissue culture plates, serum starved 
in 0.4% FCS MEM media overnight at 37◦C. Cells were then harvested by 
trypsinisation, pelleted by centrifugation and resuspended in FACs buffer (1% FCS in 
PBS) at an appropriate dilution. Cell suspensions were then added to 96-well round 
bottom plates, spun at 850 x g to pellet cells and resuspended in antibody-containing 
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FACs buffer. Antibody mixture consists of 3.67µl of antibody (human FPR1 / IgG 
isotype control) and 1µl Live/Dead viability dye in 250µl FACs buffer.  Concentration of 
the antibodies was adjusted upon reconstitution with APC-linking agent to 0.67 µg/µl. 
50µl of antibody mixtures were added to pelleted cells. Control and HFPR1 antibody 
were adjusted to 400µg for linkage to allophycocyanin (APC) conjugate as per 
manufacturer’s instructions (InnovaBiosciences).  Incubation for 30 minutes in the dark 
at 4◦C followed resuspension. Cells were then washed by adding 200µl FACs buffer to 
each well, followed by resuspension and pelleting by centrifugation. 200µl FACs buffer 
added to each well and cells were transferred to FACs tubes for reading by the flow 
cytometer. 
 
3.6.3 Gating strategy for human cultured cells using FlowJo 
 
Upon acquisition with FACSCantoII flow cytometer machine raw data was then 
exported and analysed with FlowJo software. Firstly, cell populations were gated to 
exclude debris and dead cells by plotting FSC-H against SSC-A. Then cells were gated 
accordingly to include single cells only (doublet exclusion) by plotting FSC-H versus 
FSC-A. Live/dead gating was employed by utilising the wavelength of the dye (405-
450nm) to give a population of live single cells. A histogram was then generated by 
plotting count against 635-660nm channel (APC range) to give the signal by unstained, 
IgG isotype control APC and hFPR1 APC stained cells. Median Fluorescent Intensity 
(MFI) was then calculated for statistical purposes. The gating strategy employed for 
these flow cytometry experiments demonstrated in Figure 3.3. 
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Figure 3.3: Gating strategy for FPR1 expression. Cell populations were separated 
according to the following gating strategy. Cellular debris, doublets and dead cells were 
excluded before being gated for FPR1-APC positivity. Flow cytometry runs were 
analysed with FlowJo software.  
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3.6.4 Flow cytometry analysis of inflammatory infiltrate of bleomycin/saline 
treated mice  
 
Lung lobes from WT and FPR1KO mice from day 5 and day 21 time points were 
chopped finely for rough homogenisation. Processed tissue was digested in complete 
RPMI (Sigma, UK) containing 10% FCS and L-Glucose and supplements 25μg/ml 
DNase 18μg/ml Liberase TM for 1 hour at 37°C in shaker. Following digestion 
incubation sample was mixed and filtered through 70µm cell strainer into a 50ml falcon 
tube. A 1/3ml syringe plunger was used to mash remainder lung tissue into filter and 
washed subsequently with complete media. Filtrate supernatant transferred to a new 
tube and the centrifuged at 850 x g for 10 minutes. RBC Lysis step was included to 
make sure all erythrocytes were removed by 1 minute incubation with 1ml RBC Lysis 
solution (Sigma, UK). 10ml complete media added to digest and subsequently washed 
by 850 x g centrifugation at 4°C and resuspension in PBS twice. Cells in each digest 
sample was then counted by flow cytometry at a 1/10 dilution (30µl sample plus 270µl 
PBS) with flow rate used to estimate the number of cells in a 1 minute run.  
In total five panels of antibodies were used in this experiment for the determination of 
the cell populations present in the inflammatory infiltrate following bleomycin/saline 
instillation. All antibodies were prepared in 1% BSA FACs buffer (500ml PBS, 5g BSA, 
1ml Sodium Azide) with a total of 1µg used in each reaction. The primary and isotype 
antibodies and their corresponding panel are detailed in Table 3.3. Compensation 
controls were set up with 2.5 x mix solution in a 1:1 ratio of lung sample: bone marrow 
cell suspension.  
For this experiment a 96-well format for staining and subsequent flow cytometer runs. 
Upon cell count suspensions were adjusted for 4x105 cells per well. 150µl cell 
suspension per well spun to pellet cells then resuspended in 1:1 PBS: Aqua mixture. 
Viability live/dead dye diluted 1/150 in PBS from stock solution (50µl DMSO vial). 
Plates incubated on ice for 30 minutes. Washed once in FACs buffer and resuspended 
in 100µl of FC block (stops non-specific binding). Samples were incubated on ice for 
10 minutes. Depending on antibody panel appropriate primary mix was added to each 
well (100µl) for 30 minutes on ice. Subsequently washed with FACs buffer and 
centrifuged twice. Fixation with 4% PFA required prior to cell permeabilisation with 
appropriate buffer for antibody panels 4a and 5a. Cells were washed twice in 
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Permeabilisation buffer (P buffer) followed by resuspension in 100µl buffer and 100µl 
antibody mix. Followed by a 30 minute incubation and two washes in P buffer. Plates 
stored overnight at 4°C and read on FACSCanto. This experiment was run on-site at 
MedImmune (Cambridge, UK) with the help and co-ordination of Dr John Ferguson.  
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Table 3.4: Panels of Flow cytometry antibodies for different markers of inflammatory 
cells such as neutrophils (PMNs), eosinophils, lymphocytes and M1/M2 macrophage 
(Mϕ) lineages.  
Panel  Antibody Source/Product code Marker Isotype control  
1 CD45 APC-cy7 Biolegend, 103116 Leukocytes Rat IgG2b APC-Cy7  
GR1-APC Biolegend, 560599 Granulocytes Rat IgG2a APC 
CD11b Percp Biolegend, 101230 Activated PMNs Rat IgG2a PerCP 
CD66a PE Biolegend, 134505 Activated PMNs  Mouse IgG1 PE 
F4/80 BV421 Biolegend, 123132 Mϕ Rat IgG2a BV421  
2 CD45 APC-cy7 Biolegend, 103116 Leukocytes Rat IgG2b APC-Cy7  
GR1-APC Biolegend, 560599 Granulocytes Rat IgG2a APC 
SiglecF-PE BD Biosciences, 552126 Eosinophils Rat IgG2a PE 
F4/80 BV421 Biolegend, 123132 Mϕ Rat IgG2a BV421 
3 CD45 APC-cy7 Biolegend, 103116 Leukocytes Rat IgG2b APC-Cy7  
CD3 percp Biolegend, 100326 CD3+ve T-cells Armenian Hamster 
IgG PerCP 
CD4-BV421 Biolegend, 100544 CD4+ve T-cells Rat IgG2a BV421 
CD8 FITC Biolegend, 100706 CD8+ve T-cells                           Rat IgG2a FITC 
CD49b APC eBioscience, 17-0691-52 Natural Killer cells Rat IgM APC  
NK1.1 PE eBioscience, 12-5941-83 Natural Killer cells Mouse IgG2a PE 
B220 Pe Cy7 eBioscience, 25-0452-82 B-cells Rat IgG2a Pe Cy7 
4 CD45 APC-cy7 Biolegend, 103116 Leukocytes Rat IgG2b APC Cy7 
F480 BV421 Biolegend, 123132 Mϕ Rat IgG2a BV421 
CCR7 PE cy7 eBioscience, 25-1971-82 M1 Mϕ Rat IgG2a PE Cy7 
MOMA-2 PE ABDserotec, MCA519PET Mϕ Rat IgG2b PE    
CD68 Percp 
cy5.5 
Biolegend, 137009 Mϕ Rat IgG2a PerCp 
Cy5.5 
CD206-APC Biolegend, 141708 M2 Mϕ Rat IgG2a APC 
5 CD11b Percp Biolegend, 101230 Activated Mϕ Rat IgG2b PerCP 
CD45 APC-cy7 Biolegend, 103116 Leukocytes Rat IgG2b APC Cy7 
F480 BV421 Biolegend, 123132 Macrophages Rat IgG2a BV421 
iNOS-APC Biorybt, orb113211 M1 macrophages iNOS-APC 
FIZZ-1 _RPE N/A M2 macrophages FIZZ-1 _RPE 
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3.7 In vivo procedures 
3.7.1 Mouse strains 
 
C57BL/6 (WT) mice were obtained from an in house breeding colony (Comparative 
Biology Centre, CBC). FPR1KO mice (from a C57Bl/6 background) were firstly 
obtained from Medimmune (Cambridge, UK) and then housed/bred by CBC facility. All 
animals were treated humanely in accordance with the UK Animals scientific 
Procedures Act, 1986. All procedures were performed under the UK Home Office 
licence.  
FPR1KO (643) mice were generated using a targeted genetrap-mediated mechanism 
to produce a truncated non-functional gene. Functionality testing on neutrophils at 
MedImmune (Cambridge, UK) with FPR1 agonists showed knockout of FPR1 in the 
transgenic mice colony. For the purposes of this thesis knockouts are referred to as 
FPR1KO or simply KO throughout. 
 
3.7.2 Genotyping of FPR1-deficient mice 
 
Ear punches were digested in 250μl of lysis buffer (2ml NaCl (5M), 2ml EDTA 0.5M, 
2ml Tris-HCl pH: 7.5 (1M), 2.5ml 10% SDS, 41.5ml DNAse-free water) in a heat-block 
at 55°C overnight. An equal volume of phenol was then added to each digestion 
mixture, vortexed and spun at full speed for 5 minutes. Top layer was then removed 
and added to 2-3 volumes of ethanol (100%) and 2μl 3M sodium acetate. Following 
this mixture was incubated at -80°C for 2 hours. Genomic DNA was then pelleted by 
centrifuging at full speed for 10 minutes. Supernatant decanted off and pellet was then 
left to air dry prior to resuspension in 50μl 1x Trypsin-EDTA (TE, Sigma-Aldrich UK) 
buffer. DNA was then diluted 1:50 for genotyping PCR reactions. 
Due to the genetrap deletion the fpr643 knockouts have a deletion in the FPR1 gene 
codon (proprietary to Deltagene, source of FPR1 knockout mice). Interestingly Abcam 
and other commercial antibodies have immunogenic sequences that are located in 
codons within and outside this deletion sequence therefore FPR1 will still be detected 
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in KO mice via western blot-based methodology. The endogenous gene product is only 
detected in WT C57Bl6 mice with the deletion in the knockouts resulting in an absence 
of this gene product following RT-PCR. 
 
3.7.3 Isolation of different cell populations 
3.7.3.1 Hepatic stellate cells (HSC) from mouse livers 
 
At least 2-4 livers from wild type (C57bl6) and FPR1 knockout mice were washed in 
PBS following perfusion via the Inferior vena cava (IVC). Chopped livers were digested 
for 25-30 minutes with collagenase II (2mg/ml, Roche Laboratories) and pronase I 
(10mg/ml, Roche Laboratories) diluted in 40mls of Ca2+HBSS at 37◦C. The livers were 
then mashed into fragments in ~5mls of DNase (0.25mg/ml, Roche Laboratories) 
DNase 0.1mg/ml in Ca2+HBSS (Sigma-Alrdrich, UK). After digestion they were passed 
through nylon mesh with a pipette into a beaker. The liver was washed through with 
Ca2+HBSS and made up to 50mls. Filtrate was then centrifuged for 7 minutes at 850 x 
g. The supernatant was removed and resuspended in 1ml DNase to prevent the cells 
from clumping. The mixture was made up to 50mls with Ca2+HBSS and centrifuged at 
850 x g for 7 minutes. The supernatant was removed and the cells resuspended in 1ml 
DNase. An Optiprep (Nycomed, Sigma Aldrich) sucrose gradient was prepared to 
separate the stellate cells by density. When centrifuged the sucrose separates and the 
heavy cells (hepatocytes) spin down and buoyant cell (hepatic stellates) form an upper 
layer. The lower layer contains 4.7ml working Optiprep and 3.2ml HBSSCa2+ and the 
upper layer 5.9ml working Optiprep and 8.9ml cell suspension. (Working Optiprep 
contained 25ml Optiprep / 26ml Ca2+HBSS). The digestion mixes were made up to 
8.9ml with Ca2+HBSS. The density gradient was subsequently overlaid with 1ml 
Ca2+HBSS. The gradient was then centrifuged at 1400 x g with no break for 18 minutes. 
The HSCs were removed from the gradient with a pipette from either side of the blood 
layer. The cells were put in a falcon tube with ~1ml DNase and Ca2+HBSS added up 
to 50mls. This was centrifuged for 6 minutes at 850 x g. The supernatant was removed 
and the cells resuspended in complete media consisting of Dulbecco's Modified Eagle 
Medium (DMEM; Gibco, Life Technologies), 16% FCS (Sigma-Aldrich, UK), 1mM 
pyruvate-glutamine (Sigma-Aldrich, UK), penicillin-streptomycin antibiotic (Sigma-
Aldrich, UK). The population was then seeded onto T75 flasks (Greiner) at an 
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appropriate density. Cells were incubated at 37◦C in the presence of 5% CO2 until 
ready in terms of confluence for experiments. 
 
3.7.3.2 Murine lung fibroblasts 
 
Following harvesting of organ from mice, tissue was washed in DMEM (10% FCS, 1% 
penicillin/streptomycin and 1% L-glutamine) and chopped into small pieces using 
scissors. Pieces were then washed on a 40μm filter to remove debris and red cells and 
resuspended in 10ml serum free DMEM containing 0.1% BSA and 0.2% collagenase 
type 2. This digestion mix was incubated at room temperature on a roller for 2 hours 
with occasional agitation. Suspension was then filtered through large gauze mesh 
(sterile tea strainer) followed by passage through a 100μm filter. The filtrate was then 
centrifuged at 400 x g for 5 minutes. Following multiple washes with DMEM cells were 
plated on collagen-coated plates at approximately 80000 cells/cm2.  
After 10mins the cell suspension was transferred to another collagen-coated plate and 
left to attach for 1hr. After 1hr the cells that did not attach were transferred again to 
another dish. Cells were subsequently maintained in complete DMEM with 10% FCS, 
1% penicillin/streptomycin and 1% L-glutamine at 37◦C in the presence of 5% CO2 
 
3.7.3.3 Bone-marrow derived macrophages 
 
Mice were sacrificed by cervical dislocation and hind leg bones were excised by cutting 
away all muscle tissue. Bones were then flushed through with HBSS (minus Calcium) 
using a syringe attached to a 21G needle. The entire bone marrow cell population was 
then plated on 10 cm2 dishes and incubated for 6-7 days with 5% CO2 at 37◦C. All 
growth media was supplemented with L929-conditioned medium. Supernatant was 
collected from L929 cells grown at normal conditions essentially acting as a source of 
GM-CSF, a differentiating factor for macrophages. 
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3.7.4 Bleomycin (BLM) –induced pulmonary fibrosis model 
3.7.4.1 Intratracheal BLM model protocol 
 
100µl sedative ketamine/xyzaline (2:1) diluted 1:1 in water for intraperitoneal (i.p.) 
injection to anaesthetise the animal prior to intratracheal administration. Using 
bookends connected with suture wire the mouse was positioned via front teeth 
between the two supports with a P1000 tip box beneath to keep animal flat. The tongue 
was pulled slightly out with forceps and a 200ul pipette with gel loading tip was 
positioned into bottom right corner of mouth. The tip was manoeuvred until resistance 
lessened (opening to the trachea) and the plunger of pipette was pushed several times 
due to mucus in lungs. Dosage was 0.007U intratracheal (i.t.) instillation in a 30µl 
volume (this was a previously titered dose used routinely at MedImmune, Cambridge). 
A successful dose resulted in (1) rate of breathing increase and (2) a hiccup response 
as drug is taken into the trachea. Instillation was followed by 50µl anti-sedan injection 
diluted 1:1 in saline (recovery agent) and placement into hot box in surgery room until 
recovery. Lobes were taken for RNA, protein, lung homogenate, histology and 
hydroxyproline along with serum and bronchoalveolar lavage (BAL) upon harvesting 
of animals at study endpoints 1, 5 and 21 days post-bleomycin administration. 
Bleomycin-injured and saline-treated mice were an equally weighted mix of both 
genders.  
Initial studies at MedImmune utilised power calculations for optimal numbers of 
animals for day 5 and day 21 endpoints post-bleomycin injury. From sample size 
analysis 4 mice were deemed necessary to adjust for response variability in saline vs 
bleomycin.  
Further studies at Newcastle University used at least the same number but due to 
using both males and females in some studies (Ly6G and 1 day BLM) more were 
included to account for variability in response to bleomycin on an exploratory rationale. 
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3.7.4.2 Bronchoalveoloar lavage (BAL) processing 
 
BAL fluid was isolated from animals following saline/bleomycin instillation. Between 
700-950µl PBS (5mM EDTA) retrieved from the 1000µl pumped in via rat canula 
inserted into the trachea. BAL fluid was kept on ice until centrifugation at 1400 x g for 
5 minutes. Subsequently supernatant was stored at -80°C for future use in ELISA/MSD 
multiplex assays. The cell pellet was resuspended in 200µl PBS for counting and 
cytospin preparation. 10µl of suspension was pipetted into a disposable 
haemocytometer slide and scanned/read using automatic EVE cell counter 
(NanoEntek™). For preparation of cytospins 5x104cells were pelleted onto glass slides 
using a cytocentrifuge and Shandon disposable filter funnels. Slides were air-dried for 
approximately 10 minutes and fixed for 20 minutes in acetone solution. Cytospins were 
then stained with Wright-Giemsa solution (Sigma, UK; 1% diluted 1/10 in PBST) for 20 
minutes. Differential cell counts were performed on randomly selected fields by 
counting at least 300 cells to determine the percentage of eosinophils, 
lymphocyte/mononuclear cells, neutrophils and macrophages (Figure 3.4). 
 
3.7.4.3 TGF-β1 and Periostin (OSF-2) cytokine quantitation 
 
Secreted cytokine levels were determined in BAL fluid utilising TGF-β1 ELISA duoset 
kits according to manufacturer’s instructions (R&D Systems, UK). All BAL samples ran 
in triplicate in a 96-well format with absorbance read at 450nm. Background signal was 
corrected for by reading at 540nm. Using linear regression from the standard curve 
unknown concentrations (samples) were interpolated. Periostin, OSF-2 levels were 
determined the use of an MSD single-plex platform according to manufacturer’s 
instructions (Mesoscale Discovery, USA). ELISAs were either performed at Newcastle 
or on-site at MedImmune (Cambridge, UK) by myself, Matt Bell or Jayesh Majithiya. 
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Figure 3.4: Bronchoalveolar lavage (BAL) cytospin stained with Wrights-Giemsa 
solution from which differential cell counts for neutrophils (PMN), macrophages (Mϕ), 
lymphocytes and eosinophils were performed. Examples are highlighted on the above 
sample field. Scale bar represents 100µm. 300 cells were counted in total and 
percentages of different cell populations were calculated.  
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3.7.4.4 Hydroxyproline content colorimetric assay 
 
Tissue samples (lung lobe) were hydrolysed in Kimex Corning glass tubes in 1ml 6N 
HCl acid overnight at 110°C in heat-block located in fumehood. At least 18 hours is 
required for adequate hydrolysis of tissue weighing between 100-200mg. At time of 
animal harvesting tissue is stable in hydrochloric acid indefinitely and following acid 
hydrolysis samples are again stable indefinitely. Hydroxyproline standards made up 
from 4mg/ml Calbiochem (EMD) stock. Stock was diluted 1:10 in sterile water to 
400µg/ml and subsequently 1:2 several times to generate a 12-point standard curve. 
20µl standard was pipetted to flat-bottomed 96-well plate (Greiner) and then 20µl 
sample in triplicate. Solutions A and B were made up as follows: A – 0.282g 
Chloramine T-hydrate (Sigma, UK), 2ml water, 2ml isopropanol, 16ml Citrate Acetate 
buffer. Citrate acetate buffer consisted of 5% w/v Citric Acid, 1.2% w/v Glacial Acetic 
Acid, 7.24% w/v Sodium Acetate, 3.4% w/v Sodium Hydroxide with sterile water added 
for a complete volume of 200ml (heated buffer solution at 37°C for 15 minutes to 
ensure dissolving); B – 2.5g p-dimethylaminobenzaldehyde (Sigma, UK), 9.3ml 
Isopropanol (Sigma, UK), 7.3ml Perchloric acid (Sigma, UK). Perchloric acid was 
added last at a slow rate due to an exothermic reaction. Plate was tapped to mix 
samples before 100µl Solution A was added to each well. For oxidation to occur 
samples were incubated for 20 minutes at room temperature. Solution B was then 
added to each well (100µl) for the colorimetric reaction to take place. Plates were then 
tapped to ensure mixing before incubation at 60°C for 30 minutes. Measurements were 
made using a 570nm spectrophotometer reader yielding optical density (O.D.) values 
to be interpolated from the hydroxyproline standard curve (Figure 3.5). 
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Figure 3.5: Hydroxyproline (O.H.P.) standard curve graph with O.D. (absorbance at 
570 nm) vs hydroxyproline (µg). Unknown values were interpolated using this standard 
curve in GraphPad Prism 5.0 by linear regression.  
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3.7.4.5 Analysis of pro-inflammatory cytokine release from lung homogenate via 
multiplex ELISA MesoScale Discovery (MSD) platform 
 
Secretion of interleukin 6 (IL-6), chemokine (C-X-C motif) ligand 1 (CXCL1, KC), 
interleukin 1-beta (IL-1β), macrophage chemoattractant peptide 1 (MCP-1) and 
interleukin 13 (IL-13) were measured in lung homogenates (prepared in PBS using 
homogeniser) from saline/bleomycin-treated mice using MesoScale Discovery® 
mouse pro-inflammatory 5-plex base kit (MesoScale Discovery, Gaithersburg, MD, 
USA). Protocol was carried out according to manufacturer’s instructions using 
appropriate buffers and diluents (supplied with kit). Electrochemical signals from the 
multiplex plates were analysed on SECTOR Imager 6000 instrument to measure 
cytokine levels. Light emission detected by the instrument is directly related to the 
amount of protein in lung homogenate samples. Dependent on the analyte the signal 
ranges from 10 to 1 x 106 counts with negative values equating to background noise 
(Figure 3.6). All MSD plates were performed and analysed on-site at MedImmune, 
Cambridge by myself, Alan Carruthers, Matt Bell and Jayesh Majithiya. 
 
3.7.5 Ly6G-mediated neutrophil depletion 
 
ALZET osmotic mini-pumps were implanted in C57BL6 WT and FPR1KO mice aged 
8-10 weeks old under surgical anaesthesia (induced by isoflurane) allowing systemic 
and continuous agent administration. The principle of the delivery system is based on 
the difference in osmotic pressure between the salt sleeve compartment within the 
mini-pump and the site of implantation in the animal. ALZET 4 week pumps (model 
2004) used for the 21 day bleomycin endpoint dosing animals with a release rate of 
0.25µl/hour. ALZET 7 day pumps (model 1007D) were used for the acute 1 day 
bleomycin endpoint with a release rate of 0.5µl/hour. Anti-Ly6G (2A3) and the rat 
IgG2a control (1A8) antibodies (BioXcell, USA) were used to deplete/maintain PMNs 
at an approximate concentration of 30µg/mouse/day.  
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Figure 3.6: MSD analytes: IL-6, KC, MCP-1, IL-1β and IL-13 standard curves of signal 
strength against concentration (pg/ml). IL-13 signal was too low to be detected to give 
meaningful signal (<100). Standard curves were used to interpolate cytokine 
concentrations (pg/ml) from electrochemical signal readings.  
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3.7.6 Chimera bone marrow immune cell transplantation 
 
Experiment consisted of 4 distinct groups:  
(1) WT recipient mice with WT donor bone marrow  
(2) KO recipient mice with WT donor bone marrow 
(3) WT recipient mice with KO donor bone marrow  
(4) KO recipient mice with KO donor bone marrow 
Donor mice were all female. All recipient mice (40 wildtype and 35 fpr knockout) were 
irradiated at 6.8Sv, for 6 minutes per 2 cages (carried out by Rachel Howarth). Machine 
required a long warm-up time, with the potential for miscalibration which could have 
affected overall experiment. Leg bones were dissected off donor mice and washed in 
isotonic 1% FCS PBS. Muscle/fat was trimmed off femurs/tibias and flushed with 19G 
needle with 1% FCS to generate bone marrow cell suspensions. Cell suspensions 
were all filtered through 100µm cell strainer to remove any debris. All tubes were then 
centrifuged at 400xg for 4 minutes. Pooled donor cell populations of WT and KO bone 
marrow were then centrifuged and resuspended in 5ml 1% PBS. A Red blood cell 
(RBC) lysis step was included to remove erythrocytes. Samples were resuspended in 
ACK (Ammonium-Chloride-Potassium) Lysing Buffer, 5ml for 2 minutes. Tubes were 
filled to 50ml with 1% FCS PBS to stop cell lysis and cell count was subsequently 
performed by an automatic EVE cell counter (NanoEntek™). 10µl cell suspension and 
10µl Tryphan Blue were mixed together and added to a disposable slide. Cell 
suspensions were analysed on Eve cell counter using Tryphan Blue setting to 
determine viability. 
Cell counts were as follows: WT pooled suspensions, 6.6 x 106 live cells/ml (81% 
viability) and KO pooled suspensions, 7.7 x 106 live cells/ml (87% viability). A total of 
330 x 106 WT bone marrow cells in 50ml were then resuspended in 6.6ml sterile saline 
for a concentration of 50 x 106 per ml. A total of 385 x 106 KO bone marrow cells were 
then resuspended in 7.7ml sterile saline for a concentration of 50 x 106 per ml. 1 x 107 
cells were then injected intravenously (IV) in a 100µl volume through tail vein. All 
intravenous injections carried out by Saimir Luli, Gillian Patterson and Jacqueline 
Wilson. Following re-constitution of the immune system for 6-7 weeks mice were 
treated with bleomycin/saline as previously described. 
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3.7.7 Carbon-tetrachloride (CCl4) liver fibrosis model 
3.7.7.1 Acute liver injury and fibrogenesis 
 
Wild-type (WT) C57BL6 and FPR1KO male mice were provided by Comparative 
Biology Centre (CBC, Newcastle University) and MedImmune (Cambridge, UK). Single 
intraperitoneal (i.p.) injection of carbon tetrachloride (CCl4) at a dose of 2 µl (CCl4: 
olive oil, 1:1 [v:v])/g body weight was administered for 24, 48, and 72 hours to 8–10 
week old male littermates. For statistical significance and to generate sufficient power 
for each time point 4-5 animals were used per treatment group. 
 
3.7.7.2 Chronic liver injury and fibrogenesis 
 
8–10 week old male FPR1KO and WT C57BL6 mice were injected with CCl4 
intraperitoneal (i.p.) biweekly at a dose of 2 µl (CCl4:olive oil, 1:3, [v:v])/g body weight 
during 8 weeks. For the chronic CCl4 model, animals were culled 1 day (peak) after 
the last CCl4 injection. For statistical significance and to generate sufficient power for 
each time point at least 5 animals were used per treatment group. 
Upon sacrifice of animals subjected to CCl4 treatment the liver was harvested as 
depicted in Figure 3.7 with different RNA and protein tissue originating from the large 
lobe and all three lobes comprising tissue fixed for histology. 
 
3.7.7.3 Serum damage enzyme aminotransferase level  
 
Following culling, animals were exsanguinated and blood was collect in 1.5ml 
Eppendorf tubes. Prior to centrifugation tubes were incubated at room temperature for 
20 minutes. After this period blood samples were centrifuged at 4500 x g for 10 minutes 
at room temperature. This will separate cellular debris from serum which is then 
decanted to a new Eppendorf for subsequent storage at -80°C. For analysis of 
aminotransferase levels in serum samples were defrosted and diluted 1:4 prior to 
despatch to NHS Biochemistry RVI Department. All samples processed by Susan 
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Douglas (NHS Biochemistry) for Alanine Transaminase (ALT) and Aspartate 
Aminotransferase (AST) content, two common liver damage enzymes. 
 
 
 
 
Figure 3.7: Liver histology sampling upon sacrifice of animals following acute or 
chronic CCl4 model. Diagram shows areas of median, right and left large lobes sampled 
for fixation in formalin and processing for histological staining. Red and blue squares 
depict small areas of large lobe tissue to be harvested for RNA and protein. 
 
 
 
 
3.7.8 Unilateral ureter obstruction (UUO) kidney fibrosis model 
 
Surgical procedure carried out according to aseptic protocol approved by Comparative 
Biology Centre (CBC) and Animal Scientific guidelines implemented by the home 
office.  Following anaesthesia by isoflurane plus oxygen the left ureter was exposed 
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via a surgical incision within shaved area on flank. For the UUO procedure, the left 
kidney was obstructed by ligation of the corresponding ureter with 5-0 nylon suture 
sterile wire. The incision site was then sutured and glued shut. Right ureters were left 
without ligating sutures acting as contralateral right kidney controls for each animal. 
Female mice from WT and FPR1KO litters underwent surgery. UUO model was 
examined at 5 day (n=7 WT; n=7 KO) and 12 day (n=6 WT; n=7 KO) endpoints to 
evaluate cortical immune cell infiltration and renal fibrosis respectively. Previous UUO 
studies carried out in-house used similar numbers for a significant difference to be 
observed between right kidney controls and left ligated kidneys. All surgeries carried 
out by Christopher Fox (Research Assistant) with myself and Rachel Howarth 
(Technician) assisting. 
 
3.7.9  Subcutaneous bleomycin skin/lung fibrosis model 
 
WT and FPR1KO mice were shaved, scruffed and 100µl 0.5mg/ml bleomycin/saline 
(Apollo Scientific) administered via subcutaneous injections to an area on the back 
approximately 1cm2. Daily injections continued for 4 weeks at which point animals were 
sacrificed and skin/lung samples were harvested for RNA, protein and histology. 
Numbers used for this experiment were derived on a purely exploratory basis with at 
least n=5 per saline group and n=7 per bleomycin group to account for variability in 
response. 
 
3.7.10 Statistical analysis 
Data from experiments was analysed using Prism 5.0 (GraphPad, USA) statistical 
software and expressed as mean± standard error of the mean (SEM). Statistical 
significance was analysed using Prism and compared by Student t-tests or by one way 
Analysis of Variance (ANOVA) with Bonferroni’s post-hoc correction. Significance 
denoted by p value; >0.05 (ns), <0.05 (*), <0.01 (**), <0.0001 (***). 
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4 Role of FPR1 in bleomycin-mediated pulmonary fibrosis 
4.1 Models of lung disease 
Development of lung disease models, whether in vivo or in vitro has played a major 
role in furthering our understanding of these conditions and their complex aetiologies 
& pathogenesis. Mice and human respiratory systems are luckily quite similar and the 
methods available for inducing pulmonary fibrosis are relatively easy to do.  
Despite similarities between mice and humans there are significant differences in their 
pulmonary anatomical features including airway branching and lung epithelium. Murine 
respiratory system is composed of 3 main areas: tracheobronchial, intralobular 
bronchioles and bronchioalveolar junctional duct. In the bronchial areas columnar 
epithelial types consist of basal, ciliated and Clara cells. Bronchioles branching from 
the bronchi contain ciliated, Clara and mucus-producing Goblet cells, the latter in low 
numbers in mice colonies. Alveolar airspaces are composed of type I and II epithelial 
cells (Rock and Hogan, 2011).  
Both mouse and human present efficient gas exchange surfaces in the form of their 
alveolar air spaces but the architecture has key differences despite shared features. In 
the human lung, inner tracheal width is approximately 12 mm with numerous 
intrapulmonary divisions with the both characteristics greatly increased than that of 
rodent species. Pseudostratified epithelial layers are composed of basal 
undifferentiated progenitor cells, ciliated and mucus-producing cells. One key feature 
is minimal proportion of secretory goblet cells in research mice species compared to 
humans (Rock, Randell and Hogan, 2010).  
For murine species the trachea inner diameter spans roughly 1.5 mm with basal, 
ciliated, secretory and neuroendocrine epithelial positioned along its length. With as 
little as 6-8 divisions of the airway branches in a tree-like manner the mouse lung 
expands its surface area with bronchioles leading directly to alveolar airspaces.  A 
clear distinction in these branchings is the expression of SCGB1A1, a secretoglobin, 
the marker of a true Clara cell (luminal in mice, cuboidal in humans). With a clear lack 
this marker in human Clara cells their identity is not definitive (Rock, Randell and 
Hogan, 2010). Due to these differences in cellular composition and architecture airway 
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remodelling following injury may differ between these two species therefore as with the 
in vivo models the data generated must be evaluated accordingly. 
The main question for each methodology is whether the model is translatable to the 
human disease due to the diverse nature of interstitial lung diseases (ILDs). COPD, 
IPF and emphysema are three of the most debilitating disorders but each present in 
different ways and have had vast amounts of research performed in their respective 
areas distinguishing them. The nature of Idiopathic Pulmonary Fibrosis (IPF) has 
resulted in the question being asked: are the current in vivo models available for 
inducing pulmonary fibrosis a valid tool when looking for therapeutic interventions in 
human disease?  
None of the current models of lung fibrosis directly reproduce all IPF features in mice 
as observed in the human condition (Mutsaers et al., 2004). Of tools used in research, 
murine models have presented themselves as highly translatable compared to in vitro 
methods. Cell culture-based methods including gene knockdowns, microarrays and 
co-culture experiments have limited value as cellular responses in developed assays 
may be completely different to the cellular responses within the microenvironment. 
Cells grown on plastic are phenotypically different as opposed to when the different 
cell types are organised in the tissue, with external factors affecting growth, 
proliferation and ultimately cellular processes such as migration, differentiation, 
apoptosis and extracellular matrix (ECM) production. Primary cell culture is an 
inherently flawed process hence the development of more representative co-culture 
systems but this is made difficult due to the limit on passage number of cell populations. 
Generally, it is regarded that primary cells should be used prior to their 4th passage as 
past this point they tend to lose their physiological relevance as a result of changing 
their proliferative state (ATCC Cell culture guidelines; Shay & Wright, 2000). 
Pulmonary fibrosis murine models are designed on the injury-based induction of 
fibrosis where damage-causing agent triggers inflammation, fibrogenesis and repair. 
Unchecked the process leads to an uncontrolled fibrotic response with replacement of 
functional tissue with useless scar formation. Depending on the drug action and route 
of administration the degree of reflection to the human disease will vary but the models 
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are commonly used as they highlight/display the main features of the pulmonary fibrotic 
phenotype (Mutsaers et al., 2004; Moeller et al., 2008; Moeller et al., 2006). 
 
4.1.1 Modelling pulmonary fibrosis in rodents  
In the course of pulmonary fibrosis research many different agents have been utilised 
to model lung fibrosis to determine the effect of anti-fibrotic agents and role of genetic 
defects on the overall process. Most of these studies have enabled the progression of 
disease within a few weeks as opposed to years in humans. Methods that have proven 
effective in in vivo research are fluorescein isothiocyanate (FITC), phorbol myristate 
acetate (PMA), silica, Transforming Growth Factor (TGF-β) adenoviral-mediated gene 
transfer, Th2-mediated responses, irradiation and bleomycin-induced injury (Moeller et 
al., 2006; 2008). TGF-β is heavily implicated in the fibrogenic process with release of 
this cytokine triggering pro-fibrotic events and hence is natural choice for inducing lung 
fibrosis. Sime et al. (1997) demonstrated that adenoviral-mediated TGF-β1 gene 
transfer led to a fibrotic phenotype via induction of over-expression. Compared to other 
models it is more representative of the relentless, dysregulated progression of IPF as 
it is does not require an injury phase to induce fibrosis (Moeller et al., 2006, Wilson et 
al., 2010). 
 
4.1.2 FITC-induced fibrosis  
FITC-induced lung fibrosis visualised the degree of fibrosis as a result of fluorescent 
label (Roberts et al., 1995). The intratracheal instillation triggers an immune response 
leading to infiltration and a fibrotic response (Moore and Hogaboam, 2008). This 
persistent fibrotic phenotype (up to 6 months) has allowed the study of novel anti-
fibrotic agents and viral exacerbations which is not possible in other studies (Moore 
and Hogaboam, 2008; Fisher et al., 2005; Vanella et al., 2007).  
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4.1.3 Bleomycin-induced injury fibrosis  
Bleomycin-induced pulmonary fibrosis is probably the best characterised and most 
used model to investigate IPF. Bleomycin, a successful chemotherapeutic drug, was 
found to induce pulmonary fibrosis in 20% of cancer patients treated (Limper, 2004; 
Moeller et al., 2008) therefore it appeared a natural candidate for the modelling fibrosis 
in rodents. Originally isolated from Streptomyces verticillis by Umezawa et al. (1966) 
this antibiotic family consists of two main forms: A2 and B2 with potent antitumour 
activity (Hay et al., 1991). This drug remains a key part of chemotherapy courses 
particularly in the treatment of tumours and Hodgkin’s lymphoma. The structure of this 
small peptide (Figure 4.1)  is specifically linked to its DNA damage function with its 
DNA-binding region and iron-binding region for cofactor complex formation, with 
activity limited to the cell cycle stage particularly G2 and M phases (Reinhert et al., 
2013). This reproducible method promotes the development of lung fibrosis which has 
phenotype that shares common features with the human condition. With both FITC and 
bleomycin-mediated routes there is a distinct lack of fibroblastic foci development 
(Moore and Hogaboam, 2008). The drug administration can be via a myriad of different 
methods: intratracheal, intranasal, subcutaneous or oropharyngeal and is responsible 
for DNA-damage triggering fibrogenesis (Chua et al., 2005). Bleomycin causes double-
strand targeting, among other things, telemetric DNA sequences (Nguyen and Murray, 
2012).  This widespread damage triggers cell cycle dysfunction, accumulation of 
reactive oxygen species (ROS) and decrease in NAD (nicotinamide adenine-
dinucleotide) and ATP (Grande et al., 1998). Effects in an in vitro setting are well 
characterised but the tissue pathogenesis of this small molecule’s actions are only 
partially elucidated.  This in turn elicits an acute inflammatory response followed by a 
fibrotic phase between 14-28 days in the murine model. From the cellular dysfunction 
caused by the build-up of ROS pulmonary epithelium undergoes dramatic changes 
with mass signalling events, damage and cell death. Release of cellular contents and 
vascular leakage triggers the upregulation of pro-inflammatory cytokines and 
chemokines in an acute immune response. Mass infiltration of macrophages, 
neutrophils and lymphocytes into the lung occurs as a result of the injury localised to 
the pulmonary setting is essentially a wound-healing response but due to the extent of 
the damage a fibrotic phenotype results (Scotton and Chambers, 2010). One key facet 
of the bleomycin-induced pulmonary fibrosis model is the acute injury dependence. 
Oxidative damage mediated by bleomycin and the bleomycin-induced pneumonitis 
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(BIP) pulmonary toxicity has common effects in humans and mice (Reinert et al., 2013). 
Timetabling the initial inflammatory stages in terms of the peak responses of the 
immune cells is difficult with the ‘acute’ phase spanning up to 9 days. Initially the 
bronchiolocentric injury caused by intratracheal instillation leads to perivascular 
oedema, vascular dysfunction and alveolar wall thickening (Hay et al., 2013). 
Characterisation of the inflammatory infiltrate has been done previously in hamsters 
by Chandler et al. (1983) with significant 8-fold and 10-fold increases with neutrophil 
and macrophage cell populations.  
This in turn draws into question the viability of this model when investigating lung 
fibrosis in humans but murine model does in fact present similarly to the human 
disease apart from the initial stages. Structural effects in the model correlate between 
humans and rodents thus the pattern of fibrosis matches. Cellular changes brought on 
by bleomycin administration lead to alveolar macrophage activation, hyaluronan 
synthesis, apoptosis induced by intracellular HSPs synthesis inhibition and 
upregulation of extracellular matrix genes including collagen Type I, III and VI. The 
injury causes the formation of oedema as fluid accumulates in the interstitial tissue 
which is lethal is left unchecked. 
Typically the fibrotic response takes hold after 10 days resolving the damage and 
vascular leakage by scar tissue generation by hyper-proliferation of fibroblasts and 
excessive collagen deposition. The resolution of the inflammation comes at a heavy 
price with alveolar space obliteration and reduced lung oxygen-carbon dioxide 
exchange activity (Grande et al., 1998). 
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Figure 4.1: Bleomycin glycopeptide chemical structure showing all the functional 
components required to induce DNA-damage and acute lung injury which leads to 
inflammatory then fibrotic phases. Three principal features of bleomycin A2 include a 
metal-binding domain, a DNA-binding domain and a carbohydrate domain. Adapted 
from atdbio nucleic acid-drug interactions; http://www.atdbio.com/content/16/Nucleic-
acid-drug-interactions#figure-bleomycin)  
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4.2 Characterisation of Bleomycin-induced acute injury pulmonary fibrosis in 
C57Bl6 WT and FPR1 KO mice at inflammatory and fibrotic phases  
4.2.1 Hypothesis 
The genetic ablation of FPR1 will result in a depleted pulmonary response to 
bleomycin-mediated injury both in an inflammatory and fibrotic fashion. 
4.2.2 Rationale 
Due to this receptor’s characterised role in the ligation of chemoattractant and 
migration of immune cells towards injury sites the bleomycin fibrosis model presents 
an opportunity to investigate both inflammatory and fibrotic effects when the 
expression of this receptor is nullified in knockout mice. According to the Figure 4.2 
following administration of bleomycin sulphate via the intratracheal (i.t.) route a 
targeted bronchiolocentric injury will result leading to an acute inflammatory response 
in the first week post i.t. After a chronic wound-healing response to resolve the 
widespread damage (induced by the drug) fibrosis will begin to develop after 
approximately 14 days. 3 weeks after the initial injury established lung fibrosis should 
be evident with increased fibrotic markers and loss of functional airspaces when used 
routinely by other research groups.  
Pulmonary fibrosis induced by bleomycin in FPR1KO and C57BL6 mice (aged 6-8 
weeks) was used to model IPF to ascertain effect of FPR1-deficiency at day 5 
(inflammatory phase) and day 21 (fibrotic phase) endpoints respectively.  
 
Figure 4.2: Schematic of bleomycin-induced pulmonary fibrosis model detailing the 
two distinct phases: acute inflammatory and fibrosis development beginning with 30µl 
dose of saline or 0.007U Bleomycin Sulphate. 
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4.2.3 Differences in weight gain/loss over 21 day time course post-bleomycin 
instillation 
The bleomycin-induced pulmonary fibrosis model is traditionally accompanied by a 
significant weight loss over by the time the fibrotic phase is reached (El-Medany et al., 
2005). WT bleomycin-treated mice lose up to 15% weight over the course of the 
experiment while the knockout mice maintain a consistent weight during the acute 
phase between 0% and -10%. FPR1KO mice gain weight over time up to 20% (Figure 
4.3).  In two repeat studies the weights recorded over 21 days show that the knockout 
mice are protected from this weight loss seen in wild type bleomycin-treated mice. This 
suggests a potential systemic effect; other fibrosis models should be looked at in other 
organs to determine what effect this promiscuous GPCR family is having. 
 
4.2.4 Immunohistochemistry of inflammatory cellular markers 5 days post 
bleomycin (acute phase) 
Initial bleomycin injury studies undertaken at MedImmune (Cambridge, UK) had lungs 
harvested from animals treated with drug or saline control vehicle. Lobes were taken 
for histology and IHC staining with the remainder of lung tissue prepared for RNA and 
protein isolation by tissue homogenisation. WT and FPR1KO mice were sacrificed 5 
days post-i.t. to ascertain effect of FPR1 deletion on inflammatory phase intrinsic to 
this model’s pathogenesis.  
To identify and quantify the inflammatory infiltrate within the injured tissue IHC was 
employed to stain NIMP+ neutrophils (Figure 4.4), CD68+ monocytes/macrophages 
(Figure 4.5) and CD3+ T cells (Figure 4.6). Upon injury with bleomycin (BLM) WT and 
KO did not elicit a significant response in NIMP+ cells with mean counts of 4.471 
±1.049 S.E.M. and 2 ±0.6945 S.E.M. respectively. Due to variability in the group 
NIMP+ counts there is no clear effect demonstrable by the bleomycin but a trend of 
increased WT neutrophils is displayed in comparison to KO mice (both saline controls 
and BLM injured). Although significance was not reached this may be an indication for 
a general decrease in neutrophil migration on account of the gene knockout (Figure 
4.4). 
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IHC staining for CD68 5 days post-i.t. (Figure 4.5) to quantify macrophage/monocyte 
levels in the lung tissue showed detectable elevations from control to BLM groups. This 
model is characterised by a macrophage involvement in the initial inflammatory phase. 
WT CD68+ cells increased from mean value 9.188 to 17.42 per high power field 
(±3.729 and ±2.108 S.E.M. respectively; p>0.05) but this did not reach significance. 
KO mice demonstrated a BLM macrophage response to an extent with an elevation 
from 2.963 to 9.157 CD68+ cells per field (±1.062 and ±1.854 S.E.M. respectively; 
p>0.05). A significant reduction (p<0.05) was observed between BLM treated WT and 
KO mice potentially indicating an altered migration function due to loss of the 
chemoattractant receptor.  
CD3+ staining for lymphocytes (Figure 4.6) showed no significant differences between 
WT and KO mice but displayed a slight increase upon bleomycin-treatment (means 
45.13 ±8.999 and 43.04 ±4.201 S.E.M. respectively).  
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Figure 4.3: Percentage weight gain/loss post-bleomycin injury over the course of 21 
days. Treatment groups include WT SAL (n=8), KO SAL (n=8), WT BLM (n=9) and KO 
BLM (n=10). SAL and BLEO groups equate to saline controls and bleomycin treated 
mice respectively.  
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Figure 4.4: NIMP IHC counts of bleomycin-treated lungs 5 days post-injury. Relative 
photomicrographs of neutrophils within (a) WT SAL, (b) WT BLM, (c) KO SAL and (d) 
KO BLM lungs with scale bars representing 100µm (x20 magnification). (e) Results are 
expressed as mean positive cells per high power field (hpf) SEM. Day 5 groups were 
as follows: WT SAL, n=4; KO SAL, n=4; WT BLM, n=7; KO BLM, n=7. All P values 
were calculated using a one-way analysis of variance (ANOVA) ns p<0.05. Arrows 
highlight positive cells. 
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Figure 4.5: CD68 IHC counts of bleomycin-treated lungs 5 days post-injury. Relative 
photomicrographs of macrophages within (a) WT SAL, (b) WT BLM, (c) KO SAL and 
(d) KO BLM lungs with scale bars representing 100µm (x20 magnification). (e) Results 
are expressed as mean positive cells per high power field (hpf) SEM. Day 5 groups 
were as follows: WT SAL, n=4; KO SAL, n=4; WT BLM, n=7; KO BLM, n=7. All P values 
were calculated using a one-way analysis of variance (ANOVA) *p<0.05; ns p>0.05. 
Arrows highlight positive cells. 
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Figure 4.6: CD3 IHC counts of bleomycin-treated lungs 5 days post-injury. Relative 
photomicrographs of lymphocytes within (a) WT SAL, (b) WT BLM, (c) KO SAL and (d) 
KO BLM lungs with scale bars representing 100µm (x20 magnification). (e) Results are 
expressed as mean positive cells per high power field (hpf) SEM. Day 5 groups were 
as follows: WT SAL, n=4; KO SAL, n=4; WT BLM, n=7; KO BLM, n=7. All P values 
were calculated using a one-way analysis of variance (ANOVA) ns p<0.05. Arrows 
highlight positive cells. 
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4.2.5 Bronchoalveolar lavage (BAL) evaluation at inflammatory and fibrotic 
phases 
4.2.5.1 Differential cell count 5 and 21 days post-injury 
Analysis of bronchoalveolar lavage (BAL) composition has long been used as a 
measure of the lung’s inflammatory status in human ILD cases and in vivo model 
counterparts. Following BAL fluid retrieval at time of harvesting animals at respective 
endpoints differential cell counts were performed in a blinded fashion on subsequently 
prepared BAL cytospins stained with Wright-Giemsa. Numbers of neutrophils, 
macrophages, lymphocytes and eosinophils were counted and expressed as 
percentages of the total (Figure 4.7). After 5 days (Figure 4.7 (a)) the predominant cell 
type in each group irrespective of genotype or treatment was the macrophage 
accounting for 85.47%, 75.71%, 63.54% and 77.51% in WT saline, KO saline, WT BLM 
and KO BLM groups respectively.  Interestingly there was a dramatic highly significant 
drop of ~20% with bleomycin treatment of WT mice (p<0.0001) compared to that of 
saline treated. KO injured mice demonstrated an increase in macrophage proportion 
(p<0.001). Of particular note at day 5 in BAL counts is that there was a significant 
increase (p<0.05) from control to injured WT mice in % neutrophils identified (means 
of 0.0529 ±0.0301 to 3.042 ±0.9586 respectively). No change in eosinophils or 
lymphocytes were observed (p>0.05) between any of the groups.  
At 21 days the differential cell count (Figure 4.7 (b)) looks remarkably similar to its day 
5 counterpart with the macrophages equating to the major resident cell population in 
the different treatment groups (71.13%, 69.53%, 72.8%, 78.02% WT saline, KO saline, 
WT BLM and KO BLM respectively). WT mice were not affected by bleomycin 
treatment with regards to % macrophage but there was significant increase upon injury 
to KO lungs from saline to BLM (p<0.001). Minimal neutrophils and eosinophils present 
at this endpoint indicating cessation of lung infiltration by immune cells. T cells 
displayed no difference between any of the groups regardless of genotype/treatment 
potentially indicating that they do not have a strong role in this model if taken in hand 
with the modest non-significant increase determined by CD3+ IHC on tissue sections 
(Figure 4.6).  
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Figure 4.7: Differential cell count of bleomycin/saline treated c57bl6 WT and fpr643 
KO mice of BAL cytospins stained with Giemsa. (a) 5 days post-bleomycin injury; (b) 
21 days post-bleomycin injury (D5: WT SAL, n=4; KO SAL, n=4; WT BLM, n=7; KO 
BLM, n=7 and D21: WT SAL, n=5; KO SAL, n=4; WT BLM, n=8; KO BLM, n=10) 
Macrophages (M), neutrophils (N), eosinophils (E) and lymphocytes (L) were counted 
on BAL cytospins in a blinded fashion and percentages were calculated once ~300 
cells were counted. All P values were calculated using a one-way analysis of 
variance (ANOVA) *** p<0.001; ** p<0.01; * p<0.05; ns p>0.05. 
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With this model an increase in inflammatory infiltrate is associated with lung subject to 
injury. The number of BAL leukocytes increased in a significant manner (p<0.001) 
comparing saline control groups to bleomycin-treated at 5 and 21 days post-injury for 
each genotype (Figure 4.8). 21 days post-injury C57Bl6 BAL leukocytes increased 
from a mean of 3.12x105±90466 to 2.747x106±455417 cells with treatment. FPR1KO 
BAL leukocytes increased from a mean of 2.401x105±35724 to 1.834x106±459100 
cells (Figure 4.8 (a)). In terms of total cell counts (cells/ml) at day 5 and day 21 the 
BAL component increased in bleomycin-injured groups. In the acute phase of this 
model the total cell count elevated in WT mice from saline control group (mean 
4.115x105±59644 cells/ml) to 2.62x106±376900 cells/ml 5 days post-injury (p<0.05). 
KO mice demonstrated an increase but not to significance. At 21 days post-BLM injury 
BAL total cell counts were dramatically increased (p<0.0001) from saline controls to 
fibrotic mice in a significant manner. WT BAL reached a total of 6.88x106±5.187x106 
cells/ml and KO BAL total elevated to 5.29x106±2.637x106 cells/ml (Figure 4.8 (b)). 
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Figure 4.8: Characterisation of BAL fluid day 5 and day 21 post-bleomycin instillation 
c57bl6 WT and fpr643 KO mice. (a) Total leukocyte counts in BAL, (b) Total cells in 
BAL, (c) TGF-β1 cytokine secretion levels and (d) Periostin cytokine levels post-
bleomycin injury. Results are expressed as a mean reading (from duplicate wells) 
displaying SEM (D5: WT SAL, n=4; KO SAL, n=4; WT BLM, n=7; KO BLM, n=7 and 
D21: WT SAL, n=5; KO SAL, n=4; WT BLM, n=8; KO BLM, n=10). All P values were 
calculated using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05. 
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4.2.5.2 BAL levels of TGFβ and Periostin in the bleomycin model at 
inflammatory and fibrotic phases 
Bronchoalveolar lavage (BAL) was taken at day 5 and day 21 and the supernatant 
obtained when preparing the cytospins was utilised for the analysis of cytokine levels. 
The total amount of transforming growth factor β1 isoform (TGF-β1) in the BAL of WT 
and KO treated with either saline or bleomycin was measured by ELISA. TGF-β1 is 
heavily implicated in the fibrotic mechanism by driving the differentiation of 
myofibroblasts not just in the chronic lung disease but in other organs such as liver, 
kidney and skin.  
As expected TGF-β1 signal was significantly elevated with bleomycin injury at 5 and 
21 day endpoints (Figure 4.8 (c)). At day 5 levels increased from 53.54±5.74 pg/ml to 
79.11±5.715 pg/ml (p<0.05) comparing WT control and injured mice respectively. KO 
control and injured mice displayed an identical response (p<0.05) to injury with 
cytokine levels rising from 48.13±1.514 pg/ml to 72.05±8.943 pg/ml but no difference 
was observed between WT and KO injured groups. 21 days post treatment cytokine 
signal appears to have dropped with an ablated response evident. Injury to WT causes 
a significant increase (p<0.05) but levels are lower than at 5 day endpoint, clear by 
control mean of 35.15±2.405 pg/ml rising to 56.36±6.731 pg/ml  in BLM-treated mice. 
No significant TGF-β1 cytokine response was evident in KO mice at day 21 with levels 
remaining at basal amounts of 40.98±1.517 pg/ml and 46.99±3.747 pg/ml in saline and 
BLM groups respectively (p>0.05). Perhaps by day 21 TGF-β1 is no longer required to 
potentiate the fibrotic phase and only has its major role at the beginning in fibrogenesis.  
Periostin (OSF-2), another important cytokine with defined roles in pulmonary fibrosis 
was measured in BAL by MSD singleplex (Figure 4.8 (d)). WT periostin levels at day 5 
showed a significant increase from saline to BLM-injured samples rising from 
119.1±12.57 pg/ml to 9063±1139 pg/ml respectively (mean values, p<0.001). Similar 
to the TGF-β1 response at the same endpoint the knockout mice secreted periostin in 
response to BLM-injury increasing from 93.65±10.37 pg/ml in saline controls to 
6518±1085 pg/ml in BLM-treated animals (mean values, p<0.01). Even with a sizable 
variability in cytokine level the WT BLM group the increase with injury was clear and 
there was a significant blunting of the response to bleomycin in the KO group (p<0.01). 
As with the TGF-β1 cytokine response the levels of periostin elevated as the 
pathogenesis of the acute injury model progresses. Comparison of cytokine levels at 
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the different endpoints is not possible but a trend was able to be identified. At day 21 
there was a significant increase in OSF-2 secretion between WT saline and BLM 
groups (mean values of 51.24±13.95 pg/ml to 3369±1189 pg/ml respectively; p<0.01). 
BLM-injury did not produce significant response in the KO-injured mice where only a 
modest increase was determined (mean values of 80.38±8.511 pg/ml to 1222±309.4 
pg/ml respectively). Due to the differing responses by animals of different genotypes 
there is evidence to indicate an ablated response between injured mice groups 
(p<0.05) similar to the response observed at day 5. 
 
4.2.5.3 Chemokine/cytokine secreted levels in lung homogenate of Day 5/ Day 
21 post-saline/bleomycin-treated mice 
As previously described upon harvesting of lung at respective endpoints a whole large 
lobe was homogenised in 1ml isotonic PBS buffer. The resulting homogenate was split 
into two 500µl aliquots for use in hydroxyproline (see subsequent section) and MSD 
cytokine assays. The high sensitivity of the custom-made plates means they are ideal 
for analysing low levels of cytokines present in tissue samples and due to the multi-
spot plates a variety of different analytes can be determined from low volumes of 
sample. MSD technology has been optimised for use of different sample types such 
as cell culture media, serum and complex matrices such as tissue homogenate (MSD, 
USA). The cytokine composition of the lung homogenate at day 5 and 21 endpoints 
(Figure 4.9) enabled characterisation of the microenvironment at basal (saline control) 
and injured (BLM) states.  
Interleukin-1β (IL-1β) cytokine has a well characterised role in pulmonary fibrosis and 
is recognised as key player in pro-inflammatory events hence its inclusion on the MSD 
multiplex plate (Figure 4.9 (a)). In day 5 groups the response equated to a significant 
increase from 7.329±0.842 pg/ml to 26.26±2.718 pg/ml (p<0.01) with injury to wild-type 
c57bl6. FPR1KO mice had no such response to injury with a close to saline control 
level (10.53±1.226 pg/ml) of 14.71±1.829 pg/ml when analysed at 5 days post-i.t. 
(p>0.05). However, between these two BLM-injured groups: WT and KO there was a 
significant dampening of the response (p<0.05). Interestingly, unlike other pro-
inflammatory cytokines the IL-1β production appears to be cumulative over the 
pathogenesis of the bleomycin model from the acute phase to the fibrotic phase. With 
a known role in fibrosis the data showed a significant increase in cytokine level in WT 
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mice to 54.62±9.076 pg/ml at 21 days (p<0.0001) and this was not an unexpected 
result. Other bleomycin studies performed at MedImmune (Cambridge, UK) have 
noted a similar pattern of IL-1β sustained production (data not available). As with day 
5 endpoint KO BLM–injured did not exert a notable response producing almost basal 
level of10.22±0.7351 pg/ml and as with the previous phase this equates to a significant 
(somewhat higher) reduction (p<0.0001).  
Monocyte chemotactic peptide-1 (MCP-1) was another analyte measured by the MSD 
plate (Figure 4.9 (b)). As with KC and IL-6 cytokines the pro-inflammatory response 
was limited to within the acute injury phase, day 5 with only basal readings at 21 days 
(p>0.05). There was a significant level produced in WT mice upon injury, increasing 
from 109.8±8.339 pg/ml dramatically to 857.3±58.86 pg/ml (p<0.0001). KO mice also 
elicited a significant increase of 172.7±7.023 pg/ml to 565.4±71.80 pg/ml comparing 
saline to BLM-injured but to a lesser extent (p<0.01). Comparison of the two injury 
responses with regards to MCP-1 production reveals a clear blunting (p<0.01).  
Chemokine (C-X-C motif) ligand 1 (CXCL1) or Keratinocyte chemoattractant (KC) has 
chemotactic functions promoting the migration of neutrophils and other immune cells. 
With the much smaller quantities of KC secreted than MCP-1 the MSD format is ideal 
(Figure 4.9 (c)). As with the other analytes KC level increased from saline to BLM-injury 
at day 5 (13.28±1.27 pg/ml to 46.65±2.032 pg/ml respectively; p<0.0001) and upon 
ablation of the fpr1 gene the level reduced to 31.64±3.509 pg/ml (p<0.01). KO mice 
exhibited a similar injury reaction to WT counterparts going from 13.08±0.8934 pg/ml 
to 31.64±3.509 pg/ml (p<0.001). 
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Figure 4.9: Chemokine/cytokine secreted levels in lung homogenate of D5/D21 
saline/bleomycin-treated mice. Multiplex ELISA using Mesoscale Discovery (MSD) 
platform analysing (a) Interleukin-1β (IL-1β), (b) Monocyte Chemoattractant Peptide-1 
(MCP-1), (c) KC (chemokine (C-X-C motif) ligand 1; CXCL1) and (d) Interleukin-6 (IL-
6) levels in lung homogenate prepared from right lobes except post-caval. Results are 
expressed as a mean reading (from duplicate wells) SEM (D5: WT SAL, n=4; KO SAL, 
n=4; WT BLM, n=7; KO BLM, n=7 and D21: WT SAL, n=5; KO SAL, n=4; WT BLM, 
n=8; KO BLM, n=10). All P values were calculated using a one-way analysis of 
variance (ANOVA) ns p>0.05, * p<0.05, ** p<0.01, ***p<0.001.    
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Fitting with the trend of the previous pro-inflammatory cytokine response to the 
bleomycin injury Interleukin-6 (IL-6) demonstrated a significant elevation from 
24.85±11.43 pg/ml to 173.0±47.67 pg/ml (p<0.05). KO groups did not elicit a significant 
response as part of the dampened immune response at day 5 evident with loss of a 
functional fpr1 gene in these mice (Figure 4.9 (d)). 
 
4.2.6 Analysis of pulmonary fibrosis phenotype 21 days post-saline/bleomycin 
administration 
4.2.6.1 Hydroxyproline content 
To ascertain the total lung collagen content in control and injured WT and KO mice 
homogenised samples were taken at time of harvesting (Day 5 and 21) for use in a 
hydroxyproline assay (Figure 4.10). Following protein synthesis proline is subject to 
post-translational modification in the form of hydroxylation generating 4-
hydroxyproline, a principal component of collagen. Oxidation of hydroxyproline by 4-
(Dimethylamino) benzaldehyde enables a colorimetric reaction can take place 
proportional to collagen/hydroxyproline content in acid-hydrolysed samples. 
During the acute phase, the main response to the injury is infiltration and recruitment 
of immune cells to the area following by inflammation. This then leads to fibrogenesis 
in which a wound-healing response is initiated. Proliferation and activation of 
myofibroblasts ultimately generates a fibrotic phenotype which is established by day 
21 following bleomycin dosing. At day 5 (acute phase) hydroxyproline content is at 
basal levels in WT and KO groups: 1.767±0.0856 µg and 2.145±0.1294 µg respectively 
(saline-treated); 2.356±0.1388 µg and 2.451±0.1656µg respectively (BLM-injured). 
Evidently, no collagen deposition at this stage in KO groups but in WT groups there 
was a slight increase as fibrogenesis begins post-injury. 
Day 21 hydrolysed samples showed a significant increase in hydroxyproline content in 
WT mice treated with bleomycin (day 0). Levels increased from 2.156±0.09092 µg 
(saline) to 4.105±0.3623 µg (BLM) demonstrating typical collagen deposition 
(p<0.001). As with the blunted cytokine responses at day 5 hydroxyproline content did 
not show any change with loss of the fpr1 gene (day 21) remaining at a basal level 
even with injured mice. KO bleomycin-treated group had a mean value of 2.89±0.207 
µg hence no significant response compared to control group (2.568±0.1914 µg; 
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p>0.05). Comparison of the injury groups at day 21 clearly shows reduced collagen 
deposition with loss of fpr1 expression (p<0.01). 
 
4.2.6.2 Fibrotic markers: Collagen and α-smooth muscle actin deposition 
analysed via IHC (Day 21) 
FFPE tissue sections were stained with PicroSiriusRed (PSR) to highlight collagen I/III 
deposition in order to complement previous lung collagen content data (Figure 4.11 (a-
e)). KO Saline group lungs revealed a raised collagen level compared to WT 
counterparts (p<0.01). Fixed lung tissue demonstrated an increase in percentage area 
(%) comparing saline and BLM WT groups (p<0.001) going from 3.277±0.3124 % to a 
high 14.76±2.449 % respectively. FPR1KO mice did not show this increase in 
percentage area (saline; 6.149±0.8314 % to BLM; 7.863±0.7424 %) with a significantly 
ablated response compared to wild-type counterparts (p<0.01). 
To confirm the reduced collagen deposition with ablation of the fpr1 gene RNA was 
isolated from post-caudal lobe segments and cDNA synthesised. Each sample was 
subsequently tested for pro-collagen 1 mRNA level via real-time PCR (Figure 4.11 (f)). 
WT expression rose from 0.9708±0.2868 to 5.495±1.097 relative fold change in saline 
and BLM groups respectively (p<0.01) with KO expression altering minimally upon 
injury (p>0.05). Pro-collagen 1 mRNA levels were indeed significantly depleted from 
WT BLM group to KO BLM group (2.534±0.4066 relative fold change; p<0.05). 
Alpha-smooth muscle actin (α-SMA) is a marker of activated myofibroblasts, its 
production an indicator of fibrotic tissue. Staining via indirect IHC (Figure 4.12 (a-d)) 
and subsequent densitometry analysis (Figure 4.12 (e)) yielded a percentage area as 
with PSR-stained sections. In WT mice percentage area increased from 2.858±0.3143 
% (saline) to 6.562±0.8606 % (BLM) in a significant manner (p<0.0001). KO mice 
displayed no such effect and the reduction between the respective BLM-injured groups 
(WT above and 3.605±0.2242 %) was significant (p<0.0001).  
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4.2.6.3 Histological evaluation of fibrotic sections 
In this fibrotic phase of the bleomycin model the damage is extensive with destruction 
of alveolar airspaces and loss of functionality. With hyperproliferation of myofibroblasts 
and excessive ECM production scar tissue is generated as demonstrated by Figure 
4.13. H&E immunostaining of FFPE lung sections clearly showed increased injury and 
fibrosis development in WT BLM over KO BLM group. Ideally a comprehensive scoring 
method should have been applied these sections but the criteria involved meant that 
time-limiting factors impinged upon histological evaluation. 
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Figure 4.10: Total lung collagen content ascertained by hydroxyproline colorimetric 
assay. Lung homogenate samples were prepared from right lung lobes and unknown 
quantities were interpolated from standard curve by linear regression. Results are 
expressed as a mean reading (from duplicate wells) SEM (D5: WT SAL, n=4; KO SAL, 
n=4; WT BLM, n=7; KO BLM, n=7 and D21: WT SAL, n=5; KO SAL, n=4; WT BLM, 
n=8; KO BLM, n=10). All significance values were calculated using a one-way analysis 
of variance (ANOVA); ns p>0.05, * p<0.05, ** p<0.01, ***p<0.001. 
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Figure 4.11: Collagen extracellular matrix (ECM) component deposition IHC 
percentage areas. (a) WT SAL, (b) WT BLM, (c) KO SAL and (d) KO BLM PSR stained 
FFPE lung sections were analysed by densitometry to yield (e) percentage area for 
collagen I/III. Percentage area stained of α-smooth muscle actin in FFPE sections via 
IHC. D21: WT SAL, n=5; KO SAL, n=4; WT BLM, n=8; KO BLM, n=10). Scale bars 
represent 100µm. (f) Relative expression of Procollagen 1 mRNA levels determined in 
lung tissue of saline and bleomycin-injured mice. All significance values were 
calculated using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05. 
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Figure 4.12: Extracellular matrix (ECM) producing myofibroblasts determined by 
alpha-smooth muscle actin expression. (a) WT SAL, (b) WT BLM, (c) KO SAL and (d) 
KO BLM IHC indirectly stained FFPE lung sections were analysed by densitometry to 
yield (e) percentage area ±SEM. D21: WT SAL, n=5; KO SAL, n=4; WT BLM, n=8; KO 
BLM, n=10). Scale bars represent 100µm. All significance values were calculated 
using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05. 
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Figure 4.13: H&E histological staining of lungs 21 days post-bleomycin. Day 21 wild-
type C57Bl6 (WT) and FPR1KO (KO) were treated with saline (SAL) and bleomycin 
(BLM): (a) WT SAL, n=5; (b) WT BLM, n=8; (c) KO SAL, n=4; (d) KO BLM, n=10). 
Scale bars represent 100µm. 
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4.2.6.4 Fibrogenic gene expression during fibrotic phase (day 21) 
As fibrogenesis is intrinsic to the wound-healing response and the development of the 
fibrotic phenotype, determining gene expression changes is important. The turnover 
and balance of extracellular matrix (ECM) is a key indicator of fibrosis development as 
skew in a particular direction by upregulation will shift the equilibrium leading to an 
altered ECM and the formation of scar tissue.  
Tissue inhibitor of metalloproteinases (TIMP1) mRNA expression (Figure 4.14 (a)) was 
upregulated in BLM-treated WT mice to 2.804±0.3638 fold change compared to saline 
control group, 0.9285±0.3185 (p<0.05). With loss of FPR functionality in KO mice there 
is marked reduction in TIMP1 message but not significantly. Similarly, MMP2 matrix 
metalloproteinase-2 (MMP-2) exhibited a stark increase in fold change expression from 
1.005±0.3008 basal to 13.89±3.619 compared WT saline controls (p<0.05). As with 
TIMP1 expression, MMP2 was not significantly elevated in KO mice (Figure 4.14 (b)). 
Other extracellular matrix components are deposited during fibrosis apart from 
collagens; elastin and fibronectin (Figure 4.14 (c-d) respectively) equilibrium may also 
be affected by the wound-healing response. Elastin expression was markedly 
increased in WT bleomycin groups compared to controls (mean value of 2.618±0.47 
fold change, p<0.05). As with other fibrogenic genes transcription is consistent in KO 
groups. Fibronectin, another extracellular component also showed a significant up-
regulation (4.539±0.8063 mean fold change) with BLM-injury in WT mice (p<0.01) and 
due to this higher increase above basal it was apparent that the KO-BLM group 
fibronectin gene expression (1.679±0.6882 mean fold change) was reduced compared 
to WT equivalent (p<0.05).   
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Figure 4.14: Real-time mRNA expression levels of fibrogenic markers. (a) TIMP1, (b) 
MMP2, (c) Elastin and (d) Fibronectin at 21 days post-bleomycin. Mean fold change 
calculated relative to wild-type saline control treated mice displaying SEM. D21: WT 
SAL, n=5; KO SAL, n=4; WT BLM, n=8; KO BLM, n=10). All significance P values were 
calculated using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05. 
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4.2.7 Inflammatory infiltrate cell populations in bleomycin-induced pulmonary 
fibrosis 
4.2.7.1 Hypothesis 
Protective effect in FPR1 knockouts is elicited by a change in inflammatory infiltrate 
populations in the bleomycin-mediated pulmonary fibrosis model. 
 
4.2.7.2 Rationale of follow-up study 
Rationale behind this follow-up study to the first day 5 and day 21 endpoints was to 
further investigate the protective effect observed in both phases. An extensive range 
of cellular markers in different panels of fluorescent antibodies was employed to 
determine the nature of the inflammatory cell infiltrate following bleomycin insult in lung 
digests by FACs analyses. 
 
4.2.7.3 Neutrophil activation 
Panel 1 consisted of neutrophil activation markers, CD66a and CD11b (Figure 4.15 (a-
b)). Since there was no clear effect on neutrophil infiltration in tissue via IHC the 
activation status of white blood cells was investigated to gauge if this was affecting the 
inflammatory phase of the model. Once live cells were gated to exclude debris and 
doublets, neutrophils were gated for CD66a and CD11b expression. Cells CD45+ 
(APC-Cy7) and F4/80- (Pacific Blue) were then gated for viability allowing gating for 
Gr-1, a neutrophil-specific marker. Gr-1, myeloid differentiation antigen is also known 
as Ly6G with well characterised expression on bone marrow granulocytes and 
peripheral neutrophils. The bone marrow taken at time of harvest is hence an ideal 
compensation control. For proportions of activated cells the data for this panel is 
expression as percentage of total neutrophils. The FACs analyses showed that a 
majority of the neutrophils were activated expressing CD66a and CD11b. The only 
marked change in the activation status was between WT and KO saline controls at day 
5 dropping from 86.63±2.275 % to 70.58±5.532 % respectively (p<0.05) for CD66a and 
from 88.63±1.121 % to 70.17±4.652 % respectively (p<0.01). This indeed correlates 
with a depletion of Ly6G/Gr-1+ CD45+ leukocytes with the same groups in panel 2 
(Figure 4.16 (b)) from 14.50±1.745 % to 8.96±0.053 % (mean values, p<0.01). For the 
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most part the number of neutrophils infiltrating the lung upon bleomycin injury is 
consistent in terms of proportion and activation status, at least at these endpoints.   
 
4.2.7.4 Neutrophil and eosinophil populations 
Panel 2 had the focus of distinguishing distinct populations of neutrophils (Ly6G+) and 
eosinophils (SigLecF+). These are widely regarded as specific markers making them 
ideal for our purposes. Lung digests were counted and gated excluding debris and 
doublets followed by gating for CD45+ (APC-Cy7), live cells (AmCyan-A) and low 
F4/80 expression (Pacific Blue-A). Cells were then gated according to SigLecF (PE) 
and Ly6G (APC-A) expression as shown in Figure 4.16 (a-b). High SigLecF+ low 
Ly6G+ cells constitute a small proportion of the infiltrate with consistently low levels in 
the lung digests and no change between treatment groups. Percentages appear 
slightly higher at 21 days but with no significant change (p>0.05). 
 
4.2.7.5 Lymphocytes 
A 3rd panel of antibodies was utilised to ascertain any effect on lymphocyte populations 
in the infiltrate (Figure 4.17). As with other panels cells were initially gated to exclude 
debris, doublets and to identify CD45+ (APC-Cy7) leukocytes. After checking for 
viability with AmCyan-A channel, live cells were gated for CD3+ expression (PerCP) 
then highly positive cells separated into two distinct populations of CD4+ (BV421) and 
CD8+ (FITC) T-cells. At day 5 high CD4+ low CD8+ cells remained at a consistent 
basal level (p>0.05) but at day 21 this subset % increased significantly (p<0.001) in 
WT BLM compared to WT saline (mean % of 7.318±0.4252 to 12.41±0.9353 
respectively). With no such response in the KO groups there is a significant reduction 
between BLM-injury groups dropping to 8.792±1.227 % (p<0.05). High CD8+ low 
CD4+ populations showed no difference between any of the groups regardless of 
genotype, treatment or endpoint.  
Cells gated by low CD3+ expression were subsequently gated for B-cells and Natural 
Killer (NK) cells positive for B220 (Pe-Cy7) and NK1.1 (PE)/CD49b  (APC) expression 
respectively. This allowed quantification of all the T cell lineages present in the 
bleomycin-injury model. CD3-NK1.1+CD49b+ subsets showed no response to 
bleomycin at either endpoint with no difference between WT and KO. One point of note 
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was the percentage % total CD45+ cells were at a higher baseline at day 21 than at 
day 5. This is probably due to antibody staining being performed on different days. The 
B-lymphocyte (CD3-B220+) population demonstrated a wide degree of variability in the 
different groups with no discernible trend or statistically significant responses to 
bleomycin or genotype.  
 
4.2.7.6 Macrophage M1/M2 subsets 
As for the macrophage component of the inflammatory infiltrate FACs antibody panels 
were composed of  M1 (classically activated) and M2 (alternatively activated) markers 
to determine the M1/M2 balance in the acute and fibrotic phases of the murine model. 
Macrophages were first gated to exclude debris and doublets then subsequently gated 
for expression of CD45 (APC-Cy7). Live CD45+ cells were selected according to 
MOMA-2 (PE) and CD68 (Percp-Cy5.5) gate to identify the total macrophage 
population. This was followed by viability checking through use of live/dead dye Aqua 
(AmCyan) to determine live cell populations of total macrophages. In the subsequent 
gates M1/M2 phenotype was then distinguished via CCR7 (M1) and CD206 (M2) 
expression. For the high CD206+ cells the selection was preceded by gating for FITC 
A/F (auto-fluorescence) to exclude dendritic cells (DCs) as alveolar resident 
macrophages have a well characterised high A/F. DCs are also selected out by CD68 
but splitting cells according to A/F correlates with CD206 expression. High A/F cells 
are exclusively CD206+ve which may indicate that alveolar macrophages are in fact 
being increased by bleomycin (p<0.05). Upon injury in day 21 groups WT macrophage 
CD206+ cells increased from 11.53±0.6057 % to 34.16±6.877 %. No such ramping up 
of CD206+ cells occurs in KO bleomycin-treated mice (19.12±6.182 %, p<0.05) 
compared to wild-type. These cells are also highly expressing CCR7 hinting at a mixed 
M1/M2 phenotype (Figure 4.18 (a) and (b)). 
Typically, Arginase-1 (Arg-1) is the best characterised M2 marker but the antibodies 
available were not suitable due to issues with their specificity. On account of these 
antibodies being chosen for the macrophage panels the staining strategy had to be 
amended as iNOS and Fizz-1 have intracellular antigens. For their inclusion an extra 
fix and permeabilisation step was required in the staining protocol with other antibodies 
specific for surface antigens. This significantly increased the protocol time but provided 
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the best characterisation of the M1/M2 balance in vivo. Following debris and doublet 
exclusion cells were gated from CD45+ (APC-Cy7) and live/dead status (AmCyan). 
These live CD45+ cells were gated for auto-fluorescence (A/F) then for F4/80+ 
(BV421) CD11b+ (PerCp) to give the population of activated macrophages. Finally for 
this panel CD45+F4/80+CD11b+ macrophages were separated into distinct FIZZ-1+ 
(RPE) and iNOS+ (APC) populations to yield M2 and M1 macrophages (Figure 4.19).  
Inducible nitric oxide synthase (iNOS) expression by macrophages was determined to 
have no response to saline/bleomycin treatment or genotype change in terms of overall 
CD45+ve leukocytes (Figure 4.19 (a)). Interestingly, when cells were gated against 
Fizz-1+ expression a similar pattern as with CD206+ cells were elucidated, shown in 
Figure 4.19 (b). C57Bl6 groups at day 5 showed no response above basal levels but 
at day 21 there was a clear response to BLM with regards to Fizz-1+ percentage 
(p<0.01) increasing from 13.93±0.9681 % to 36.5±6.036 % respectively. This response 
is ablated in KO mice with a significant reduction to 20.37±5.761 % in the BLM group 
compared to WT counterpart (p<0.05).  
The effect is distinct with CD206 but a similar pattern is seen with Fizz-1. Separation 
between this antibody’s positive and negative controls wasn’t perfect but a true signal 
was exhibited by this stain. Probably the best strategy is to be cautious with this result 
but the fact that it correlates the other marker (CD206) supports the theory that M2 
macrophages are reduced in KO mice with bleomycin-induced pulmonary fibrosis 
compared to WT mice. 
If this study was to be repeated a refined panel of antibodies for macrophage staining 
should be used to further elucidate the M1/M2 balance in the inflammatory infiltrate. 
This could be achieved by the use of an 8 colour panel consisting of CD45, Aqua 
(viability dye), F4/80, CD11b, FITC A/F, CD206, iNOS and Fizz-1. For the latter 
secondary antibodies would be used to boost the signal to make it more 
distinguishable. For the neutrophil activation markers CD11b and CD66a the gate 
began when the bone marrow compensation control and the lung digest PMN peaks 
cross. Rather than expression as a percentage of the parent population the data was 
expressed as percentage in relation to total CD45+ve leukocyte live cells. Due to the 
high auto-fluorescence exhibited by macrophages manual gating was required on 
account of the different strategy for gating on live dead cells. One shortcoming of this 
108 
 
study was the fact that both time points: day 5 and day 21 did not occur on the same 
day. Ideally both endpoints should have been done on the same day to prevent 
differences that occur in the processing and staining of lung samples and the bone 
marrow compensation controls. This may account for different baseline levels in saline 
controls between the two endpoints. 
 
 
 
 
 
 
 
 
Figure 4.15: Activated neutrophil populations post-bleomycin injury at day 5/21 
ascertained by multi-colour flow cytometry. (a) CD66a and (b) CD11b expression (see 
appendix A (i)). Results are expressed as a mean % of total Gr1+ve leukocytes (PMN) 
±SEM (D5: WT SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=7 and D21: WT 
SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=5). All p values were calculated 
using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05 and ** p<0.01. 
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Figure 4.16: Neutrophil vs Eosinophil populations post-bleomycin injury at day 5/21 
ascertained by multi-colour flow cytometry. (a) SigLecF and (b) Ly6G expression (see 
appendix A (ii)). Results are expressed as a mean % of total CD45+ve leukocytes 
±SEM (D5: WT SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=7 and D21: WT 
SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=5). All p values were calculated 
using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05 and ** p<0.01. 
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Figure 4.17: Lymphocyte populations post-bleomycin injury at day 5/21 ascertained 
by multi-colour flow cytometry. (a) CD4, (b) CD8, (c) NK1.1 CD49b and (d) B220 
expression (see appendix A (iii)). Results are expressed as a mean % of total CD45+ve 
leukocytes ±SEM (D5: WT SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=7 and 
D21: WT SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=5). All p values were 
calculated using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05 and *** 
p<0.001. 
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Figure 4.18: Macrophage panel 1 post-bleomycin injury at day 5/21 ascertained by 
multi-colour flow cytometry. (a) Moma2 CD68 (b) F4/80 CD11b, (c) High CCR7 High 
CD206 expression (see appendix A (iv)). Results are expressed as a mean % of total 
CD45+ve leukocytes ±SEM (D5: WT SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, 
n=7 and D21: WT SAL, n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=5). All p values 
were calculated using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05. 
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Figure 4.19: Macrophage panel 2 post-bleomycin injury at day 5/21 ascertained by 
multi-colour flow cytometry. (a) iNOS (b) Fizz-1 expression (see appendix A (v)). 
Results are expressed as a mean % of total CD45+ve leukocytes ±SEM (D5: WT SAL, 
n=4; KO SAL, n=6; WT BLM, n=6; KO BLM, n=7 and D21: WT SAL, n=4; KO SAL, 
n=6; WT BLM, n=6; KO BLM, n=5). All p values were calculated using a one-way 
analysis of variance (ANOVA) ns p>0.05, * p<0.05 and ** p<0.01. 
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4.2.8 Ly6G-mediated neutrophil depletion and the bleomycin model 
4.2.8.1 Rationale 
Research regarding the bleomycin model and the mechanism of its pathogenesis in 
the pulmonary setting is still incomplete. Following its induced pneumonitis activity 
upon the acute injury there is a notable influx of inflammatory cells particularly 
neutrophils, macrophages and lymphocytes. Neutrophilia as well as eosinophilia and 
macrophage activation all play roles in IPF-like patterns of fibrosis and perpetuating 
the bleomycin-induced oxidative damage (Grande et al., 1998). No specific study has 
ascertained the effect of neutrophils in this model but depletion-mediated 
investigations of macrophages with agents such as clodronate have proven their 
effects (Murray et al., 2011). The dysfunction of neutrophils has been investigated in 
other organs including the liver. Neutrophils play a pivotal role in inflammatory 
responses but depending on the organ setting fibrosis may not require this. Recent 
research by Moles et al. (2013) has elucidated that neutrophils are redundant in liver 
fibrosis. S100A9 -/- knockouts with severely impaired PMN recruitment have no effect 
on the activation of myofibroblasts and their deposition of collagen and other ECM 
markers. In fact in the liver setting, neutrophils are being shown to have an important 
in the pathogenesis of cancer specifically hepatocellular carcinoma (HCC, Wilson et 
al., 2015). Induction of lung injury is associated with neutrophil influx with other immune 
cells but little evidence is documented to support pathogenesis in the bleomycin model.  
In order to determine the role of neutrophils in this model a mini-pump based strategy 
was employed to deplete PMNs at acute and fibrotic phase time points of 1 and 21 
days respectively. Anti-Ly6G antibody is specifically engineered to target neutrophils 
which express the marker. Unlike other depletion antibodies such as anti-granulocyte 
receptor-1 (Gr-1) mAb (RB6-8C5) anti-Ly6G only binds Ly6G as opposed to Ly6C, a 
marker present on a wider set of different cell populations such as dendritic cells, 
lymphocytes and monocytes (Daley et al., 2008). Being able to specifically knockout 
neutrophils via this strategy is important in determining their effect in this acute injury-
driven model. As for the implantation of the antibody via a mini-pump system, this 
different from many cases in the literature where repeated intraperitoneal (i.p.) 
injections are common place (Daley et al., 2008; Moles et al., 2013). Regardless of the 
endpoint used mini-pumps were surgically installed two days prior to drug/saline 
instillation. The rationale behind this was to deplete the neutrophils in the animal before 
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the initial acute phase following the BLM i.t. while allowing enough time for any viable 
neutrophils at the time of the depletion regimen to complete their circulatory life span. 
Our two days of neutrophil depletion was essentially overkill to make sure no 
neutrophils were present either in the blood or in the lung environment. Studies 
investigating neutrophil dynamics and trafficking in the SPECT-CT imaging of PMN 
(radiolabelled) trafficking of bone marrow neutrophils (1011) allowed quantification of 
the marginated and circulating pools as they move through the lung showing that 
circulating neutrophils have a 10 hours lifespan (Farahi et al., 2012). Therefore, prior 
to the start of my study neutrophils will no longer be viable and no new cell populations 
will be induced as a result of the injury agent.  
Basic features of neutrophils and other immune cells have long been subject to 
assumptions about their functional capabilities and characteristics. Investigations are 
accurately defining key components of this immune cells including cell trafficking 
ability, lifespan and even size. Indeed Guck et al. (2001) determined that the 
approximate diameter of a live, un-manipulated PMN was 5µm by a laser-capture-
based method. Before then quantification of a neutrophil had only been done on fixed 
tissue. Clearly there is still much to learn about this key mediator of the adaptive 
immune response with respect to its own characteristics and role in disease.  
 
4.2.8.2 Hypothesis 
Neutrophils expressing abundant proportions of FPR1 play an integral part in the 
pathogenesis of the bleomycin-mediated pulmonary fibrosis in vivo model. Ly6G-
induced depletion of neutrophils prior to bleomycin injury will attenuate the 
inflammatory and fibrotic responses. 
4.2.8.2.1 Aims 
Elucidation of bleomycin model with regards to its pathogenesis and the role of 
neutrophils were evaluated by systemic administration of control IgG/Ly6G antibody 
via surgically implanted ALZET osmotic mini-pumps. Depletion 2 days prior to 
bleomycin injury at day 0 will remove short-lived Ly6G+ neutrophils and the effect on 
the pathogenesis of the in vivo model will be determined. 
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4.2.8.3 Acute 1 day injury for proof of PMN concept 
4.2.8.3.1 Histology 
As a proof of concept study for the neutrophil depletion an acute time point was used 
to make certain Ly6G+ granulocytes were indeed ablated. FFPE tissue sections 
stained for neutrophils via IHC demonstrated a significant reduction in NIMP+ cells 
from a mean of 54.4±9.5 (IgG-treated mice) to a mere 9.04±2.076 in Ly6G-depleted 
lungs (p<0.001). From basal untreated (U/T) lungs a mean count of 20.82±1.774 cells 
was determined, dramatically increasing with bleomycin instillation even after one day 
(p<0.01) in control IgG-pretreated mice (Figure 4.20). 
CD68+ staining through IHC showed comparable numbers in U/T, IgG BLM and Ly6G 
BLM groups with no significant increase/decrease (p>0.05). Ly6G-mediated depletion 
of neutrophils did not affect macrophage recruitment in the lungs of injured WT mice 
or due to early endpoint the infiltration of CD68+ cells had not reached its peak (Figure 
4.21). 
CD3+ lymphocytes displayed a gradual decrease with bleomycin treated mini-pump 
administered mice (Figure 4.22). In Ly6G+ neutrophil depleted mice injured with BLM 
CD3+ mean counts were significantly reduced to 28.61±3.161 compared to U/T 
(44.6±0.813; p<0.001) and IgG BLM (37.77±1.722; p<0.05) groups. Reduction of 
neutrophils involved in the innate immune response to the acute bleomycin injury 
appeared to directly influence lymphocyte infiltration. 
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Figure 4.20: Neutrophils for neutrophil depletion of acute bleomycin-treated mice. 
Relative photomicrographs of NIMP+ve neutrophils within WT bleomycin IgG/Ly6G 
PMN depleted and untreated control treated lungs (x20 magnification). Groups were 
(a) U/T (n=5), (b) IgG BLM (n=5) and (c) Ly6G BLM (n=5) with scale bars representing 
100µm. Positive cells indicated by arrows. Results are expressed as (d) mean positive 
cells per high power field (hpf) displaying SEM. All P values were calculated using a 
one-way analysis of variance (ANOVA) **p<0.01; ns p<0.05. 
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Figure 4.21: Macrophage counts for neutrophil depletion of acute bleomycin-treated 
mice. Relative photomicrographs of CD68+ve macrophages within WT bleomycin 
IgG/Ly6G PMN depleted and untreated control treated lungs (x20 magnification). 
Groups were (a) U/T (n=5), (b) IgG BLM (n=5) and (c) Ly6G BLM (n=5) with scale bars 
representing 100µm. Positive cells indicated by arrows. Results are expressed as (d) 
mean positive cells per high power field (hpf) displaying SEM. All P values were 
calculated using a one-way analysis of variance (ANOVA) ns p<0.05. 
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Figure 4.22: Lymphocyte counts for neutrophil depletion of acute bleomycin-treated 
mice. Relative photomicrographs of CD3+ve lymphocytes within WT bleomycin 
IgG/Ly6G PMN depleted and untreated control treated lungs (x20 magnification). 
Groups were (a) U/T (n=5), (b) IgG BLM (n=5) and (c) Ly6G BLM (n=5) with scale bars 
representing 100µm. Positive cells indicated by arrows. Results are expressed as (d) 
mean positive cells per high power field (hpf) displaying SEM. All P values were 
calculated using a one-way analysis of variance (ANOVA) **p<0.01; *p<0.05 and ns 
p<0.05. 
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4.2.8.4 BAL cytospin counts of acute bleomycin Ly6G model  
Total BALF cellular count performed by Automatic EVE cell counter (NanoEntek) 
demonstrated clear immune cell infiltration with bleomycin 1 day endpoint. Mean U/T 
total cells/ml increased from 222000±43290 to 417500±23936 (IgG, p<0.01) and 
400000±10000 (Ly6G, p<0.01) showing a clear response (Figure 4.23 (a)).  
Differential cell counts as with others performed showed a heavy proportion of 
macrophages (over 80%). Using the total cell counts above the number of cells per 
millilitre was calculated for U/T, IgG BLM and Ly6G BLM groups (Figure 4.23 (b)). 
Macrophage mean counts increased in BLM-injury groups from untreated groups 
(2.742±0.2397 x105 cells/ml) significantly. Control group instilled with IgG antibody 
developed a normal response to bleomycin doubling their macrophage numbers, 
5.848±1.29 x105 cells/ml (p<0.0001). Due to small numbers there was variability in 
these differential counts perhaps leading to this vast increase. Ly6G-depleted mice 
also showed increased numbers of macrophages, 4.537±0.1146 x105 cells/ml (p<0.05) 
compared to U/T group). Eosinophils and lymphocytes were not counted in great 
numbers from BAL cytospins with no detectable changes with respect to antibody 
treatment or bleomycin. The key difference evident in the BAL counts was the 
upregulation of the neutrophil population from 0.00799±0.004717 x105 cells/ml in U/T 
group to 0.5971±0.3288 x105 cells/ml in control BLM pretreated with IgG antibody 
(p<0.01). No such increase occurred with comparison of U/T and Ly6G-BLM groups 
(0.1309±0.04454 x105 cells/ml) but the responses by the bleomycin-injured groups 
was clearly compromised (p<0.05). As with the tissue infiltration of the BAL within the 
lungs was depleted of neutrophils by mini-pump osmotic transfer of Ly6G antibody.  
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Figure 4.23: Total and differential BAL cell counts from neutrophil depleted 1 day 
bleomycin-treated mice. (a) Total cell count and (b) differential cell count from Ly6G 1 
day bleomycin (BLM) model with untreated (U/T; n=5), isotype (IgG) mini-pump 
bleomycin-treated mice (n=5) and neutrophil-depleted (Ly6G) mini-pump bleomycin-
treated mice (n=5). Data represented by cells/ml±SEM. All P values were calculated 
using a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05, ** p<0.01, 
***p<0.001. 
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4.2.8.5 Gene expression of inflammatory markers with Ly6G-treated acute 
bleomycin-injured animals 
mRNA gene expression levels of different cytokines are evaluated to assess effect of 
depletion treatment (Figure 4.24). S100A9, a myeloid cell marker was diminished in 
Ly6G antibody treated group relative to IgG bleomycin injured controls. Relative gene 
expression was decreased from a mean fold change of 0.5724±0.169 to 0.1411±0.061 
with Ly6G-mediated neutrophil depletion (p<0.05). IL-6 and MCP-1 mRNA levels were 
similar with both antibody treatments and subsequent bleomycin injuries (p>0.05). IL-
10 expression was amplified in IgG bleomycin group two-fold over that in Ly6G 
bleomycin group but not significantly (p>0.05). KC (murine IL-8 equivalent), an 
inflammatory cytokine, mRNA levels were increased in control IgG group compared to 
neutrophil-depleted mice (p>0.05).  
 
4.2.8.6 Inflammatory cytokine levels in Ly6G/IgG acute bleomycin-injured mice 
as determined by MSD analysis 
Comparison of IL-1β, MCP-1, KC and IL-6 pro-inflammatory cytokines in Ly6G and 
IgG-BLM injured lung homogenate demonstrated no differences (Figure 4.26; p>0.05). 
This pro-inflammatory panel was designed to evaluate key cytokines secreted by 
immune cells upon infiltration of the lung and translocation to sites of acute bleomycin 
injury. Antibody incubation prior to bleomycin administration had no effect on 
production of cytokines at this 24 hour endpoint, perhaps indicating that cytokine 
response does not occur in earnest till day 5 (Figure 4.25). 
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Figure 4.24: Real-time mRNA expression levels of myeloid markers and cytokines in 
acute Ly6G-bleomycin versus IgG controls. (a) S100A9, (b) IL-10, (c) IL-6, (d) KC and 
(e) MCP-1 cytokine/chemokine genes. Groups were as follows U/T (n=5), IgG BLM 
(n=5) and Ly6G BLM (n=5).Mean fold change normalised to GAPDH was calculated 
relative to control IgG treated mice displaying SEM. All P values were calculated using 
unpaired t-tests. ns p>0.05 and * p<0.05. 
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Figure 4.25: Chemokine/cytokine secreted levels in lung homogenate of Ly6G/IgG 
pre-treated mice subject to bleomycin injury. Multiplex ELISA using Mesoscale 
Discovery (MSD) platform analysed (a) Interleukin-1β (IL-1β), (b) Monocyte 
Chemoattractant Peptide-1 (MCP-1), (c) KC (chemokine (C-X-C motif) ligand 1; 
CXCL1) and (d) Interleukin-6 (IL-6) levels in lung homogenate prepared from right 
lobes except post-caval. Results are expressed as a mean reading (from duplicate 
wells) SEM (IgG BLM, n=5; Ly6G BLM, n=5). All P values were calculated using 
unpaired t-tests. ns p>0.05. 
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4.2.8.7 Fibrotic 21 day endpoint preceded by IgG/Ly6G mini-pump installation 
Staining by PSR for collagen I/III deposition in control and neutrophil-depleted mice 
was calculated as percentage area (Figure 4.26). IgG-BLM and Ly6G-BLM groups 
demonstrated a clear reduction in collagen staining (p<0.05) from a mean of 
5.187±1.138 % to 2.072±0.4422 %. Neutrophil depletion as proved by the acute study 
ablated collagen deposition at 21 day endpoint. Alpha-SMA, marker of activated 
myofibroblasts displayed low levels of percentage area staining (Figure 4.27). A minor 
increase was observed in control IgG bleomycin-treated mice from saline levels 
(p>0.05). Ly6G-BLM group (mean percentage of 1.872±0.08675 %) demonstrated 
lower levels of staining compared to IgG-BLM group, 2.993±0.5079 %) but it was non-
significant (p>0.05). 
 
4.2.8.8 Immune cells with neutrophil-depletion of bleomycin-injured mice 
NIMP+ staining via IHC of FFPE sections revealed minimal positive staining with 
approximately 0.5 cells per high power field (Figure 4.28). This fibrotic endpoint would 
have low levels of neutrophils typically as immune cell response to acute injury is long 
completed hence low numbers in control IgG groups. Low levels of NIMP positive cells 
at this endpoint may indicate decreased pump efficiency towards end of study and 
recovery of neutrophil population.  
CD3+ staining of formalin-fixed tissue sections allowed the determination that 
lymphocytes showed no significant changes across antibody treatments or injury 
(Figure 4.29). Numbers increased with neutrophil depletion perhaps indicating a 
downstream effect on lymphocyte recruitment (p>0.05).  
Macrophages were stained by CD68 via IHC illuminating an increase with bleomycin 
treated mice implanted with control IgG antibody to 23.69±3.061 mean cells/field 
(Figure 4.30). With ablation of neutrophils in Ly6G-bleomycin treated group there was 
a significant reduction in macrophage infiltration, 16.04±2.019 cells/field (p<0.05). Only 
so much can be interpreted from this data due to the non-significant response from 
saline to bleomycin groups.  
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Figure 4.26: Collagen deposition in Ly6G-treated bleomycin-injured mice. Relative 
photomicrographs of PSR stained tissue sections of WT bleomycin IgG/Ly6G PMN 
depleted and saline control treated lungs (x20 magnification). (a) IgG Saline (n=4), (b) 
Ly6G Saline (n=4), (c) IgG BLM (n=9) and (d) Ly6G BLM (n=8) sections were analysed 
by densitometry. Results are expressed as (e) mean percentage area (%) per high 
power field (hpf) SEM. Scale bars represent 100µm. All P values were calculated using 
a one-way analysis of variance (ANOVA) ns p>0.05, * p<0.05. 
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Figure 4.27: α-SMA deposition in Ly6G-treated bleomycin-injured mice. Relative 
photomicrographs of α-SMA indirectly stained tissue sections of WT bleomycin 
IgG/Ly6G PMN depleted and saline control treated lungs (x20 magnification). (a) IgG 
Saline (n=4), (b) Ly6G Saline (n=4), (c) IgG BLM (n=9) and (d) Ly6G BLM (n=8) 
sections were analysed by densitometry. Results are expressed as (e) mean 
percentage area (%) per high power field (hpf) SEM. Scale bars represent 100µm. All 
P values were calculated using a one-way analysis of variance (ANOVA) ns p>0.05, * 
p<0.05. 
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Figure 4.28: Neutrophil population in Ly6G-treated bleomycin-injured mice. Relative 
photomicrographs of NIMP indirectly stained tissue sections of WT bleomycin 
IgG/Ly6G PMN depleted and saline control treated lungs (x20 magnification); (a) IgG 
Saline (n=4), (b) Ly6G Saline (n=4), (c) IgG BLM (n=9) and (d) Ly6G BLM (n=8) 
sections were analysed for positive cells. Results are expressed as (e) mean cells/field 
(hpf) ±SEM. Scale bars represent 100µm. All P values were calculated using a one-
way analysis of variance (ANOVA); ns p>0.05. 
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Figure 4.29: Lymphocyte population in Ly6G-treated bleomycin-injured mice. Relative 
photomicrographs of CD3 indirectly stained tissue sections of WT bleomycin IgG/Ly6G 
PMN depleted and saline control treated lungs (x20 magnification); (a) IgG Saline 
(n=4), (b) Ly6G Saline (n=4), (c) IgG BLM (n=9) and (d) Ly6G BLM (n=8) sections were 
analysed for positive cells. Results are expressed as (e) mean cells/field (hpf) ±SEM. 
Scale bars represent 100µm. All P values were calculated using a one-way analysis of 
variance (ANOVA) ns p>0.05. 
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Figure 4.30: Macrophage population in Ly6G-treated bleomycin-injured mice. Relative 
photomicrographs of CD68 indirectly stained tissue sections of WT bleomycin 
IgG/Ly6G PMN depleted and saline control treated lungs (x20 magnification); (a) IgG 
Saline (n=4), (b) Ly6G Saline (n=4), (c) IgG BLM (n=9) and (d) Ly6G BLM (n=8) 
sections were analysed for positive cells.  Results are expressed as (e) mean cells/field 
(hpf) ±SEM. Scale bars represent 100µm. All P values were calculated using a one-
way analysis of variance (ANOVA) ns p>0.05, * p<0.05. 
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4.2.8.9 BAL TGFβ1 cytokine level in IgG/Ly6G pretreated bleomycin-injured 
C57Bl6 mice  
Detectable levels of TGFβ1 at the day 21 endpoint preceded by Ly6G-mediated 
neutrophil depletion were determined by performing a duoset ELISA on BAL 
supernatant (Figure 4.31). Low levels were expected at this later endpoint as the signal 
is elevated during acute inflammation stage of model (Figure 4.9). There was a 
possible reduction in the level of TGFβ1 in the Ly6G-treated bleomycin group 
compared to isotype control-treated mice. TGFβ1 cytokine level increased significantly 
from 43.32±8.419 pg/ml to 68.44±6.445 pg/ml with bleomycin injury (p<0.05). This up-
regulation was not present in Ly6G-treated mice and BLM-injured mice at day 21 
produced a lower level of TGFβ1, mean of 47.37±7.127 pg/ml significantly reduced 
from IgG pre-treated BLM group (p<0.05). Loss of neutrophils appears to be directly 
affecting fibrogenic cytokine secretion. 
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Figure 4.31: TGFβ1 levels (pg/ml) detectable in bronchoalveolar (BAL) fluid in Ly6G 
21 Day bleomycin neutrophil depletion study. Basal levels of TGFβ1 in saline 
IgG/LY6G-treated controls ~60pg/ml. IgG bleomycin-treated group levels increased 
minimally to ~100pg/ml while Ly6G-treated mice demonstrated no increase in analyte. 
Groups were as follows: IgG Saline (n=4), (b) Ly6G Saline (n=4), (c) IgG BLM (n=9) 
and (d) Ly6G BLM (n=8). All P values were calculated using a one-way analysis of 
variance (ANOVA) ns p>0.05; * p<0.05. 
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4.2.8.10 MSD pro-inflammatory cytokine levels in IgG/Ly6G pre-treated 
bleomycin-injured C57Bl6 mice at day 21 
Lung homogenate was prepared from lung lobes as previously with other bleomycin 
endpoints for analysis for multiple pro-inflammatory analytes using an MSD format 
(Figure 4.32). Due to time point assessed cytokine levels were low but still detectable. 
At this day 21 endpoint BLM groups had slightly elevated levels of IL-1β cytokine 
(Figure 4.32 (a)) which increased from 1.83±0.1156 pg/ml to 5.278±0.8865 pg/ml 
(p>0.05) with injury to control IgG antibody mini-pump mice. FPR1KO mice had a 
similar response to injury rising from mean level of 2.321±0.2493 pg/ml to 4.466±1.364 
pg/ml (p>0.05).  
Monocyte chemotactic peptide-1 (MCP-1) was another analyte measured by the MSD 
plate (Figure 4.32 (b)). WT mice, regardless of pre-treatment with IgG/Ly6G antibodies 
(Day -2) and saline/bleomycin dosing at day 0, exhibited consistent levels of MCP-1 in 
their lung homogenates (p>0.05). The absence of MCP-1 cytokine upregulation is 
probably due to the endpoint based in the fibrotic phase in which inflammation is 
completed. 
Chemokine (C-X-C motif) ligand 1 (CXCL1) or Keratinocyte chemoattractant (KC) was 
secreted by mice in this study in low quantities (Figure 4.32 (c)). Apart from one outlier 
in Ly6G BLM group all mice secreted low basal levels of cytokine in each study group 
with no differences determined (p>0.05).  
Interleukin-6 (IL-6) demonstrated a significant elevation from 7.123±2.658 pg/ml to 
22.77±3.02 pg/ml (p<0.01) in control IgG pre-treated mice from saline to bleomycin 
groups respectively. Ly6G pre-treated groups did not elicit a significant response with 
a reduced 11.42±1.973 pg/ml IL-6 level in Ly6G-BLM group compared with IgG-BLM 
control injury group (p<0.05). The secretion of IL-6 is sustained in this study at day 21 
and loss of neutrophils with Ly6G-mediated depletion appeared to directly affect this 
process (Figure 4.32 (d)). 
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Figure 4.32: Inflammatory mediator levels in lung homogenate in Ly6G-neutrophil 
depleted mice harvested at 21 days post-bleomycin. Lung homogenate from IgG 
Saline (n=4), Ly6G Saline (n=4), IgG BLM (n=9) and Ly6G BLM (n=8) groups were 
assayed by MSD. Results are expressed as a mean reading from duplicate wells 
displaying SEM. All P values were calculated using a one-way analysis of variance 
(ANOVA) ** p<0.01; *p<0.05; ns p>0.05. 
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4.2.9 24 hour BLM-injured mice and determination of effect on PMNs at 
response peak 
4.2.9.1 Hypothesis 
At 24 hours post-bleomycin injury the inflammatory response in terms of immune cell 
recruitment to sites of damage will be at its peak. 
4.2.9.2 Aims  
A minimal immune cell profile was demonstrated at day 5 therefore a shorter endpoint 
was used in order to potentially determine a peak response with respect to neutrophils 
and the inflammation phase. 24 hours was used as neutrophils are the first wave of 
the innate immune response so upon treatment with bleomycin these cells will be the 
first to localise to the site of injury and due to their short lived nature. 
 
4.2.9.3  Rationale  
By evaluation of the different immune cells via differential cell counts of BAL cytospins 
and distinct cellular markers: CD68, NIMP and CD3 immunohistochemistry there will 
be evidence as to whether a bleomycin response is occurring after 24 hours post i.t. 
and whether this is greater than at later endpoints within the acute inflammatory phase 
of the bleomycin-injury model.   
 
4.2.9.4 Immunohistochemistry of immune cellular markers in FFPE tissue 
sections 
NIMP+ staining by IHC revealed relatively low numbers of granulocytes at day 1 
(Figure 4.33). Between WT SAL and WT BLM groups a slight increase from a mean 
count of 6.910±1.731 cells/field to 9.725±1.437 cells/field respectively (p>0.05). KO 
control saline group and bleomycin-treated displayed a marked reduction in NIMP+ 
cells compared to wild type mice. KO BLM group had an average count of 
3.212±0.8461 cells/field demonstrating significant reduction compared to bleomycin-
treated WT mice (p<0.01). 
CD68 positive cells were clearly elevated with bleomycin administration in WT mice 
(Figure 4.34). WT SAL group mean count was increased from 6.68±1.834 cells/field to 
15.52±1.157 cells/field with acute injury at day 0 (p<0.001). This response was blunted 
in the KO groups with no significant increase between saline and bleomycin injured 
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mice (p>0.05). In terms of cell population proportion macrophages are the major cell 
type upregulated in the inflammatory infiltrate 24 hours post injury rather neutrophils 
as previously assumed.  
Lymphocyte staining with anti-CD3 (Figure 4.35) showed no difference in the number 
of T-cells per high power field between treatments or genotype (p>0.05). This endpoint 
appears to be premature for T-cell infiltration into the lung microenvironment following 
acute injury. 
 
4.2.9.5 BAL cytospin differential cell counts  
Differential cell counts of cell populations present in BALF were typically predominantly 
macrophages with no difference between groups (Fig 4.36). Macrophage levels 
remained consistent across the different groups exhibiting no change (p>0.05). No 
significant increase or decrease in percentage eosinophils/lymphocytes relative to total 
cell count (cells x105/ml) was calculated. Neutrophils showed no significant change in 
count at this endpoint (p>0.05).  
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Figure 4.33: Neutrophil infiltration of bleomycin-injured lungs 24 hours post i.t. FFPE 
sections were stained indirectly for NIMP via IHC and positive cells per high power field 
were calculated (x20 magnification). (a) WT SAL (n=5), (b) WT BLM (n=12), (c) KO 
SAL (n=4) and (d) KO BLM (n=8) sections were analysed for positive cells. Results are 
expressed as (e) mean cells/field (hpf) ±SEM. Scale bars represent 100µm. Results 
were analysed by one-way ANOVA ** p<0.01. 
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Figure 4.34: Macrophage infiltration of bleomycin-injured lungs 24 hours post i.t. FFPE 
sections were stained indirectly for CD68 via IHC and positive cells per high power 
field were calculated (x20 magnification). (a) WT SAL (n=5), (b) WT BLM (n=12), (c) 
KO SAL (n=4) and (d) KO BLM (n=8) sections were analysed for positive cells. Results 
are expressed as (e) mean cells/field (hpf) ±SEM. Scale bars represent 100µm. 
Results were analysed by one-way ANOVA *** p<0.001. 
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Figure 4.35: Lymphocyte infiltration of bleomycin-injured lungs 24 hours post i.t. FFPE 
sections were stained indirectly for CD3 via IHC and positive cells per high power field 
were calculated (x20 magnification). (a) WT SAL (n=5), (b) WT BLM (n=12), (c) KO 
SAL (n=4) and (d) KO BLM (n=8) were analysed for positive cells. Results are 
expressed as (e) mean cells/field (hpf) ±SEM. Scale bars represent 100µm. Results 
were analysed by one-way ANOVA ns p>0.05. 
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Figure 4.36: Differential cell count of BAL cytospins prepared from 24 hour 
bleomycin/saline treated c57bl6 WT and FPR1 KO mice. Macrophages, neutrophils, 
eosinophils and lymphocytes were counted on BAL cytospins in a blinded fashion and 
percentages were calculated once ~300 cells were counted. Groups were as follows: 
(a) WT SAL (n=5), (b) WT BLM (n=12), (c) KO SAL (n=4) and (d) KO BLM (n=8).  All 
P values were calculated using a one-way analysis of variance (ANOVA) ns p>0.05. 
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4.2.9.6 BAL TGF-β1 level as a measure of injury response 
Total cytokine level (pg/ml) was measured by duoset ELISA (R&D) in BAL samples 
harvested from each animal 24 hours post-i.t. (Figure 4.37). Elevations in level were 
observed in both WT and KO groups from saline to bleomycin treatments but these 
responses were non-significant (p>0.05). At this stage in the inflammatory phase is 
commencing with macrophage infiltration into the injured area starting, during the acute 
phase initiation of fibrogenesis occurs with accumulation of TGF-β1. After 24 hours 
there is not a dramatic increase in fibrogenic cytokine levels suggesting that further 
accumulation is required in order for a significant TGF-β1. 
 
4.2.9.7 Inflammatory cytokine profile determined by multiplex MSD analysis  
As with the other endpoints of 5 and 21 days lung homogenate was prepared from the 
large lobes harvested from mice (WT and KO) treated with saline/bleomycin. Samples 
were run on sensitive MSD plates pre-coated with multiple antibodies for detection of 
multiple analytes: IL-1β, MCP-1, KC and IL-6; a selection of pro-inflammatory cytokines 
known to upregulated with bleomycin injury. As shown in Figure 4.38 the levels of these 
analytes did not change with injury or genotype (p>0.05). Probably by day 5, in which 
a clear response was shown, accumulation of cytokines has occurred due to prolonged 
secretion by infiltrating immune cells which at day 1 are only commencing their 
response to injury. 
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Figure 4.37: TGF-β1 cytokine release 24 hours post—bleomycin injury. Levels of 
TGFβ1 in saline/bleomycin treated WT/KO mice assayed in BAL fluid via an indirect 
ELISA in different groups of mice as follows: WT SAL (n=5), (b) WT BLM (n=12), (c) 
KO SAL (n=4) and (d) KO BLM (n=8). Mean pg/ml was generated from duplicate 
wells±SEM by linear regression against a standard curve. All P values were calculated 
using a one-way analysis of variance (ANOVA) ns p>0.05. 
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Figure 4.38: Chemokine/cytokine secreted levels in lung homogenate of 24 hour 
saline/bleomycin-treated mice. Multiplex ELISA using Mesoscale Discovery (MSD) 
platform analysing (a) Interleukin-1β (IL-1β), (b) Monocyte Chemoattractant Peptide-1 
(MCP-1), (c) KC (chemokine (C-X-C motif) ligand 1; CXCL1) and (d) Interleukin-6 (IL-
6) levels in lung homogenate prepared from right lobes except post-caval. Results are 
expressed as a mean reading (from duplicate wells) SEM (WT SAL, n=4; KO SAL, 
n=4; WT BLM, n=7; KO BLM, n=8). All P values were calculated using a one-way 
analysis of variance (ANOVA) ns p>0.05.  
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4.2.9.8 Oropharyngeal administration as an alternative method to bleomycin 
treatment 
For reproduction of the model carried out at MedImmune (Cambridge) a different 
method of delivery was investigated. The oropharyngeal (OA) route has been shown 
previously in lung injury models to be a viable way of administrating drug agents. To 
determine which the optimal method for bleomycin administration was routes were 
researched. Among other drug the OA method has been utilised previously for 
bleomycin instillation (Lakatos et al., 2006). Consequently, the OA route was 
investigated at time points of 24, 48 and 72 hours were utilised to gauge initial acute 
injury and the inflammatory profile associated with this model. Evaluation of these early 
time points would give the best indication of an inflammatory response to the bleomycin 
injury if delivery was successfully achieved. 
 
4.2.9.8.1 Differential cell counts at acute time points for assessment of neutrophilia 
Determination of bronchoalveolar lavage (BAL) immune cell profiles (Figure 4.39) was 
key in identifying the success of this model. In all three time points macrophages were 
the major component of the BALF cellular profile, all above 90% of the total cell count. 
Neutrophils were elevated in (a) 24 hours post-bleomycin administration to 
approximately 5.634% (p<0.05) which subsequently reduced (b) 48 hours post-
bleomycin (2.37%; p>0.05) and reduced to 0% after (c) 72 hours. The other immune 
cells (eosinophils and lymphocytes) showed minimal responsiveness to control saline 
and bleomycin treatment via this method. 
 
4.2.9.8.2 Gene expression at acute bleomycin endpoints 
Gene expression was assessed at 24, 48 and 72 hours post-bleomycin instillation via 
quantitative real-time PCR (Figure 4.40). S100A9 expression (a) increased at 24 hours 
post-instillation from a mean fold change 2.909 to 7.848 comparing saline control and 
bleomycin-treated mice respectively. By 48 hours and 72 hours expression of this 
myeloid marker decreased to baseline levels (0.9172 and 1.642 mean fold change 
respectively) suggesting a peak response within 24 hours. Interleukin-6 (IL-6) cytokine 
mRNA levels (b) at the respective endpoints demonstrated increases at 24 hours 
(1.123 to 6.971 mean fold change), 48 hours (0.5326 to 7.439 mean fold change) and 
72 hours (6.767 to 20.33 mean fold change) when comparing saline and bleomycin-
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treated mice. Results indicate a cumulative secretory effect as levels appear to 
increase over the 3 days. KC, mouse equivalent of human IL-8 (c) shows no increase 
at 24 or 48 hours post-bleomycin instillation between control or bleomycin groups. At 
72 hours KC levels increase in both controls and bleomycin groups with no significant 
difference.  
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Figure 4.39: BAL cytospin differential cell counts at acute timepoints post-OA 
saline/bleomycin treatment. (a) 24 hours (n=3), (b) 48 hours (n=3) and (c) 72 hours 
(n=3) post injury/control treatment total macrophages (M), neutrophils (N), eosinophils 
(E) and lymphocytes (L) were counted. Percentage of total cells (approximately 300 
cells and mean values for each group were calculated. For statistical significance 
unpaired t-tests were performed. ns p>0.05. 
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Figure 4.40: Gene expression of pro-inflammatory markers at 24, 48 and 72 hours 
post-OA saline/bleomycin treatment. mRNA levels of (a) S100A9, (b) IL-6 and (c) KC 
were determined by real-time PCR with GAPDH used as a housekeeping gene and 
expression normalised to control group (saline). n=3 per group at each time point. For 
statistical significance a one-way analysis of variance (ANOVA) was performed. ns, 
p>0.05. 
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4.2.10 Bone marrow chimera generation to determine cells responsible for FPR 
knockout protective effect 
4.2.10.1 Hypothesis 
Cells of non-phagocyte origin have an effect on the pathogenesis of bleomycin-
mediated pulmonary fibrosis as well as neutrophils and other immune cells. 
4.2.10.2 Aims  
 
Utilisation of a bone marrow chimera model was employed to determine the role of 
architectural cells such as epithelium and fibroblasts as well as bone-marrow derived 
immune cells in the bleomycin-induced pulmonary fibrosis model. Another aim of this 
study was to find out whether the protective effect found at 21 days post-bleomycin 
treatment is conserved in bone marrow-reconstituted mice.  
After donor harvesting irradiated recipient mice were IV injected with 1 x 107 cells per 
bone marrow suspension corresponding to the following groups: 
Group 1 - WT recipient – WT donor bone marrow                                                                     
Group 2 - WT recipient – KO donor bone marrow                                                 
Group 3 - KO recipient – WT donor marrow                                                            
Group 4 - KO recipient – KO donor marrow 
 
4.2.10.3 Rationale 
Irradiation of the bone-marrow derived component of the immune system was 
necessary to build upon previous studies which demonstrated a protective effect 
against lung fibrosis with ablation of mfpr1 gene. FACs analysis of the inflammatory 
infiltrate showed little change in difference cell populations, apart from macrophage 
M1/M2 balance, potentially indicating a role for FPR1 expression on architectural cells 
in the bleomycin model.  
As the principal location for stem cells production bone marrow is the hub for controlling 
the immune system. Haematopoiesis is the process by which immune cells are 
differentiated from haematopoietic stem cells to form distinct cell populations.  Two 
distinct lineages are derived from these precursor cells: lymphoid and myeloid which 
subsequently differentiate into T-cell subsets: CD4, CD8, NK cells, B-lymphocytes and 
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myeloid populations such as neutrophils, macrophages, eosinophils, basophils, 
platelets and erythrocytes respectively.  
Neutrophils are short-lived, hence their rapid circulation and clearance. Mature 
neutrophils are divided into two main subsets upon granulopoiesis from myeloid 
granulocyte precursors: circulating (1-2%) and marginated. This enables an efficient 
innate immune system response to damage and infection and due to neutrophil high 
turnover rate (up to 211 cells per 24 hours in healthy adults) adaptive immunity is rapidly 
attained. The bone marrow is in essence the site of birth and death of the neutrophil 
with a majority of mobilisation occurring there as well clearance (Zhao et al., 2011; 
Casanova et al., 2013; Manz and Boettcher, 2014). The nature of neutrophils and their 
production has proved an integral part of the project’s bleomycin investigations due to 
their role in both innate and adaptive immune responses which are intrinsically linked 
to this model.  
 
4.2.10.4 Observations throughout chimera experiment including 
reconstitution and bleomycin administration 
Over the course of the bone marrow depletion and reconstitution with donor cells from 
either wild type or knockout mice a number of observations were recorded over the 7 
week period before bleomycin treatment. Donor leg bones yielded a high number of 
cells which was optimal for the experiment as this made successful reconstitution of 
the recipient’s bone marrow significantly more probable. Irradiated mice typically 
display several signs of sickness as the procedure is severe affecting their bodies in a 
widespread, systemic fashion. During reconstitution the immune system is essentially 
immunocompromised/deficient so mice were supplied with antibiotic-treated water 
(Baytril) throughout to reduce/eliminate chances of opportunistic infection. The 
procedure is also typically associated with weight loss but some of the chimeric groups 
lost up to 20% (within project licence parameters), possibly due to complicating factors 
arising from the irradiation procedure. 
Following bone marrow transplantation all mice lost weight with most recovering over 
time. However, over the course of the re-formatting of the immune system multiple 
mice were found dead or required culling due to internal bleeding and some instances 
of severe bleeding subcutaneously. Apparently, a number of mice developed clotting 
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defects after irradiation and donor cell injection. Characteristically of a chimera 
experiment several mice exhibited hair loss and greying of the remainder due to action 
of the radiation on hair follicles. Also noted was the appearance of dry skin around 
neck, head and shoulders not specifically in any group/genotype/gender. In particular 
cases this problem was associated with obvious skin inflammation typified by skin 
reddening and discharge. In cases of severe skin inflammation mice were treated with 
green clay (n=25) and claws were cut to reduce consequences of scratching.  
Indeed in a small number of mice before onset of bleomycin administration skin 
inflammation were treated with subcutaneous dexamethasone steroid (2mg/kg; n=3) 
in conjunction with green clay to reduce the likelihood of a systemic inflammatory 
response which would have skewed the fibrotic endpoint. All groups were also 
switched to corn cob bedding and given soft nesting material to be less irritating on 
inflamed/sore skin.  
In order to minimise the likelihood of excessive weight loss as a result of the irradiation 
procedure and the bleomycin treatment, mice were fed exclusively a diet gel (normal 
calorie). This was necessary in certain cases where mice exhibited broken and missing 
teeth. CBC and veterinary staff concluded that the radiation administered to the mice 
could had affected the way in which calcium is incorporated into the teeth as they grew 
affecting the overall strength.  
From the point of bleomycin administration to the endpoint 21 days weights were taken 
for each mouse daily. The lack of weight loss observed in FPR1KO mice with previous 
bleomycin studies was not observed in this chimera experiment. No difference was 
apparent between any of the groups, some saline-treated animals lost as much or more 
weight than bleomycin-treated mice, probably due to irradiation background effects 
(Figure 4.41). 
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Figure 4.41: Weight percentage gain/loss post-bleomycin injury to different chimera 
groups. Treatment groups were as follows: 1-4 SAL (n=5 per group) and 1-4 BLM with 
different chimeric groups. Bleomycin-injured chimera groups were as follows: 1- WT-
WT (n=8); 2- WT-KO (n=11); 3- KO-WT (n=6); 4- KO-KO (n=7). Percentage weight 
gain/loss calculated from original starting weight prior to bleomycin instillation.  
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4.2.10.5 Analysis of pulmonary fibrosis via PSR and alpha-SMA staining of 
bone marrow chimera FFPE tissue sections 
Sirius red percentage area stained of paraffin-embedded lung tissue (Figure 4.42 (a)) 
demonstrated no significant increase between saline and bleomycin groups although 
there was a perceptible rise in collagen deposited between group 1 saline mean 
6.84±1.199 % and group 1 BLM mean 8.65±1.206 % (p>0.05). Between respective 
bleomycin-treated chimeric groups there were demonstrable reductions in PSR 
staining. Groups 2 (WT recipient with KO donor) mean of 5.336±0.4731 % and Group 
4 (KO recipient – KO donor) mean of 4.157±0.3301 % displayed significantly reduced 
levels compared to Group 1 (WT recipient WT donor; p<0.05 and p<0.01 respectively). 
Homogeneous chimeras showed the greatest difference in percentage area.  
Alpha-SMA immunohistochemistry (Figure 4.42 (b)) stained displayed a similar 
pattern/trend with elevated percentage area in Group 1 bleomycin-treated chimeras 
over saline controls (non-significant). Alpha-SMA immunohistochemistry resulted in 
low levels of percentage area stained but a maximal response was only evident in 
bleomycin-treated Group 1 (WT recipient- WT donor; mean of 4.15±0.6641 %) 
compared to its respective saline control mean of 2.74±0.3295 % (p>0.05). 
Hydroxyproline (total collagen content) assay (Figure 4.43) showed no clear 
differences between saline and bleomycin-treated mice in any of the chimeric groups 
regardless of genotype or recipient/donor mixture (p>0.05). This may be due to 
incomplete hydrolysis of samples but this seems unlikely. The problem is probably due 
to the nature of the model, potentially indicating the unsuitability of the bleomycin 
pulmonary fibrosis model in irradiated chimera mice. 
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Figure 4.42: ECM production in chimera lung injured with bleomycin. Sections stained 
with PSR (a) for collagens I/III. (b) α-SMA production and results calculated as mean 
percentage area stained for different groups; 1-4 SAL (n=5 per group) and 1-4 BLM. 
Bleomycin-injured chimera groups were as follows: 1- WT-WT (n=8); 2- WT-KO 
(n=11); 3- KO-WT (n=6); 4- KO-KO (n=7). All p values calculated with Prism 5.0 
software and analysed by a one-way ANOVA ns p>0.05.; * p<0.05. Relative 
photographs displayed in appendix B (i-ii). 
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4.2.10.6 Immune cell counts in chimera mice  
Immunohistochemistry for markers of different immune cells was carried out to 
determine the tissue infiltrate in the chimeric mice (Figure 4.44 (a-b)). CD68+ 
(macrophage/monocyte marker) population showed relatively similar levels in FFPE 
tissue with a slight increase in the WT-WT chimera group, mean of 45.98±6.645 
cells/field, over its saline control (mean cells 33.45±3.555/field) and the other groups’ 
treatments (p>0.05).  
NIMP (neutrophil marker) staining showed, to an extent, differing levels of neutrophil 
infiltration. Higher numbers than expected were observed at 21 days in this chimera 
experiment. Increased cells per high power field were demonstrated between saline 
and bleomycin-treated mice of groups 1 and 2 although not to significance (p>0.05). 
Levels in groups 3 and 4 remained at a consistent level with no change in neutrophil 
localisation in the tissue. 
 
4.2.10.7 Total cell counts in bronchoalveolar lavage (BAL) fluid following 
bleomycin injury in chimera mice 
BAL total cell counts performed for each group and their treatments showed the 
proportions of cell populations in the extracellular fluid within the pulmonary 
microenvironment (Figure 4.45). There was a clear increase in the BAL total cell count 
with bleomycin administration of Group 1 chimeric mice from a mean cells/ml 
2.26±0.3381 increasing significantly to mean of 8.15±1.161 x105 cells/ml (p<0.001). In 
bleomycin-treated chimera groups there were significant reductions (p<0.01) when 
comparing group 1 (WT-WT) to the other donor-recipient groups possibly indicating 
that this group was the only chimeric combination that mounted a response to 
bleomycin. 
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Figure 4.43: Immune cell counts of chimera lung injured with bleomycin. Sections 
stained with (a) CD68 for macrophages and (b) NIMP for neutrophils and results 
calculated as mean cells/high power field (hpf); 1-4 SAL (n=5 per group) and 1-4 BLM. 
Bleomycin-injured chimera groups were as follows: 1- WT-WT (n=8); 2- WT-KO 
(n=11); 3- KO-WT (n=6); 4- KO-KO (n=7). All p values calculated with Prism 5.0 
software and analysed by one-way ANOVA * p<0.05. Relative photographs displayed 
in appendix B (iii-iv). 
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Figure 4.44: Total BAL cell counts from bone marrow chimera bleomycin-treated 
WT/KO mice. Total cell counts represented by cells/ml±SEM. Treatment groups were 
as follows: 1-4 SAL (n=5 per group) and 1-4 BLM with different chimeric groups. 
Bleomycin-injured chimera groups were as follows: 1- WT-WT (n=8); 2- WT-KO 
(n=11); 3- KO-WT (n=6); 4- KO-KO (n=7).  All p values were calculated using a one-
way analysis of variance (ANOVA). ns p>0.05, ** p<0.01, ***p<0.001. 
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4.2.11  Conclusion of findings 
4.2.11.1 Bleomycin-injury induced pulmonary fibrosis and effect of FPR 
deletion 
The in vivo model for investigating pulmonary fibrosis is limited due to the nature of its 
pathogenesis (acute and fibrotic). Features observed during studies involving 
bleomycin are facets/caveats of the model itself not necessarily the disease it is 
purposed to mimic. The distinct phases of the bleomycin model: acute and fibrotic are 
unlike the pathogenesis of IPF presented in the literature. Lung fibrosis is not an acute 
process but in a way this an advantage of the in vivo model as fibrosis is able to develop 
in a matter of weeks not months or years as is typically the case in human patients. 
Some individuals are genetically predisposed to ILD development or some have 
moderate lung function then an exacerbating effect like a virus or opportunistic 
infection comes along and the conditions worsens. Human fibrotic disease is far more 
complicated than the pathogenesis of different in vivo models but the nature of these 
short-term manifestations of disease makes them ideal for therapeutic agent 
development in a high-throughput fashion. 
Due to its already characterised role on immune cells as a chemoattractant receptor 
(Zhang et al., 2010) the loss of the FPR gene would be expected to alter inflammation. 
The blunting of the inflammatory cytokine profile at day 5 fits with FPR’s role in the 
migration of neutrophils and also macrophages to sites of damage. Without a normal 
inflammatory response being mounted through decreased secretion of IL-6, MCP-1, 
IL-1β and KC, the acute injury phase of the bleomycin is dampening affecting 
downstream events in the pathogenesis due to the intrinsic linking to the development 
of the fibrotic phase. The dysfunctional response equates to protection against the 
formation of fibrotic scar tissue as determined by histology and extracellular matrix 
(ECM) production after 21 days. Ablation of the FPR1 in mice has been revealed to be 
of importance in a cigarette-smoke extract (CS) based model lung emphysema 
showing a role for this receptor for inflammation in the lung mediated by neutrophils 
(Cardini et al., 2012).  
Previously, FPR’s role in pulmonary inflammation has been determined in terms of a 
cigarette-smoke (CS) extract-based emphysema model involving similar knockout 
mice. Cardini et al. (2012) showed reduced infiltration by neutrophils and macrophages 
with FPR deletion implicating it as a key player in inflammation and tracking of immune 
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cells to damage sites. Typically pulmonary fibrosis, in particular IPF, is not regarded 
as an inflammatory condition where repeated insults and damage propagate 
fibrogenesis and an aberrant wound-healing response. In this respect the bleomycin 
model differs significantly as it relies on an acute injury driving the entire process.  
To determine the role of FPR on fibrosis more pulmonary fibrosis models would need 
to be utilised preferably with a pathogenesis that does not rely on directed inflammation 
in response to targeted injury by chemical agents (bleomycin or FITC). A TGF-β 
adenoviral overexpression method develops in a significantly different manner and 
would strengthen whether or not this receptor is a player in fibrosis disease 
mechanism. The use of this model could indeed be related to findings from the 
bleomycin studies. At day 5 during the acute phase of inflammation, fibrogenesis is 
beginning to occur and TGF-β1 cytokine is secreted. Of note was the fact that there 
was no difference in the BAL levels of this pro-fibrogenic cytokine. Although the signal 
waned by day 21 in knockout mice, the onset of the wound-healing response appears 
to be TGF-β1 independent which may be of interest with regards to the adenovirus 
model employed by multiple research groups (Sime et al., 1997; Murray et al., 2011). 
In order to fully understand the role of the fpr1 gene in pulmonary fibrosis, a different 
model (preferably non-inflammation driven) should be used. Without replication of the 
effect in a different model the effects determined with the bleomycin injury may only be 
model-dependent.  
 
4.2.11.1.1 Neutrophils in the pathogenesis of the bleomycin model 
Ly6G-positive neutrophils were successfully depleted by mini-pump administration of 
soluble antibody over defined periods in an acute or fibrotic bleomycin model. The 
continuous delivery of the antibodies is preferable to repeated injections on a daily 
basis with a reduced chance of mis-dosing due to the mini-pump’s osmotic action. 
Proof of concept short-term study which depleted neutrophils 2 days prior to bleomycin 
injury displayed reduced NIMP positivity in FFPE sections and PMNs in BAL cytospins. 
Effectively neutrophils are being drastically reduced in depleting antibody treatments 
compared to control IgG mini-pumps which ultimately triggered a downstream effect 
on ECM deposition specifically collagen as indicated by PSR immunohistochemistry. 
Alpha-SMA, a key marker of activated myofibroblasts showed a similar pattern but did 
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not reach significance. One major limitation of this study was the fact that when 
hydroxyproline assay was performed to determine total lung collagen content no 
difference was detected between any of the treatments groups. This may be due to 
incomplete hydrolysis of tissue prior to the colorimetric assay.  
Other things to consider when interpreting the mild/moderate effect seen in the mini-
pump study in terms of ECM production may be due to dosage of bleomycin and the 
age of mice used. Typically mice were 6-8 weeks old with a mix of males and females 
depending on stock of mice available. Some groups have reported that male mice 
develop worse fibrosis in response to bleomycin compared to females. If groups were 
mixed, treatments groups were given an even spread of males/females in case there 
were any differences. Due to the nature of the Ly6G experiment with the surgical 
implantation of a mini-pump 2 days prior to intratracheal dosing other things may have 
been at play. The procedure itself could have caused inflammatory events and the 
antibodies themselves may have triggered a systemic response resulting in higher 
numbers of neutrophils responding to bleomycin injury in IgG controls. This may 
account for the increased NIMP positivity determined in the acute bleomycin mini-
pump study compared to the traditional 1 day bleomycin study. The nature of the 
ALZET mini-pump system minimises animal interference, infection and systemic 
toxicity (Perkins et al., 2008). The implantation and the securing of the installed mini-
pumps may have played a role, animals are prone to scratch uncomfortable areas in 
particular surgery sites. This will potentially break the skin causing inflammation and 
the recruitment of immune cells in a systemic response which may account for higher 
numbers determined at acute time point.  
Long-term effects of mini-pump installation are hard to gauge but may have had an 
effect on the overall fibrotic response with cells in an inflammatory state rather than 
initiating wound-healing and progression to a fibrotic phenotype. 21 days post-
saline/bleomycin in IgG/Ly6G mini-pump WT mice a fibrotic reaction is occurring with 
increased collagen deposition as well as α-SMA production. Levels of the pro-
fibrogenic cytokine TGF-β1 were elevated in control IgG group, lower than at day 5 
endpoint (~20pg/ml) indicating fibrogenesis and the development of fibrosis. With the 
mild effect observed with IHC and no difference in lung collagen content it appears that 
a different endpoint should be utilised to investigate fibrosis, perhaps 28 days as 
fibrosis may not be fully developed at 21 days.  
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4.2.11.2 Flow cytometry-based approach for analysis of inflammatory 
infiltrate induced by bleomycin injury 
Markers evaluated in FACs phenotyping experiment would need refining for precise 
determination of inflammatory infiltrate. The antibody panels for differing ‘activation 
states’ of macrophages yielded preliminary indications of macrophage phenotype 
present at the time points of 5 day and 21 days.  
Specific M2 markers for alternatively activated macrophages are complicated by the 
presence of the distinct population of resident alveolar macrophages in the lung 
microenvironment. CD206, mannose receptor is both of subsets making it difficult to 
interpret whether a decrease in M2 macrophages is shown or simply a reduction in 
alveolar macrophage population. Previous findings at 21 days post-bleomycin injury 
demonstrated a protective effect upon ablation of the fpr1 gene which may correlate 
with this reduction in macrophages. The use of another M2 marker, Found in 
inflammatory zone (FIZZ) 1 for staining of the lung digests strengthens the hypothesis 
that a reduction in M2 macrophages is responsible for the dampened fibrotic response.  
FIZZ-1 has previously been demonstrated to be important in Th2 immune response 
implicated in trophic/tissue remodelling functions (Jones, 2013). Increases in 
alternatively activated macrophages as part of a Th2-mediated response to PLC-/- 
Trypanosoma brucei brucei infection have been characterised by FIZZ-1 expression. 
Clarification of its M2 marker status is somewhat cemented by further studies in vitro 
where IL-4/IL-13 treatment of peritoneal macrophages isolated from different 
transgenic mice species (BALB/c C57Bl/6) induced its expression (Chung et al., 2007). 
Polarisation by Colony-stimulating factor-1 (CSF-1) in vivo exhibits a similar effect in 
neonatal mice to the aforementioned in vitro experiments (Jones, 2013).  
A key point to note is that FIZZ-1 is recognised as being produced by the bleomycin 
model (Liu et al., 2004) with some studies showing localisation to lung epithelium not 
macrophages in rat bleomycin-injured lung. IL-4/IL-13 induce lung FIZZ-1 expression 
on a wider scale than previously considered which may be a thing to consider when 
evaluating the macrophage marker FACs data from the present bleomycin study. Part 
of the experimental design for this study eliminated this doubt due to gating for 
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CD45+ve cell populations which would have excluded epithelial cells from the FACs 
analysis. 
FIZZ-1 is a RELM-α – resistin-like molecule originating from the FIZZ/RELM family with 
itself and other family members (FIZZ2/RELM-β, FIZZ3/resistin, and RELM-γ) 
associated historically with allergic exacerbations in the lung in the context of asthma. 
This 9.4 kilodalton protein is intracellularly localised with a conserved 10 cysteine 
amino-acid motif with expression documented in asthma-associated inflammation. 
FIZZ-1 is expressed in macrophages, bronchial epithelium and type II alveolar 
epithelial cells (AECs) (Chung et al., 2007).  
With regards to the inflammatory infiltrate the populations lung digests were 
determined showing little difference in immune cells apart from macrophages 
expressing M2 (alternatively activated) markers. Neutrophils (total and activated) and 
eosinophils displayed consistent low levels with respect to the repertoire of CD45+ 
leukocytes. Evaluation of the infiltrate in the tissue at day 5 implies that peak neutrophil 
population may have migrated to injury site prior to this. The innate immune response 
occurs typically in a short period after damage triggering downstream processes 
(Fafyatis and Farina, 2012). Investigation was required for the peak immune response 
to be determined as low levels of infiltration were evident at day 5, even with 
accumulation of secreted inflammatory cytokines. Harvesting of animals 24 hours post-
injury/saline instillation allowed further evaluation of acute phase of bleomycin model. 
Indeed more neutrophils and macrophages were infiltrating the lung tissue post-
bleomycin and a reduced response was clear in knockout mice. A less developed pro-
inflammatory cytokine response was evident at this earlier endpoint than at 5 days.  
CD4+ lymphocytes showed increased infiltration to the lung 21 days post-bleomycin in 
wildtype mice with a reduced response in knockout group. Due to FPR’s status as a 
major chemoattractant on primarily neutrophils it is logical to assume that the loss of 
FPR will affect neutrophil functionality. Neutrophils have demonstrated the ability to 
interact with T-cells displaying cross-talk properties (Thewissen et al., 2011). Impaired 
neutrophils with deficient FPR expression subsequently leads to impaired CD4+ T cell 
recruitment.  
One of the key findings from the FACs analyses of the different cellular markers at day 
5 and day 21 post-bleomycin was reduction in alternatively activated macrophages in 
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FPR knockout mice compared to WT controls. Total macrophages were elevated 
during fibrotic phase in C57Bl6 mice which according to literature represents the M2 
macrophages which play a recognised role in wound-healing and tissue remodelling 
(Wynn, 2008; Brown et al., 2009). A point to consider is that CD206+ macrophage 
population are also high in CCR7 expression which implies a mixed M1/M2 phenotype. 
Cells may be subject to transdifferentiation with initiation and resolution of 
inflammation. There is a degree of controversy regarding the differentiation of 
macrophages into distinct subsets with recent research highlighting potential temporal 
and spatial regulation of macrophage phenotype (Porcheray et al., 2005; Murray et al., 
2014). Other research highlights specificity of macrophage subset markers with M1 
marker, inducible nitric oxide synthase (iNOS) differential suppression in alternatively 
activated macrophages on account of Arginase activity (Munder et al., 1998).These 
CD206+ macrophages exhibited high auto-fluorescence which is a common feature of 
alveolar macrophages resident in the pulmonary microenvironment. While CD206 has 
been associated with anti-inflammatory macrophage populations (Porcheray et al., 
2005) it is also regarded as a marker of alveolar macrophages not specifically M2 
macrophages (Kaku et al., 2014) drawing the FACs analyses of this panel into 
question. The inclusion of another macrophage antibody panel strengthened the data 
from the first set of markers especially with regards to FIZZ-1+ population.  
Another thing to consider about FIZZ-1 as an M2 marker is expression is not solely 
restricted to alternatively activated macrophages. FIZZ-1 is also localised to lung 
epithelium in rat bleomycin models with IL-4/IL-13 able to induce lung FIZZ-1 
expression on a wider scale than previously considered (Liu et al., 2004). With FIZZ-
1+ expressing macrophages having low iNOS expression and fitting with the same 
pattern as that of CD206+ macrophages the evidence for a reduction in M2 
macrophages with FPR deletion during bleomycin-induced pulmonary fibrosis is 
somewhat strengthened and a potential mechanism for the reduced fibrosis may be 
proposed. Reduction in M2 macrophages (recognised as players in the wound-healing 
response) in bleomycin-injured mice upon ablation of fpr1 gene at 21 days is potentially 
responsible for protective effect. 
MOMA-2, a glycoprotein macrophage marker was used due to its high degree of 
specificity for mononuclear phagocytes and also on account of its distinction from 
MOMA-1. MOMA-1, metallophilic macrophages are localised in spleen and peripheral 
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lymph nodes as part of the spleen marginal zone while MOMA-2 is used to determine 
total macrophages in lymphoid tissue and other organs such as the lung (Leenan et 
al., 1994). Determination of neutrophil activation status during acute and fibrotic 
phases seemed a reasonable angle to pursue due to little difference in neutrophil 
recruitment in the tissue. Upon activation PMNs migrate to sites of injury via innate 
homing mechanism increasing expression of different markers CD62L (L-selectin), 
ICAM-1, CD54, FCYRII (cd32), C5a receptor (CD88), CD66a and CD11b (Fortunati et 
al., 2008). 
Sialic acid binding immunoglobulin-like lectin F (SigLecF) expression denoted the 
eosinophil population in the inflammatory infiltrate. This eosinophil-specific receptor 
has a conserved cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), 4 
immunoglobulin (Ig)-like domains as well as a transmembrane component. SigLecF 
shares a degree of homology with SigLec8, its human counterpart expressed on 
eosinophils due to a convergent evolution, both of which have glycan ligand recognition 
function acting as adhesion receptors (Tateno et al., 2005). As yet no research has 
reported an effect of FPR1 upon eosinophil migration/function and the numbers are so 
minimal that there effect on the bleomycin is more than likely small. 
4.2.11.3 Chimera mice injured with bleomycin 
Although a set dose of 10 grays (6.8 Sv) was used to irradiate the mice prior to bone 
marrow transplantation if the machine was not calibrated properly the effects on the 
recipient mice could have catastrophic. This could potentially explain why the mice 
developed such severe problems and complications over the reconstitution period.  
The irradiation procedure could also explain the mild effect observed in the chimera 
mice following bleomycin instillation. In radiation-induced models of pulmonary fibrosis 
as well as eradicating the host’s immune system (bone marrow cell populations) 
epithelial cells are damaged. These resident populations may undergo epithelial-
mesenchymal transdifferentiation (EMT) leading to myofibroblast and the development 
of a wound healing response. Also due to this EMT-driven process anti-inflammatory 
cytokines are secreted which if localised in the lung at the time of bleomycin/saline 
instillation could have hampered the acute inflammatory response by alternatively 
activated macrophages. Parallels can be drawn to radiation-induced lung fibrosis and 
the chimera bleomycin-injury model (Ding et al., 2013). 
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4.2.11.4 Fibrotic marker variability between different bleomycin studies 
Variability in different fibrotic markers, for examples ECM production was evident 
between studies including the initial day 21 endpoint conducted at MedImmune, the 
Ly6G-mediated depletion study and the bone marrow chimera study. One thing to 
consider with this is that each study was analysed separately with different 
densitometry thresholds used each time for the PSR and α-SMA stains with the Nikon 
analysis software. Due to the difference in presentation in the histology perhaps some 
animals did not receive an optimal dose of bleomycin making groups (in particular 
injured mice) more variable thus creating inter-study differences. Another point to 
consider is the mice composing the groups in the different studies some of which were 
mixed gender. 
 
 
4.3 Summary of bleomycin-injury in vivo studies 
 FPR1KO mice are protected from bleomycin-induced pulmonary fibrosis 
compared to wildtype counterparts with dampened inflammation at 1 day and 5 
days post-injury and fibrotic responses at 21 days post-injury. 
 FPR1KO mice exhibited a switch in macrophage phenotype to M2 class in 
fibrotic phase. 
 Ly6G-mediated depletion experiments demonstrated a neutrophil drop in 
bleomycin model along with a decrease in ECM production and CD68+ve 
macrophages/monocytes. 
 Chimera experiments showed no clear effect of bone marrow reconstitution on 
the bleomycin model of pulmonary fibrosis. 
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5 Role of FPR1 in fibrosis in multiple organ in vivo models 
5.1 Hypothesis 
From the initial investigations of pulmonary fibrosis via the bleomycin-induced model 
using FPR1KO (fpr643) transgenic mutant mice the formyl-peptide receptor 1 (FPR1) 
has demonstrated a potential role in this microenvironment. In other organs, however, 
the cellular composition differs thus altering the pathogenesis of fibrosis in that 
particular environment. Indeed, most fibrogenesis mechanisms follow a similar process 
triggering a dysregulated wound-healing response. Investigation of in vivo fibrosis 
models in liver, kidney and skin were undertaken to elucidate effects on FPR1’s role in 
fibrosis. Different microenvironments have altered neutrophil involvement in the 
pathogenesis of their fibrotic mechanisms therefore this chemoattractant receptor will 
have a differential role in multiple organs.  
 
5.2 General fibrosis mechanism 
Wound-healing is an essential process in the body preventing infection and 
degradation of tissue responsible for key functions. Programmed cell death (apoptosis) 
enables turnover of damaged cells (usually epithelium) and regeneration. This is a 
prevailing feature of the liver where injured tissue is replaced following inflammatory, 
remodelling and resolving events. In the normal response there is no long-term 
damage but in the case of repeated injury/damage functionality is lost even in 
regenerative organs such as the liver. The scheme postulated by Wynn (2004; 2007) 
displays the breakdown of the haemostatic mechanism resulting in the fibrotic 
phenotype. Quiescent fibroblast transformation to activated myofibroblast is a typical 
feature of the transition from fibrogenesis to fibrosis.  
 
5.3 Liver fibrosis: an overview 
5.3.1 Organ functionality 
As a major part of the endocrine system the liver is responsible for a range of different 
homeostatic functions. Typically the liver is the largest gland in the human body which 
in adults may weigh up to 2.5% of total body weight (Si-Tayeb et al., 2010; Juza and 
Pauli, 2014). Within the adult liver multiple different cell types coordinate such as 
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hepatocytes, cholangiocytes, endothelial cells, sinusoidal endothelial cells, pit cells, 
kupffer macrophages and hepatic stellate cells (Si-Tayeb et al., 2010). Essentially the 
liver is composed of multiple lobes, each lobule separated by portal tracts. Each portal 
tract is made up of a portal vein, an arterial vessel and a bile duct, the close proximity 
of the blood supply enables transport of oxygenated blood to the lobule. Hepatocytes, 
cholangiocytes (biliary epithelial cells, BECs), endothelium, hepatic stellate cells 
(HSCs) and resident immune cells all work in concert to fulfil the liver’s 
endocrine/exocrine functions (Si-Tayeb et al., 2010).  
 
5.3.2 In vivo liver injury models 
Different experimental models are available for investigating each of these factors but 
as with any in vivo study no single model will answer all the questions due to their 
limited nature. Studies involving mice and rats have greatly increased our knowledge 
of the liver disease both at injury level and in terms of fibrosis as a concept. The 
heterogeneity of the CLD has proved a problem for research often requiring multiple 
model strategies to elucidate pathways. Different approaches have been developed 
over the years to replicate the key features of different liver disease modalities. 
Commonly characterised are the Bile duct ligation (BDL) cholestatic injury model and 
toxin-mediated liver injury methods. BDL have been extensively used in rats and mice 
causing acute obstructive jaundice in under 2 weeks (Marques et al., 2012). Carbon 
tetrachloride (CCl4) and thioacetamide (TAA) are damaging agents used to induce 
injury responses are routinely applied to rodents to allow investigation of liver 
fibrogenesis and fibrosis (Liedtke et al., 2013; Traber et al., 2013).  
Research models employed depend on research questions as particular models are 
more applicable in certain situations. Of the in vivo tools available two main types exist: 
classical models which have some features of CLD but not all and those models which 
specifically mimic particular CLDs: immunodefects, viral infections, gene deletions for 
autoimmune/cholestatic liver diseases. Most models are not enough by themselves to 
present a conclusive therapeutic option but they are opportunities for the pathogenesis 
of CLDs to be elucidated (Liu et al., 2012). 
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Figure 5.1: Schematic of hepatic fibrogenesis. Liver injury leads to initiation with 
quiescent hepatic stellate cells (HSCs) differentiating to activated HSCs. Fibrogenesis 
occurs and this is perpetuated to yield a reversible fibrotic phenotype with 
hyperproliferation and excessive ECM deposition. Adapted from Lee and Friedman 
(2011).  
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5.3.3 Liver fibrogenesis 
5.3.3.1 Acute CCL4  
For my purposes CCl4 was the optimal model to use as its effects closely correlate with 
different stages and features of human liver fibrosis. These include inflammation, 
regeneration, myofibroblast proliferation and fibrotic phenotype if regimen is continued 
long enough. A single dose of CCl4 results in what has been described as ‘centrizonal 
necrosis and steatosis’ triggers massive hepatocyte centrilobular death (Fujii et al., 
2010). CCl4 is metabolised by hepatocytes rapidly which generates CCl3° free radicals. 
This metabolite is degraded further to form reactive oxygen species (ROS) triggering 
lipid peroxidation and membrane impairment. Cytochrome CYP2E1 oxidase system is 
activated by CCl4 metabolism causing the radical formation (Wu et al., 1996). 
Due to the regenerative ability of the liver CCl4 is used routinely for studying its acute 
and chronic effects. CCl4 is only active for a short time with secretion occurring in 24 
hours. This is the main reason behind its use with acute end-points of 1, 2 and 3 days. 
These end-points are equivalent to ‘snapshots’ for the early responses to injury: (1) 
Inflammation; (2) Fibrogenesis; (3) Resolution. All of these processes are overlapping 
in chronic CCl4 model with repeated CCl4 i.p. injections perpetuating the wound-healing 
response leading to a fibrotic nodular scar tissue pattern (Marques et al., 2012).  
This invaluable tool is highly replicable essentially allowing insight into the CCl4 
metabolism effects on tissue in terms of damage level, inflammatory response, 
proliferation and fibrogenesis – the normal wound-healing response.  
 
5.3.4 Liver fibrosis  
5.3.4.1 Chronic CCl4 
Chronic toxic injury with carbon tetrachloride in rodent models is similar to human 
disease in that an aberrant dysregulated wound-healing response is initiated and 
sustained with repeated applications. With HSC activation from quiescent precursors 
15% of cells in the liver suddenly have the ability to transform an organ. Development 
of a myofibroblast phenotype changes the balance of ECM in the liver with proliferation 
and excessive deposition by newly non-quiescent stellate cells. As more and more 
collagen, proteoglycans, fibronectin and hyaluronic acid are produced the regulation 
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mechanisms are impaired. The MMP and TIMP feedback loops are disrupted in this 
hepatotoxic environment eventually leading to scar tissue generation (Jang et al., 
2008). After 4 weeks of biweekly CCl4 intraperitoneal injections hepatic fibrosis is 
exhibited, 8 weeks cirrhosis develops and advanced micronodular fibrosis is 
demonstrated after 12 weeks. Repeated CCl4 administration is causing chronic liver 
injury leading to chronic liver fibrosis (Liedtke et al., 2013; Constandiou et al., 2005). 
Due to the similar pattern of disease progression in the CCl4 model and human CLD, 
many of the same biomarkers are used for assessment. These include liver function 
tests (damage enzyme levels), fibrogenic stress and gene expression biomarkers. 
PicroSiriusRed (PSR) staining is an established tool for evaluation of tissue section 
fibrosis level and spread (Constandiou et al., 2005). Histology is graded (usually via 
Isaak Score) as with human biopsies accordingly for collagen deposition and portal 
inflammation (Jang et al., 2008).  
 
5.4 Acute CCl4 model 
5.4.1 Hypothesis 
Fpr-/- null transgenic mice will have a depleted immune response to toxic injury (24 
hours) but I foresee no change in fibrogenesis (48 hours) and resolution (72 hours) 
mechanisms in the liver. Ultimately, the deletion of FPR1 will have no effect on the 
development of liver fibrosis via CCl4 administration. 
5.4.2 Aims  
From acute administration CCl4, 1:1 volume ratio with vehicle olive oil, and subsequent 
harvesting of blood and liver tissue at short-term endpoints of 24, 48 and 72 hours the 
effect of fpr1 deletion on the early fibrogenesis processes would be elucidated. This 
initial 72 hours is comprised of the different stages of the wound-healing response with 
endpoint effectively acting as ‘snapshot’. By 24 hours the immune response has been 
initiated in response to the damage caused by degradation of CCl4. After 48 hours 
fibrogenesis is occurring as myofibroblast activate and are subject to excessive 
proliferation. With 72 hours the injury is already resolving itself which is a testament to 
the liver’s regenerative capacity. By evaluation of KO mice compared to WT mice 
during these stages of the fibrogenesis the effect of FPR1 and its activity on the wound-
healing response could be elucidated. 
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5.4.3 Liver weight (LW) to body weight (BW) ratio at acute endpoints 
LW/BW ratios are used routinely to gauge liver damage and as an index of this organ’s 
regeneration capacity (Figure 5.2). The LW/BW ratio was dramatically reduced with 
CCl4 in KO mice at 24 hours (0.04447±0.008308) compared to vehicle control 
(0.002017±0.0003558; p<0.0001) and WT CCl4 group, 0.04643±0.003675 (p<0.01). All 
groups at other endpoints exhibit no change in LW/BW ratio except for 72 hours where 
a significant increase in LW/BW ratio (p<0.05) was determined. The effect observed 
during the inflammatory, initiation phase of the toxic injury response may be due to 
altered proliferation with loss of FPR expression.  
 
5.4.4 Serum damage enzyme markers 
In response to human liver disease and in vivo injury by carbon tetrachloride Alanine 
aminotransferase (ALT) and Aspartate aminotransaminase (AST) are secreted by the 
liver into the blood. The liver produces more ALT than AST after liver injury acting as 
a more specific liver function test (Vroon and Israili, 1990; Marshall, 2012). In human 
liver disease AST and ALT can be potentially increased <8 and <5 times respectively 
compared to healthy serum biochemistry in alcoholic fatty liver disease and <4 times 
of normal patients in non-alcoholic fatty liver disease (Nyblom et al., 2004).   
Following sacrifice blood was harvested from each animal and processed to obtain 
serum in which the above analytes were measured by catalytic activity (Figure 5.3; 
NHS Biochemistry department). Blood is composed of plasma (55%), erythrocytes 
(45%) and leukocytes (<1%). Centrifugation following animal sacrifice of blood 
samples separates cells from the plasma layer equating to serum (minus clotting 
factors). Plasma is principally made up of water (91%), blood proteins (7%) and 
nutrients (2%) which is then able to be analysed to determine levels of hepatocellular 
injury. Upon acute injury with CCl4 liver function tests indicated secretion of ALT and 
AST with higher levels than olive oil (vehicle) controls. 24 hours post-injury WT and 
KO mice both exhibited increases in serum U/L but no difference between WT and KO-
injured mice was detected (p<0.01 and p>0.05 respectively). After 48 hours both 
genotypes produced similar levels with CCl4 injury, wildtype mice elicited a significant 
response with an increase to 6036±1077 U/L (p<0.01) while knockout mice elicited a 
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significant increase from 52±4 U/L, vehicle to 6943±829.4 U/L (p<0.001). With the 
acute model consisting of a single injection (vehicle/toxin) following the initial injury the 
inflammation is replaced by fibrogenic processes leading to resolution by 72 hours. By 
this time ALT levels have dropped compared to earlier endpoints with U/L similar to 
vehicle control levels.  
With the other less specific serum damage enzyme, AST levels followed a similar trend 
as with ALT. 24 hours post-injury both WT and KO mice have increased serum 
concentrations with knockout exhibiting a significant increase over control group 
(p<0.01) elevating from mean U/L of 288±28 (OO) to 5136±1533 (CCl4). WT mice 
exhibited a significant increase also (p<0.0001). 
With a high degree of variability between samples in KO CCl4 group there is no 
difference detected when compared with WT CCl4 mice. By 48 hours (proliferation 
phase) AST levels show consistent raised levels in CCl4 groups with means of 
6384±522.3 U/L (WT; p<0.01) and 7008±636.3 U/L (KO; p<0.001) and with resolution 
of injury (72 hours) serum concentrations are depleted to near baseline as with ALT.  
Both ALT and AST liver responses to injury display no difference with loss of FPR 
expression potentially indicating a compensation mechanism during the inflammatory 
response for altered chemotactic function. Ultimately the response to liver damage 
during fibrogenesis in terms of these liver function tests was unchanged with fpr1 gene 
ablation. 
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Figure 5.2: Liver weight (LW, g) to body weight (BW, g) ratios from acute CCl4-injured 
mice. Harvested at 24, 48 and 72 hours after 1:1 Carbon tetrachloride (CCl4): Olive oil 
(OO) intraperitoneal (i.p.) injection. All groups had a minimum of 4-5 mice analysed 
with values expressed as mean LW/BW and SEM displayed. All analysis performed by 
a one-way ANOVA * p<0.05; ** p<0.01; **** p<0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
172 
 
5.4.5 Fibrogenic gene expression at acute CCl4 endpoints 
At the different stages of fibrogenesis mRNA gene expression a variety of markers 
either pro-inflammatory or fibrogenic were analysed by quantitative real-time PCR. 
During the inflammatory initiation phase of acute liver injury (24 hours post-CCl4 
(Figure 5.4) collagen 1 (col1) expression relative to WT vehicle control remained at a 
consistent level with no increase/decrease upon injury ranging from 1.222 to 1.947 fold 
change (p>0.05). At this stage of acute liver injury the myeloid cell marker S100A9 
expression was increased with CCl4 injection. Relative gene expression increased from 
WT OO (2.097) to WT CCl4 (26.57) and KO OO (1.345) to KO CCl4 (24.99). The spread 
of these results was large with a sizable SEM of 18.29 and 10.72 in the toxin-treated 
groups respectively (p>0.05). Both cytokines IL-6 and KC were elevated in the liver of 
CCl4 treated mice after 24 hours but this was no significant compared to vehicle 
controls or each other (p>0.05).  
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Figure 5.3: Serum damage enzyme concentrations after acute CCl4 treatment. 24, 48 
and 72 hours post-injection (a) ALT and (b) AST U/L were assayed by colorimetric 
analysis in vehicle olive oil (OO) and carbon tetrachloride (CCl4) treated C57Bl6 (WT) 
and fpr-/- (KO) transgenic mice. All groups had a minimum of 4-5 serum samples 
analysed with values expressed as mean U/L and SEM displayed. All analysis 
performed by a one-way ANOVA; ** p<0.01, *** p<0.001 and **** p<0.0001. 
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Figure 5.4: Gene expression 24 hours post-CCl4 treatment. mRNA levels of (a) Col1, 
(b) IL-6, (c) KC and (d) S100A9 were assayed via real-time PCR. All groups, olive oil 
(OO) and carbon tetrachloride (CCl4) treated had a minimum of 4-5 samples analysed 
with values expressed as mean fold change relative to WT vehicle controls (normalised 
to GAPDH housekeeping gene) and SEM displayed. All analysis performed by a one-
way ANOVA; * p<0.05 and p>0.05. 
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48 hours post-CCl4 injection fibrogenesis is beginning to occur with production of 
extracellular matrix (ECM) markers associated with activation of hepatic stellate cells 
(HSCs) and the wound-healing response (Figure 5.5). α-SMA gene expression was 
up-regulated non-significantly in WT and KO CCl4 groups compared to vehicle controls; 
11.43±5.827 fold and 35.02±14.3 fold change respectively. Collagen I expression was 
increased in a similar fashion at this ‘snapshot’ of fibrogenesis with levels of 
7.632±1.383 (WT; p>0.05) and 16.48±5.367 (KO) fold change compared to vehicle 
controls (p>0.05). TIMP1, a regulator of ECM production also demonstrated an 
increase in expression with CCl4 injury and levels increased to 46.26±10.61 (WT) and 
78.39±18.41 (KO) fold change. Due to variability between liver cDNA samples no 
significance was attained by this response (p>0.05). Fibronectin, another ECM protein 
produced during fibrogenesis was increased in both WT (p>0.05) and KO (p>0.05) 
CCl4 groups compared to vehicle counterparts. No apparent difference between injured 
groups in the expression pattern of this protein (p>0.05).  
 
72 hours post-CCl4 injection the wound-healing response is underway with 
inflammatory events replaced by the resolution of the damaged areas by ECM 
production and HSC activation. mRNA levels (Figure 5.6) of α-SMA increased in CCl4-
treated groups (WT, p<0.05; KO, p>0.05) compared to that of vehicle controls 
irrespective of genotype. TIMP1 expression also rose in injured mice after 72 hours in 
WT and KO groups to 1.58±0.9781 fold change and 0.8836±0.3415 fold change 
respectively compared to vehicle controls (p>0.05). Monocyte chemoattractant peptide 
1 (MCP-1) production by drug-treated livers demonstrated little or no change in gene 
expression with minimal fold change between vehicle control and CCl4 groups 
(p>0.05). Myeloid cells, denoted by S100A9 expression, were increased from vehicle 
controls (mean of 0.4094±0.1569) to 3.536±2.151 fold change in C57Bl6 injured livers. 
Knockout expression of S100A9 elevated from 0.4828±0.2484 to 2.274±1.186 mean 
fold change in vehicle and CCl4 groups respectively (p>0.05). Although primarily a 
marker of neutrophils S100A9 is localised in monocytes and B-lymphocytes (Li et al., 
2009) which is more likely responsible for the mRNA levels detected by real-time PCR. 
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Figure 5.5: Gene expression 48 hours post-CCl4 treatment. mRNA levels of (a) α-
SMA, (b) Col1, (c) TIMP1 and (d) Fibronectin were assayed via real-time PCR. All 
groups, olive oil (OO) and carbon tetrachloride (CCl4) treated had a minimum of 4-5 
samples analysed with values expressed as mean fold change relative to WT vehicle 
controls (normalised to GAPDH housekeeping gene) and SEM displayed. All analysis 
performed by a one-way ANOVA * p<0.05. 
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Figure 5.6: Gene expression 72 hours post-CCl4 treatment. mRNA levels of (a) α-
SMA, (b) TIMP1, (c) S100A9 and (d) MCP-1 were assayed via real-time PCR. All 
groups, olive oil (OO) and carbon tetrachloride (CCl4) treated had a minimum of 4-5 
samples analysed with values expressed as mean fold change relative to WT vehicle 
controls (normalised to GAPDH housekeeping gene) and SEM displayed. All analysis 
performed by a one-way ANOVA * p<0.05. 
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5.4.6 Immunohistochemistry of different cellular markers after acute CCl4 
application  
5.4.6.1 Alpha-SMA, a marker of activated HSCs, deposition 
Hepatic stellate cell (HSC) differentiation from quiescent to activated myofibroblast 
form is characterised by among other things alpha-smooth muscle actin. 24 hours post-
CCl4 injection following densitometry analysis the percentage area stained did not 
increase further than that of vehicle controls ranging from means of 0.34 to 0.55% 
(p>0.05). Corresponding with the fibrogenesis phase occurring 48 hours post-injury α-
SMA production is elevated in both WT and KO mice. Upon transdifferentiation of 
quiescent stellate cells to their activated form the mean percentage area increased 
from 0.48±0.06% in olive oil vehicle WT controls to 2.001±0.2681% in CCl4 group 
(p<0.01). In fpr1-deficient mice the area increased from a mean of 0.5±0.1183% to 
1.877±0.3045% in vehicle and CCl4 groups respectively (p<0.01). No clear difference 
is evident between genotypes at this endpoint. After 72 hours α-SMA deposition levels 
were clearly increased in WT CCl4 (mean area of 1.98±0.2498%; p<0.001) over the 
corresponding control from baseline percentage area stained (mean of 0.44±0.075%). 
Knockout mice demonstrated a non-significant increase (p>0.05) with CCl4 treatment 
to a mean area of 1.575±0.641% from vehicle control group. Both genotypes undergo 
fibrogenesis in the liver with CCl4 application and resolution of the acute response by 
72 hours followed a similar pattern. 
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Figure 5.7: Alpha-Smooth Muscle Actin production in acute CCl4-injured livers after 
24, 48 and 72 hours. All groups, olive oil (OO) and carbon tetrachloride (CCl4) treated 
had relative photomicrographs of FFPE wildtype (WT) and FPR knockout (KO) liver 
sections (see appendix C) stained indirectly via IHC of (x10 magnification) and had a 
minimum of 4-5 mice. Data was then analysed via densitometry using Nikon 
microscope software with results expressed as a mean percentage area stained 
±SEM. All p values were calculated using a one-way analysis of variance (ANOVA); * 
p<0.01; *** p<0.001 and ns p>0.05. 
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5.4.6.2 Proliferation in acute CCl4 model 
With fibrogenesis hepatocytes enter a state of hyper-proliferation and IHC staining of 
proliferating cell nuclear antigen (PCNA) will indicate how the wound-healing response 
is progressing. PCNA positivity is exhibited by lymphocytes and hepatocytes, with 
hepatocytes positive cells per high per field (hpf) giving an indication of liver 
proliferation following injury. At 24 hours PCNA demonstrated no difference between 
controls and CCl4 groups (p>0.05) with mean positive cells per field ranging from 
2.712±0.4198 to 3.604±0.215. After this inflammatory, initiation phase the liver 
progresses to fibrogenesis at 48 hours post-CCl4. Both WT and KO mice demonstrated 
an elevated PCNA positive count in WT injured groups in a significant manner with 
mean counts of 44.08±6.718 (p<0.0001) and 31.45±10.22 (p<0.0001) respectively. 
This fibrogenesis stage is associated with hyper-proliferation phenotype so this is of 
no surprise. No difference apparent between WT and KO in the CCl4 groups (p>0.05). 
Loss of the FPR1 receptor does not affect hepatocyte proliferation which may be due 
to the fact that it has been primarily characterised in immune cells. Resolution of the 
CCl4 response by 72 hours is evident by a decreased proliferation but still significant 
response in injured groups from mean cells/field 3.426±0.15 increasing to 17.49±4.704 
in WT mice and means of 3.84±0.3712 rising to 18.5±4.558 cells/field in KO 
counterparts (p<0.05).  
 
5.4.6.3 Neutrophil recruitment in WT/KO mice post-acute CCl4 
Neutrophil recruitment is a major feature of the response to liver injury and this is 
apparent by the NIMP positive cells elevated with CCl4 after 24 hours. Both WT and 
KO mice showed demonstrable surges in PMN numbers but no apparent difference 
between genotypes. Mean cells/field increased from 2.25±0.5617 to 43.86±6,438 upon 
injury in C57Bl6 mice (p<0.001) while knockout mice exhibited a similar infiltration with 
1.72±0.1868 cells/field rising to 35.25±6.537 cells/field in CCl4-treated mice (p<0.001) 
By 48 hours post-CCl4 neutrophil levels have dropped drastically to 20.96±3.34 and 
20.71±4.71 cells/field in WT and KO CCl4 groups, both showed significant responses 
over vehicle controls p<0.01 and p<0.01 respectively. No difference was detected 
between genotypes in terms of neutrophil recruitment at this endpoint, which is 
testament to the defined stages of the wound-healing response shown by analysis of 
livers injured with CCl4 within 72 hours. Indeed the neutrophil response was fully 
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resolved by 72 hours post-CCl4 treatment with no significant increase over vehicle 
controls. 
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Figure 5.8: Proliferating cell nuclear antigen (PCNA)-positive hepatocytes in acute 
CCl4-injured livers after 24, 48 and 72 hours. All groups, olive oil (OO) and carbon 
tetrachloride (CCl4) treated had relative photomicrographs of FFPE wildtype (WT) and 
FPR knockout (KO) liver sections (see appendix C) stained indirectly via IHC of (x20 
magnification) and had a minimum of 4-5 mice. Data was then analysed via counting 
software on the Nikon microscope with results expressed as mean positive cells per 
high power field (hpf) ±SEM. All p values were calculated using a one-way analysis of 
variance (ANOVA); **** p<0.0001, * p<0.05 and ns p>0.05. 
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Figure 5.9: Neutrophil recruitment in acute CCl4-injured livers after 24, 48 and 72 
hours. All groups, olive oil (OO) and carbon tetrachloride (CCl4) treated had relative 
photomicrographs of FFPE wildtype (WT) and FPR knockout (KO) liver sections (see 
appendix C) stained indirectly via IHC for NIMP (x20 magnification) and had a minimum 
of 4-5 mice. Data was then analysed via counting software on the Nikon microscope 
with results expressed as mean positive cells per high power field (hpf) ±SEM. All p 
values were calculated using a one-way analysis of variance (ANOVA); ** p<0.01; *** 
p<0.001 and ns p>0.05. 
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5.4.6.4 CD68+ve macrophages in CCl4-injured livers 
Resident kupffer macrophages are a main responder to hepatocellular injury by carbon 
tetrachloride drug (1:1 ratio with vehicle) driving fibrogenesis as a producer of TGF-β 
cytokine. After each time point: 24, 48 and 72 hours post-CCl4 there was an increase 
in the number of CD68 positive cells per high power field (x 20 magnifications) from 
that of vehicle olive oil resident populations. 24 hours post-injury the majority of the 
inflammatory response is made up of neutrophils with a lesser response by 
macrophages. CD68+ve cells/field were increased in WT mice from a mean of 
57.86±2.739 (vehicle) to 79.8±1.85 (CCl4) in a significant response (p<0.001). KO 
groups exhibited a similar increase at this endpoint with a more dramatic increase to 
82.96±4.58 mean positive cells per hpf (p<0.001). With loss of FPR1 there may be a 
compensatory mechanism at play here due to dampened neutrophil response in this 
phase. In the fibrogenesis phase at 48 hour endpoint CD68 macrophages increase 
their population correlating with increases in ECM production and fibrogenic markers. 
Both WT and KO livers demonstrated significant increases in macrophage infiltration 
(mean counts of 95.2±14.4 cells/field (p<0.001) and 109.2±7.823 cells/field (p<0.001)). 
Indeed it is at this endpoint during the wound-healing response that the peak level of 
macrophage recruitment is observed. This immune infiltration is dampened by 72 
hours with resolution of the injury but significant elevations were determined compared 
to vehicle controls. WT levels rose from 42.91±4.382 to 79.36±3.154 mean cells/field 
(p<0.0001) and KO mice displayed an increase from 39.31±2.402 to 75.7±1.707 
cells/field (p<0.0001) showing a dampened recruitment of this cell population by 72 
hours indicating that this TGF-β reservoir is no longer required with resolution of injury.  
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Figure 5.10: Macrophage recruitment in acute CCl4-injured livers after 24, 48 and 72 
hours. All groups, olive oil (OO) and carbon tetrachloride (CCl4) treated had relative 
photomicrographs of FFPE wildtype (WT) and FPR knockout (KO) liver sections (see 
appendix C) stained indirectly via IHC for CD68 (x20 magnification) and had a 
minimum of 4-5 mice. Data was then analysed via counting software on the Nikon 
microscope with results expressed as mean positive cells per high power field (hpf) 
±SEM. All p values were calculated using a one-way analysis of variance (ANOVA); 
*** p<0.001; **** p<0.0001 and ns p>0.05. 
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Figure 5.11: Lymphocyte recruitment in acute CCl4-injured livers after 24, 48 and 72 
hours. All groups, olive oil (OO) and carbon tetrachloride (CCl4) treated had relative 
photomicrographs of FFPE wildtype (WT) and FPR knockout (KO) liver sections (see 
appendix C) stained indirectly via IHC for CD3 (x20 magnification) and had a minimum 
of 4-5 mice. Data was then analysed via counting software on the Nikon microscope 
with results expressed as mean positive cells per high power field (hpf) ±SEM. All p 
values were calculated using a one-way analysis of variance (ANOVA) ns p>0.05. 
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5.4.6.5 Lymphocyte populations upon acute CCl4 liver injury 
CD3 positive lymphocytes displayed consistent counts at each endpoint regardless of 
phase, treatment (vehicle or CCl4) or fpr1 expression with no significant responses 
determined (p>0.05). With fibrogenesis in this acute model lymphocytes do not play a 
role during the inflammatory (24 hours post-CCl4), fibrogenesis (48 hours post-CCl4) 
and resolution phases (72 hours post-CCl4). 
 
5.4.7 Summary of FPR’s role in fibrogenesis mediated by acute CCl4 treatment 
Co-ordination of multiple cell types such as hepatic stellate cells (HSCs), hepatocytes, 
kupffer macrophages and neutrophils is responsible for hepatic fibrogenesis. The 
resulting effect is production of extracellular matrix (ECM) protein and activation of 
myofibroblasts. With regards to the loss of the chemoattractant receptor, FPR1 there 
appears to be a minimal effect on the initial response to toxin-induced injury. A slight 
reduction in neutrophil infiltration during the inflammatory phase has little effect on 
hepatocyte proliferation and macrophage resident populations. Alpha-SMA deposition 
occurs mainly at fibrogenesis phase with no difference between CCl4 injured livers of 
WT and KO livers.  
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5.5 Chronic CCL4 model 
5.5.1 Serum damage enzyme markers 
As with the human disease serum ALT and AST levels were elevated with hepatic 
fibrosis induced by CCl4 (Figure 5.12). No difference detectable between CCl4 groups 
with either marker (p>0.05). ALT serum concentrations increased from mean values of 
187.2±46.43 (WT OO) and 158.0±52.18 (KO OO) to 6934±805.3 (WT CCl4) and 
5147±776.3 (KO CCl4) in a significant response (p<0.0001 and p<0.001 respectively, 
Figure 5.12 (a)). ALT is a more specific marker for liver damage than AST due to highly 
localised nature in that particular organ. AST is secreted in CCl4-injured groups in a 
similar manner to ALT but due to its less specific secretion profile responses are 
notably less dramatic in WT and KO mice. WT mice exhibited an increase (p>0.05) 
with toxin treatment knockouts exhibited a significant response increasing from a mean 
concentration of 1115±481.8 U/L (vehicle) to 5104±1329 U/L (CCl4; p<0.05) but this 
most likely due to variability in individual readings (as indicated by increased S.E.M.; 
Figure 5.12 (b)). Between chronically injured groups there is no difference in responses 
following the same patterns determined in fibrotic score and collagen deposition. 
 
5.5.2 Fibrotic score and hydroxyproline content 
Analysis of total collagen content was achieved by a hydroxyproline assay of acid-
hydrolysed liver samples (Figure 5.13). Hydroxyproline content (µg) was derived from 
absorbance readings and normalised to weight of tissue pre-hydrolysis. Following 8 
weeks of biweekly i.p. injections of vehicle/toxin both WT and KO mice exhibited 
significant increases in total collagen content (p<0.05). C57Bl6 increased from 
0.2412±0.08704 µg/g to 1.034±0.1895 µg/g (olive oil to CCl4 respectively) and KO mice 
displayed a similar response from 0.4204±0.08710 µg/g to 1.202±0.1945 µg/g (olive 
oil to CCl4 respectively).  
Scoring of chronic CCl4 model via PSR stained sections (Figure 5.14) showed no 
difference in the rank/level of fibrosis between WT and KO mice, both demonstrated 
more than 2 hepatic vessels bridging together by non-functional scar formation and 
multi-layered ECM deposition. Some mice from either genotype scored between ranks 
due to a lack of homogeneity between different lobes. WT and KO exhibited significant 
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increases in fibrotic score with CCl4 regimen compared to vehicle controls (p<0.0001) 
with mean values of 2.944±0.1002 and 3. 
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Figure 5.12: Serum liver damage enzymes released during chronic CCl4 model. Liver 
function serum markers (a) ALT and (b) AST measured in U/L in WT vehicle (OO, n=5), 
KO vehicle (OO, n=6), WT CCl4 (n=9), KO CCl4 (n=9) groups after 8 weeks of biweekly 
carbon tetrachloride (CCl4) or olive oil (OO)  injections. Mean U/l of different groups 
expressed with SEM displayed. All p values were calculated using a one-way analysis 
of variance (ANOVA); * p<0.05, *** p<0.001, **** p<0.0001 and ns p>0.05. 
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Figure 5.13: Hydroxyproline content of chronic CCl4-treated WT/KO mice. Total 
collagen content per g of wet tissue was assayed in WT vehicle (OO, n=5), KO vehicle 
(OO, n=6), WT CCl4 (n=9), KO CCl4 (n=9) groups after 8 weeks of carbon tetrachloride 
(CCl4) or olive oil (OO) biweekly injections. Mean hydroxyproline content (µg/g) of 
different groups expressed with SEM displayed. All p values were calculated using a 
one-way analysis of variance (ANOVA); * p<0.05. 
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Figure 5.14: Fibrotic score of chronic CCl4-treated WT/KO mice. Scoring ranked 
animals according to severity of bridging fibrosis and scar tissue formation in WT 
vehicle (OO, n=5), KO vehicle (OO, n=6), WT CCl4 (n=9), KO CCl4 (n=9) groups after 
8 weeks of biweekly carbon tetrachloride (CCl4) or olive oil (OO) injections. Means of 
different groups expressed with SEM displayed. All p values were calculated using a 
one-way analysis of variance (ANOVA); **** p<0.0001. 
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5.5.3 Fibrotic marker gene expression 
Gene expression levels of different markers showed variable responses to chronic liver 
injury with repeated CCl4 dosing (Figure 5.15). Pro-collagen 1 mRNA levels were used 
to measure collagen 1 gene expression in vehicle/toxin treated livers. Expression of 
collagen 1 increased (relative to WT vehicle control mean of 2.117±0.6844 fold) in WT 
CCl4 group to 77.68±10.9 fold higher (p<0.001). With ablation of the fpr gene mice did 
not elicit a significant increase in gene expression but a notable elevation was evident 
in CCl4 group (mean fold change: 40.2±9.683, p>0.05) hence between WT and KO 
injured groups a significant reduction in collagen 1 expression was determined 
(p<0.05). The regulator of ECM production, Tissue Inhibitor Of Metalloproteinases 1 
(TIMP1) gene expression showed a similar pattern with a significant mean fold change 
increase relative to WT vehicle control, 4.019±1,435 (OO) to 71.56±12.93 in CCl4 group 
(p<0.01). With TIMP1, as with collagen 1 expression there was a significant reduction 
(p<0.05) between WT and KO-injured groups (mean fold change decreasing from 
71.56±12.93 to 36.37±7.39 respectively) probably caused by a less significant 
response in KO animals (p>0.05).  Alpha-SMA, a major marker of activated 
myofibroblasts was expressed at high levels in CCl4-injured groups with ~3-fold and 
~2.5-fold increases compared to WT vehicle control in WT and KO mice respectively 
(p>0.05). MMP2 and MMP9 metallopeptidase, regulators of the extracellular matrix 
(ECM) expression exhibited a significant increase of 6-fold and 4-fold over wild-type 
vehicle controls with CCl4 treatment respectively (p>0.05). Pro-inflammatory cytokines, 
KC and MCP-1 were notably increased in chronic injury groups; 9.915±2.336 fold 
increase of KC mRNA levels (p>0.05) and to a non-significant extent with MCP-1 
(p>0.05) respectively over WT vehicle control group. Secretion of these cytokines in 
the chronic CCl4 model indicates the overlapping processes of inflammation, 
fibrogenesis and the resolution occurring simultaneously in fibrotic liver tissue. 
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Figure 5.15: Fibrogenic and inflammatory marker gene expression in chronic CCl4-
treated WT/FPR1KO mice. Liver mRNA levels of (a) α-SMA, (b) collagen 1, (c) 
MMP2, (d) TIMP1, (e) KC and (f) MCP-1 were assayed by quantitative PCR in WT 
vehicle (OO, n=5), KO vehicle (OO, n=6), WT CCl4 (n=9), KO CCl4 (n=9) groups after 
8 weeks of biweekly carbon tetrachloride (CCl4) or olive oil (OO) injections. Fold 
change was calculated relative to WT vehicle (normalised to GAPDH housekeeping 
gene) to generate relative gene expression. Mean fold change of different groups are 
expressed with SEM displayed. All p values were calculated using a one-way 
analysis of variance (ANOVA); *** p<0.001, ** p<0.01 and *p<0.05. 
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5.5.4 Immunohistochemistry  
5.5.4.1 H&E  
Haemotoxylin and eosin (H&E) staining of chronic CCl4 tissue sections demonstrated 
the characteristic scar formation with the biweekly treatment as indicated in Figure 
5.16. Hepatocyte centrilobular death is evident with CCl4 administration. From H&E 
sections inflammation and infiltration is similar between WT and KO CCl4 overall. Some 
KO CCl4 showed increased inflammation but with others it clearly down. KO mice 
showed variability in their immune response to the CCl4 biweekly treatment possibly 
indicating compensation mechanisms to the loss of FPR expression resulting in altered 
inflammatory infiltrate profiles. 
 
5.5.4.2 Sirius Red  
PicroSiriusRed (PSR) staining of collagen I/III in FFPE liver sections (4µm) 
demonstrated similar levels of pixel intensity upon densitometry analysis in CCl4-
treated groups (Figure 5.17). Both WT and KO displayed significant increases in PSR 
percentage area (p<0.0001) from olive oil (mean % areas of 0.478±0.1128 and 
0.5356±0.1025 respectively) to CCl4 groups (mean % areas of 2.979±0.2451 and 
3.731±0.2489 respectively).   Collagen deposition showed no apparent 
increase/decrease between genotypes but both genotypes displayed clear bridging 
fibrosing patterns compared to vehicle controls.  
 
5.5.4.3 Alpha-SMA: an indicator of HSC activation during liver fibrosis 
Chronic CCl4 biweekly injections induced alpha-smooth muscle actin fibre formation 
with clear elevations in percentage area from olive oil vehicle controls to CCl4 in wild-
type and knockout mice (Figure 5.18). WT mice mean positive area staining increased 
from 0.3367±0.02617 % to 3.618±0.3456 % in vehicle and drug-treated groups 
respectively (p<0.0001). KO mice also elicited a significant increase (p<0.001) in α-
SMA mean positive area staining from 0.3761±0.07252 % to 2.549±0.3781 % in 
vehicle and drug-treated groups respectively. Although a slight reduction in positive 
staining was observed in KO mice compared to WT this difference was non-significant 
(p>0.05) with fibrosis developing in both genotypes to a similar severity. This was also 
indicated by IHC, histology, serum markers and hydroxyproline content. 
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Figure 5.16: H&E highlighted histological features of chronic CCl4. Relative 
photomicrographs of sections stained directly of WT and KO livers harvested after 8 
weeks of biweekly carbon tetrachloride (CCl4) or olive oil (OO) regimen (x20 
magnification). (a) WT vehicle (OO, n=5), (b) WT CCl4 (n=9), (c) KO vehicle (OO, n=6) 
and (d) KO CCl4 (n=9) groups with arrows indicating areas of damage and scar 
formation. 
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Figure 5.17: PSR collagen staining of chronic CCl4 / vehicle-treated WT/KO livers. 
Relative photomicrographs of sections stained directly for collagen I/III in WT and KO 
livers (x10 magnification, scale bar represents 100µm) were analysed using 
densitometry. (a) WT vehicle (OO, n=5), (b) WT CCl4 (n=9), (c) KO vehicle (OO, n=6), 
and (d) KO CCl4 (n=9) groups were subject to 8 weeks of biweekly treatment. Arrows 
indicate areas of bridging fibrosis and collagen deposition. Results are expressed as 
mean percentage area ±SEM. All p values were calculated using a one-way analysis 
of variance (ANOVA); **** p<0.0001. 
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Figure 5.18: α-SMA production by activated stellate cells in chronic CCl4 model. 
Relative photomicrographs of sections stained indirectly for α-SMA content in WT and 
KO livers (x10 magnification, scale bar represents 100µm) were analysed using 
densitometry. Arrows indicate area of ECM deposition and activated myofibroblasts. 
(a) WT vehicle (OO, n=5), (b) WT CCl4 (n=9), (c) KO vehicle (OO, n=6), and (d) KO 
CCl4 (n=9) groups were subject to 8 weeks of biweekly treatment. Results are 
expressed as mean percentage area ±SEM. All p values were calculated using a one-
way analysis of variance (ANOVA); *** p<0.001 and **** p<0.0001. 
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5.5.4.4 Proliferation of hepatocytes after chronic CCl4 
In order to assess proliferation Proliferating cell nuclear antigen (PCNA) staining via 
IHC was performed on FFPE liver sections (Figure 5.19). PCNA has a well 
characterised role as a DNA sliding clamp with an essential role in DNA replication 
(Maga and Hübscher, 2003). Positive PCNA staining was exhibited by both 
proliferating liver hepatocytes and lymphocytes, the latter excluded from analysis. 
Numbers of positively stained hepatocytes were used as an index for proliferation 
following vehicle/drug treatment in WT and KO mice. Olive oil and CCl4 groups for each 
genotype showed no difference in PCNA, therefore proliferation was not affected by 
FPR1 expression (p>0.05). PCNA expression in hepatocytes did increase significantly 
with drug treatment over vehicle control (p<0.05) with average counts of 16.42±2.987 
cells/field and 16.11±2.903 cells/field in WT and KO CCl4-treated groups respectively. 
 
5.5.4.5 NIMP, neutrophil marker 
During the course of chronic liver fibrosis induced by CCl4 repeated application injury 
responses are renewed with every subsequent injection. Even highly fibrotic liver are 
undergoing inflammatory reactions with infiltrate increased in CCl4-treated mice. 
Staining for neutrophil-specific NIMP expression through IHC methods was increased 
in WT hepatotoxin-treated compared to vehicle controls (Figure 5.20, reflected by 
mean positive cells elevation to 6.403±0.9007 from 1.647±0.142 per high power field 
(p<0.01). KO mice also exhibited significantly increased mean counts from 
1.58±0.1495 (vehicle) to 8.807±1.177 (CCl4) per field (p<0.0001). Despite this 
increased response no difference between WT and KO drug-treated groups was 
detected (p>0.05).  
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Figure 5.19: Proliferation in chronic CCl4 model via PCNA positive hepatocytes. 
Relative photomicrographs of sections stained indirectly for PCNA via IHC of WT and 
KO livers (x20 magnification, scale bar represents 100µm) were analysed using 
counting software on Nikon microscope. Arrows indicate PCNA+ve hepatocytes. (a) 
WT vehicle (OO, n=5), (b) WT CCl4 (n=9), (c) KO vehicle (OO, n=6), and (d) KO CCl4 
(n=9) groups were subject to 8 weeks of biweekly treatment. Results are expressed as 
mean positive cells per high power field ±SEM. All p values were calculated using a 
one-way analysis of variance (ANOVA) * p<0.05; ns p>0.05. 
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Figure 5.20: Neutrophil infiltration in chronic CCl4 model. Relative photomicrographs 
of sections stained indirectly for NIMP via IHC of WT and KO livers (x20 magnification, 
scale bar represents 100µm) were analysed using counting software on Nikon 
microscope. Arrows indicate NIMP+ve neutrophils. (a) WT vehicle (OO, n=5), (b) WT 
CCl4 (n=9), (c) KO vehicle (OO, n=6), and (d) KO CCl4 (n=9) groups were subject to 8 
weeks of biweekly treatment. Results are expressed as mean positive cells per high 
power field ±SEM. All p values were calculated using a one-way analysis of variance 
(ANOVA); ** p<0.01; **** p<0.0001 and ns p>0.05. 
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5.5.4.6 CD68, macrophages/monocytes marker 
CCl4-injured mice exhibited an elevated macrophage/monocyte (CD68+) count 
compared to vehicle-treated mice (Figure 5.21). Kupffer cells are liver-specific 
macrophages with known roles in different liver diseases such as hepatitis, 
steatohepatitis, alcoholic liver disease, allograft rejection and in particular liver fibrosis 
(Kolios et al., 2006). CD68+ cells increased significantly (p<0.05) in WT mice from OO 
group (61.60±2.187 cells/field) to CCl4 group (107.9±12.46 cells/field). Knockouts also 
demonstrated an increase and the response displayed significance (p<0.01). CD68+ 
Kupffer cells were elevated from mean counts of 59.68±2.326 cells/field (vehicle) to 
123.6±11.35 cells/field (CCl4) but when compared with WT groups no difference was 
detected (p>0.05). 
 
5.5.4.7 CD3, total T-cell population marker 
CD3+ lymphocyte cells were evaluated via IHC in liver tissue sections following chronic 
application of vehicle/CCl4 (Figure 5.20). No difference was determined between WT 
OO and WT CCl4 groups (p>0.05). KO CCl4 group (mean 13.8±0.6463 cells/field) 
displayed elevated CD3 positivity (p<0.01) from vehicle control group (8.532±1.367 
cells/field). Chronic injured mice demonstrated a significant increase upon ablation of 
fpr1 gene compared to WT counterpart (p<0.05).  
202 
 
 
 
Figure 5.21: Macrophage accumulation after repeated CCl4 injury and fibrosis 
development. Relative photomicrographs of sections stained indirectly for CD68 via 
IHC of WT and KO livers (x20 magnification, scale bar represents 100µm) were 
analysed using counting software on Nikon microscope. Arrows indicate CD68+ve 
macrophages. (a) WT vehicle (OO, n=5), (b) WT CCl4 (n=9), (c) KO vehicle (OO, n=6), 
and (d) KO CCl4 (n=9) groups were subject to 8 weeks of biweekly treatment. Results 
are expressed as mean positive cells per high power field ±SEM. All p values were 
calculated using a one-way analysis of variance (ANOVA); * p<0.05; ** p<0.01 and ns 
p>0.05. 
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Figure 5.22: Lymphocyte localisation in fibrotic livers in chronic CCl4 model. Relative 
photomicrographs of sections stained indirectly for CD3 via IHC of WT and KO livers 
(x20 magnification, scale bar represents 100µm) were analysed using counting 
software on Nikon microscope. Arrows indicate CD3+ve lymphocytes. (a) WT vehicle 
(OO, n=5), (b) WT CCl4 (n=9), (c) KO vehicle (OO, n=6), and (d) KO CCl4 (n=9) groups 
were subject to 8 weeks of biweekly treatment. Results are expressed as mean positive 
cells per high power field ±SEM. All p values were calculated using a one-way analysis 
of variance (ANOVA); ** p<0.01 * p<0.05 and ns p>0.05. 
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5.5.5 Conclusion of fpr1 deletion on the CCl4 liver-injury model 
Chronic liver fibrosis as induced by repeated CCl4 administration was not affected in 
terms of fibrosis. Fibrotic protein markers: collagen, α-SMA as well as hepatocyte 
proliferation (as indicated by PCNA marker) demonstrated no difference between WT 
and KO mice. The overlapping processes of inflammation, fibrogenesis and resolution 
coordinate in the chronic CCl4 model. With no protective effect demonstrated in this 
organ as opposed to the bleomycin-induced pulmonary fibrosis model it is apparent 
that the environment may have an effect on FPR1’s role in fibrosis. With collagen, a 
key part of the ECM and the developing scar tissue in fibrosis, showing no significant 
difference between WT and KO there is apparent correlation with previous studies 
stating a redundancy for neutrophils in liver fibrosis. Defective PMN recruitment in 
S100A9 -/- null mice did not have an effect on liver fibrosis in the CCl4 model (Moles 
et al., 2013). FPR1 is expressed abundantly on neutrophils and was originally 
characterised as a chemoattractant receptor. In FPR1 deficient mice responses to 
chemotactic peptides will be compromised equating to an impaired neutrophil 
response. As neutrophils have been deemed unimportant in this chronic liver injury 
model it is unsurprising that WT and FPR1KO mice display no significant differences 
though is important to bear in mind that multiple factors are responsible for neutrophil 
infiltration such as S100A9, chemokine and cytokine receptors and secreted proteins 
and a myriad of different processes. Redundancy of these processes has been 
highlighted in neutrophil research therefore the lack of the effect of FPR1 may be linked 
to this highly conserved process.  
An altered inflammatory profile was observed after the 8 week regimen which may 
indicate that the loss of functional mfpr1 gene results in a compensatory response in 
the infiltrating immune cell populations. The altered chemotactic ability of neutrophils 
and macrophages may have reduced clearance of the organ following inflammation 
triggered by ROS generation. Loss of FPR1 will have affected expression of other 
receptors perhaps increasing levels of other members of the FPR family in particular 
mFPR2. Despite its low affinity the nature this receptor is promiscuous in nature, the 
absence of its high affinity counterpart could have well resulted in its up-regulation. 
The increased counts that were analysed by immunohistochemistry correlated with 
basic histology where a variable immune response was observed.   
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5.6 Unilateral ureter obstruction (UUO) kidney fibrosis model 
5.6.1 Hypothesis 
Since the UUO model is not characterised as a neutrophil-dependent mechanism fpr-
/- null mice will exhibit no change in pathogenesis and resulting fibrotic phenotype. 
5.6.2 Aims 
Human Chronic Kidney Disease (CKD) is modelled by obstruction of the left kidney in 
the UUO murine setting. Since this is a mechanical model of renal fibrosis and not a 
toxin-mediated injury mechanism the pathogenesis is different from the other in vivo 
models investigated. For evaluation of the effect of the formyl-peptide receptor ligation 
and downstream signalling on renal fibrosis in vivo the UUO murine model was 
employed. Utilisation of the knockout FPR1 null mice allows the role of FPR1 activity 
to be elucidated in this organ setting. Examination of the left ureter’s obstruction at day 
5 and day 12 allowed two key parts of renal fibrosis in this model to be assessed via 
histological means.  
 
5.6.3 CKD in vivo experimental models 
Animal experimental models of CKD present a novel resource for the investigation of 
inflammation and fibrosis in the kidney to determine valid translational targets. There 
are a variety of different models available for the study of CKD in vivo which utilise 
different approaches including the 5/6 nephrectomy (primarily rat), adriamycin 
nephropathy, nephrotoxic serum (NTS) nephritis, diabetic nephropathy, chronic 
nephrotoxicity, ischaemia reperfusion and unilateral ureteral obstruction (UUO) tools 
(Eddy et al., 2012). Most of these models are well characterised in mechanistic 
investigations of CKD highlighting important contributions by such as the renin-
angiotensin system (5/6 nephrectomy), mononuclear cells (adriamycin nephropathy), 
antibody-mediated glomerular injury (NTS), hyperglycemia (diabetic-associated CKD), 
folic acid and aristolochic acid (nephrotoxicity) and acute injury as precursor to CKD. 
All of these models are used to reduce RRT rates by enhancing renal outcome (Satoh 
et al., 2001; Eddy et al., 2012). 
 
The UUO model is a valid, high throughput tool for studying renal disease on account 
of its pathogenesis’ similarity with a variety of disorders encompassed by the term 
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CKD. Surgical ligation of the left ureter results in renal inflammation, progressive 
damage and fibrosis (Klahr & Purkerson, 1994) similar to obstructive nephropathy 
(ObN) in humans. Blocking of urine and waste product excretion triggers 
hydronephrosis and tubulointerstitial damage (Klahr, 2000). Obstruction is typified by 
vasoconstriction, leukocyte infiltration and fibrosis development by scar tissue 
formation (Guo et al., 2001). Structural changes are evident in the cortical region in 
this model by tubular dilatation and interstitial expansion. The mechanism is mediated 
by a mechanical injury rather than any specific injury agent. It is most commonly used 
in the screening of agonists and antagonists due to its ability to translate across to 
human disease (Zeisberg and Kalluri, 2013). 
 
The UUO fibrosis model of progressive damage shares a degree of homology to the 
overall process of chronic kidney disease on account of the loss of nephron tissue. As 
with other fibrotic diseases fibrotic tissue is replaced by scar tissue with widespread 
destruction of parenchyma. As with other organ models of fibrosis in vivo the 
pathogenesis relies on an aberrant wound-healing response resulting from epithelial 
trans-differentiation and remodelling of the tissue. This leads to tubular dilatation and 
interstitial expansion with loss of parenchyma lining, atubular glomeruli generation and 
an interstitial-focussed deposition of extracellular matrix (ECM) fibrotic markers: 
collagen and fibronectin principally. Once in the fibrotic stage the UUO is virtually 
irreversible with permanent structural changes as the urinary pole of the capsule 
disconnects from the atrophic proximal tubular segment. Due to the interstitial focus 
and the preservation of distal tubular integrity of the model cortical region 
measurements are the standard method of assessing fibrosis via various staining 
techniques (Forbes et al., 2012).  
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5.6.4 Mechanism of UUO model 
 
To assess the effect of the deletion of FPR1 on renal fibrosis the UUO model was 
utilised with surgeries performed by Christopher Fox (Research Assistant) and 
assisted by myself and Rachel Howarth (Technician). Following obstruction mice were 
harvested at 5 days and 12 days for evaluation of infiltration and fibrotic phases (shown 
in Fig 5.23). Contralateral controls were comprised of right uninjured kidneys providing 
basal levels for immunohistochemistry and histological scoring. 
 
 
Figure 5.23: Mechanical injury of left kidneys with evaluation at early inflammatory 
stages (Day 5) and fibrotic phase (Day 12) following progressive damage. Obstruction 
of left kidneys (LK) as pictured while right kidney (RK) is left as a contralateral control 
for each animal. 
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5.6.5 Renal histology via PAS stain 
Periodic acid Schiff’s (PAS) staining of 4µm FFPE kidney tissue highlighted large 
carbohydrate structures in basement membranes and connective tissues which 
constitute components of renal tubules and interstitial areas respectively. Tubular 
dilatation and interstitial expansion are the two main histological measures of kidney 
damage mediated by the mechanical injury in this model. With injury tubules in cortical 
region dilate and interstitial area expands due to excessive extracellular matrix 
production. Essentially this histological scoring enables evaluation of the robustness 
of the UUO model by gauging the consistency of the mechanical injury through semi-
quantification of cortical regions.   
5 days (5D) post-ligation tubular dilatation (TD) and interstitial expansion (IE) were 
determined using PAS-stained tissue sections and a superimposed 10 x10 grid (Figure 
5.24a). Interstitial expansion and tubular dilatation scores (%) were calculated by 
number of intersections located in tubular structures or interstitial areas divided by total 
grid intersections (maximum of 81). Any intersections present in glomeruli bodies were 
subsequently subtracted from the total number of intersections. WT 5D IE scores 
increased upon injury from mean of 9.113% (control group) to 18.76% in a significant 
manner (p<0.0001). KO mice exhibited a similar response to ureter ligation (p<0.0001) 
with the IE score rising from 9.05% (RK) to 18.31% (LK). TD scores for WT and KO 
UUO mice were elevated from 10.65% and 10.55% (contralateral) to 21.98% and 
25.00% (ligated) respectively in similar responses (p<0.0001 both groups). After 5 days 
scoring indicates a consistent progressive injury from the initial mechanical procedure.  
At 12 days post-UUO tubular dilatation (TD) or interstitial expansion (IE) scores were 
semi-quantified by number of grid intersections counted using a 10 x 10 grid (Figure 
5.24b). IE scores displayed no difference between WT and KO mice each rising from 
8.25% and 8.725% (contralateral) mean values respectively to 21.38% and 19.65% 
respectively in obstructed kidneys (p<0.0001 both groups). TD scores in WT and KO 
mice also increased from mean values of 10.16% and 10.55% (unobstructed) to mean 
values of 18.79% and 21.41% (obstructed) respectively (p<0.0001 both groups).  
From the highly similar injury responses demonstrated in the cortical region scoring 
the robustness of the model is evident.  
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5.6.6 Day 5 UUO: Immune cell infiltrate 
With histological staining displaying similar levels of injury with both WT and KO 
evaluation of the immune cell infiltrate in the tissue was carried out by IHC analysis 
using different cellular markers: CD68 for macrophages, CD3 for lymphocytes and 
NIMP for neutrophils (Figure 5.25 (a), (b) and (c))  
The UUO is associated with leukocyte infiltration but neutrophils are regarded as 
having a minimal role (Figure 5.25a). At day 5 0.5571±0.1343 cells/field were counted 
on average for WT injured kidneys and KO had 0.7705±0.1283 cells/field (p<0.05) with 
no apparent difference between left kidneys groups (p>0.05). Although both genotypes 
displayed increased NIMP+ counts compared to contralateral control right kidneys the 
response is minimal.  
CD68 macrophage infiltration observed in the cortices of obstructed kidneys (Figure 
5.25b) exhibited little difference between WT and KO (p>0.05). Average IHC counts of 
5.908±1.043 and 7.083±1.06 cells/field (WT and KO LK groups respectively) showed 
clear increases compared to contralateral WT (p<0.01) and KO (p<0.001) kidneys 
(1.078±0.1445 cells/field and 0.9424±0.1104 cells/field mean values respectively).  
CD3 lymphocytes represent most subsets of T-cells excluding B-cells and Natural 
Killer (NK) cells. The determination of T-cell involvement is important to assess the 
immune cell infiltration (Figure 5.25c). CD3+ IHC counts increased in response to 
ureter ligation (WT: 45.33±3.291 cells/field; KO: 36.98±7.716 cells/field) with both 
genotypes exhibiting a shift in immune cell populations compared to non-injured 
controls (p<0.0001 and p<0.001 respectively). No difference between left-injured 
kidneys from WT and KO groups was elucidated (p>0.05). 
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Figure 5.24: Histological scoring of UUO injured (LK) and control contralateral (RK) 
kidneys in WT/KO mice. Relative photomicrographs imaged at x20 magnification and 
analysed for interstitial expansion and tubular dilatation at (a) 5 days (n=7 WT and n=6 
KO animals) and (b) 12 days (n=7 WT and n=7 KO animals) post-surgery. Results are 
expressed as mean grid intersections per high power field ±SEM. All p values were 
calculated using a one-way analysis of variance (ANOVA); **** p<0.0001. 
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Figure 5.25 (a): Immune cell infiltration 5 days post-UUO in injured (LK) and control 
contralateral (RK) kidneys in WT/KO mice. Relative photomicrographs of sections 
indirectly stained for NIMP+ve neutrophils of (a) WT RK, (b) WT LK, (c) KO RK and (d) 
KO LK groups (imaged at x20 magnification, scale bar represents 100µm). Groups are 
as follows: n=6 WT and n=7 KO animals. Results are expressed as (e) mean positive 
cells per high power field ±SEM. All p values were calculated using a one-way analysis 
of variance (ANOVA); * p<0.05; ns p>0.05. 
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Figure 5.25 (b): Immune cell infiltration 5 days post-UUO in injured (LK) and control 
contralateral (RK) kidneys in WT/KO mice. Relative photomicrographs of sections 
indirectly stained for CD68+ve macrophages of (a) WT RK, (b) WT LK, (c) KO RK and 
(d) KO LK groups (imaged at x20 magnification, scale bar represents 100µm). Groups 
are as follows: n=6 WT and n=7 KO animals. Results are expressed as (e) mean 
positive cells per high power field ±SEM. All p values were calculated using a one-way 
analysis of variance (ANOVA); *** p<0.001; ** p<0.01. 
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Figure 5.25 (c): Immune cell infiltration 5 days post-UUO in injured (LK) and control 
contralateral (RK) kidneys in WT/KO mice. Relative photomicrographs of sections 
indirectly stained for CD3+ve lymphocytes of (a) WT RK, (b) WT LK, (c) KO RK and 
(d) KO LK groups (imaged at x20 magnification, scale bar represents 100µm). Groups 
are as follows: n=6 WT and n=7 KO animals. Results are expressed as (e) mean 
positive cells per high power field ±SEM. All p values were calculated using a one-way 
analysis of variance (ANOVA); **** p<0.0001; *** p<0.001; ns p>0.05. 
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5.6.7 Fibrotic marker expression: PSR, ALPHA-SMA 
At day 12 post-ligation fibrotic markers were evaluated via immunohistochemistry to 
determine if differences were exhibited between WT and KO injured mice (Figure 
5.26). PicroSiriusRed (PSR) staining of collagen in the ECM displayed no difference 
between genotypes in response to obstruction. WT left-ligated kidneys displayed a 
significant response to progressive injury increasing from control RK mean value of 
1.517±0.571 % area to 8.457±0.5707 % area (p<0.0001). A similar fibrotic response 
was shown by KO mice rising from contralateral mean of 0.7351±0.2031 %  to 
8.057±0.9559 % in injured left kidneys (p<0.0001). Most collagen deposition was 
observed by tubular wall regions and glomeruli fitting with this models pathogenesis.  
Alpha-SMA IHC, a marker of activated myofibroblasts presumably abundant after this 
length of time after obstruction due to the progressive nature of the obstruction damage 
effects and fibrosis development. Typically, fibrosis begins to develop after 10 days 
post-ligation with wide scale obliteration by 14 days (Shao et al., 2010). Densitometry 
of anti-α-ASMA stained FFPE-sections (Figure 5.27) demonstrated an increase in 
obstructed compared to right kidneys but this change was relatively small. Both WT 
and KO showed elevated α-SMA % area in cortical regions of injured kidneys (LK) 
compared to controls (RK). WT mice demonstrated this with RK % area 
(0.7667±0.09215 mean value) escalating with injury to 2.826±0.3955 % (mean area, 
p<0.0001). Knockouts were subject to a similar fibrotic response evident by day 12 
rising from 1.156±0.1243 % area to 2.837±0.3305 % area mean value in RK and LK 
groups respectively (p<0.05). 
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Figure 5.26: PSR staining of kidneys 12 days post-UUO in injured (LK) and control 
contralateral (RK) kidneys in WT/KO mice. Relative photomicrographs of sections 
directly stained for collagen I/III of (a) WT RK, (b) WT LK, (c) KO RK and (d) KO LK 
groups (imaged at x20 magnification, scale bar represents 100µm). Groups are as 
follows: n=7 WT and n=7 KO animals. Results are expressed as (e) mean percentage 
area per high power field (hpf) ±SEM. All p values were calculated using a one-way 
analysis of variance (ANOVA); **** p<0.0001. 
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Figure 5.27: α-SMA production by kidneys 12 days post-UUO in injured (LK) and 
control contralateral (RK) kidneys in WT/KO mice. Relative photomicrographs of 
sections indirectly stained for α-SMA of (a) WT RK, (b) WT LK, (c) KO RK and (d) KO 
LK groups (imaged at x20 magnification, scale bar represents 100µm). Groups are as 
follows: n=7 WT and n=7 KO animals. Results are expressed as (e) mean percentage 
area per high power field ±SEM. All p values were calculated using a one-way analysis 
of variance (ANOVA); **** p<0.0001; * p<0.05; ns p>0.05. 
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5.6.8 Immune cell infiltration at day 12 post-UUO ligation 
As for immune cells no difference in macrophage (CD68+ve) cells was exhibited at 12 
days between genotypes (Figure 5.28). Even with the progressive injury the infiltrate 
remains the same when comparing the different genotypes. WT and KO control 
kidneys increased from 1.455±0.2473 cells/field and 1.364±0.2033 cells/field 
respectively to 6.66±0.8541 cells/field and 7.063±0.3254 cells/field respectively 
(p<0.0001). KO mice elicited a similar effect upon injury with an increase in mean 
counts of 1.364±0.2033 cells/field to 7.063±0.3254 cells/field (p<0.0001).  
CD3+ lymphocyte staining via IHC of WT and KO kidney sections (Figure 5.29) 
revealed significant responses to progressive injury over contralateral controls 
(p<0.0001) albeit less T-cells were recruited than at 5 days post-ligation. WT mean 
counts increased from 1.455±0.2473 cells/field (RK control) to 13.09±1.27 cells/field 
(LK) while KO mean counts rose from 1.364±0.2033 cells/field (RK control) to 
9.457±0.5241 cells/field (LK) in a significant manner (p<0.0001). With ablation of the 
gene WT LK and KO LK exhibited a significant difference (p<0.01). Apparently 
deficiency of this formyl-peptide receptor-1, a major chemoattractant receptor leads to 
downstream effects on T-cell infiltration in the fibrotic kidney. 
 
5.6.9 Conclusion of fpr1-deletion effect on kidney fibrosis in UUO model 
From histological scoring, immune cell IHC counts and ECM deposition at 5 days and 
12 days post-surgery there was apparently no difference between injured kidneys of 
WT and KO mice. The nature of the injury process in this model was mechanical in 
origin resulting in a progressive development of fibrosis. The microenvironment of the 
kidney is different from that of the lung and liver which leads to an alternative fibrotic 
pathogenesis. Bleomycin and carbon tetrachloride induce acute injury processes 
triggering fibrogenesis and ultimately fibrosis if left unchecked. Ligation of kidneys in 
the UUO model instigates a very different pathogenesis and both WT and KO mice 
develop renal fibrosis in a similar manner. Perhaps this organ model is not the right 
method of analysing the role of fpr1 due to the lack of a neutrophil response. Without 
a motivated granulocyte-driven infiltration phase formyl-peptide may not have a 
demonstrable effect in this setting. However, in an acute injury focussed methodology 
such as ischaemia reperfusion this chemoattractant receptor may have more a 
significant effect. 
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The effect of FPR1 deletion on the development of kidney fibrosis via mechanical injury 
was quite ambiguous. The process of the injury via ligation of the left ureter is distinct 
from the acute injury mediated by bleomycin in the lung or toxin-mediated liver fibrosis 
in the CCl4 model. From the endpoints in this study there is no difference in the 
mechanical injury and the resulting fibrotic phenotypes as indicated by histological 
scoring and ECM deposition. As with the liver the fibrotic process in the renal setting 
is different from the pulmonary bleomycin model with regards to the microenvironment 
and the caveats of the UUO model itself. The pathogenesis of this model is not 
neutrophil-driven which may affect the role of FPR1 on the development of fibrosis.  
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Figure 5.28: Macrophage infiltration 12 days post-UUO in injured (LK) and control 
contralateral (RK) kidneys in WT/KO mice. Relative photomicrographs of sections 
indirectly stained for CD68+ve macrophages of (a) WT RK, (b) WT LK, (c) KO RK and 
(d) KO LK groups (imaged at x20 magnification, scale bar represents 100µm). Groups 
are as follows: n=7 WT and n=7 KO animals. Results are expressed as (e) mean 
positive cells per high power field ±SEM. All p values were calculated using a one-way 
analysis of variance (ANOVA); **** p<0.0001. 
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Figure 5.29: Lymphocyte infiltration 12 days post-UUO in injured (LK) and control 
contralateral (RK) kidneys in WT/KO mice. Relative photomicrographs of sections 
indirectly stained for CD3 of (a) WT RK, (b) WT LK, (c) KO RK and (d) KO LK groups 
(imaged at x20 magnification, scale bar represents 100µm). Groups are as follows: 
n=7 WT and n=7 KO animals. Results are expressed as (e) mean positive cells per 
high power field ±SEM. All p values were calculated using a one-way analysis of 
variance (ANOVA) **** p<0.0001; ** p<0.01; ns p>0.05. 
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5.7 Subcutaneous bleomycin skin fibrosis model 
5.7.1 Hypothesis 
As the SC bleomycin model does not follow the same pattern as the acute intratracheal 
instillation of bleomycin (with the latter’s pathogenesis consisting of an inflammatory 
and fibrotic phases) the fpr transgenic mutants will not display the same protective 
effect as this dependent on an influx of neutrophils specifically in the pulmonary setting. 
5.7.2 Aims 
Determination of the effect of fpr1-deletion on skin and lung fibrosis by subcutaneous 
(s.c.) injection of bleomycin for 28 days. Systemic scleroderma has been previously 
determined to be caused by SC administration of bleomycin every other day (Fullard 
et al., 2012). This rare autoimmune disease in humans shows fibrotic patterns and 
lesion formation in skin in an aberrant wound-healing response and is successfully 
modelled by repeated bleomycin administration to focal areas (Ardett, 2014). With daily 
injections the systemic effect is greater and fibrosis develops in the lungs. This 
contrasts with the acute injury induced by intratracheal delivery of the same drug 
characterised previously with reduced mortality and severity of response (Yamamoto 
et al., 1999; Gupte et al., 2009).  
 
5.7.3 Weight change over 28 day period for different treatment groups 
Saline treated mice stayed consistently within 10% of original weight while WT 
bleomycin group displayed a stark decrease (10-20% loss) upon week 3 of injection 
regimen with recovery to basal weight after 4 weeks. KO saline and bleomycin groups 
remained at roughly similar levels throughout treatments displaying no significant 
weight loss at week 3 unlike WT mice (Figure 5.30). 
222 
 
WT SAL
0 1 2 3 4
-10
-5
0
5
10
1
2
3
4
5
6
Week
P
e
rc
e
n
ta
g
e
 w
e
ig
h
t 
c
h
a
n
g
e
 (
%
)
KO SAL
0 1 2 3 4
0
5
10
15
20
1
2
3
4
5
Week
P
e
rc
e
n
ta
g
e
 w
e
ig
h
t 
c
h
a
n
g
e
 (
%
)
WT BLEO
0 1 2 3 4
-30
-20
-10
0
10
1
2
3
4
5
6
7
Week
P
e
rc
e
n
ta
g
e
 w
e
ig
h
t 
c
h
a
n
g
e
 (
%
)
KO BLEO
0 1 2 3 4
-10
0
10
20
30
40
1
2
3
4
5
6
7
Week
P
e
rc
e
n
ta
g
e
 w
e
ig
h
t 
c
h
a
n
g
e
 (
%
)
  
Figure 5.30: Weight change over course of 4 week regimen of daily bleomycin SC 
injection. Percentage weight change calculated accordingly from weight at day 0 and 
measured at weekly intervals in saline and bleomycin-treated WT and KO mice. 
Groups were as follows: (a) WT SAL (n=6), (b) WT BLM (n=7), (c) KO SAL (n=5) and 
(d) KO BLM (n=7). 
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5.7.4 Pulmonary fibrosis extracellular development following SC bleomycin  
Skin fibrosis was not induced by the daily bleomycin injections but the systemic 
application of the drug did have an effect in the lung setting. PSR staining showed an 
increase in collagen deposition with bleomycin-treated mice regardless of genotype to 
3.884% and 3.508% area stained from 1.292% and 1.780% (controls) in WT and KO 
mice respectively (p>0.05). Both wild type and knockout showed an increase when 
comparing saline and bleomycin groups but no significant difference observed 
between different genotype bleomycin groups (Figure 5.31). 
 
5.7.4.1 Hydroxyproline content of lung right lobe subjected to daily s.c. 
bleomycin injections 
Total collagen content as measured by this hydroxyproline assay demonstrated no 
significant difference between saline and bleomycin-treated or wild type and knockout 
groups (Figure 5.32). Mean values interpolated from an 8-point standard curve ranged 
from 1.028 to 1.224 with no significant response to repeated injury. Perhaps due to the 
systemic nature of the repeated injury response to bleomycin rather than a targeted 
bronchiolocentric mechanism pulmonary fibrosis does not develop to such a severity 
as observed previously. 
 
5.7.5 Pulmonary fibrogenic marker: secreted TGFβ1 levels present in BAL fluid 
Bronchoalveolar lavage (BAL) fluid from saline control and bleomycin-treated WT and 
KO mice was tested for levels of TGFβ1 cytokine via duoset ELISA (Figure 5.33). Upon 
repeated systemic injury with BLM the pro-fibrogenic cytokine is up-regulated 
compared to controls. WT and KO saline controls (mean values of 33.08±6.147pg/ml 
and 43.66±5.373pg/ml respectively) increased to 151.3±36.12pg/ml and 
148.5±42.26pg/ml with SC bleomycin administration (p<0.05 both groups). After 28 
days of bleomycin injections the responses by WT and KO mice is similar with no 
difference in response (p>0.05).  
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Figure 5.31: Collagen staining by PSR in lung sections from mice subcutaneously 
injected with bleomycin for 28 days. Sections from (a) WT SAL (n=6), (b) WT BLM 
(n=7), (c) KO SAL (n=5) and (d) KO BLM (n=7) groups were analysed via densitometry 
to yield (e) mean percentage (%) area (scale bars = 100µm). All p values calculated 
using one-way analysis of variance (ANOVA); ns p>0.05. 
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Figure 5.32: Hydroxyproline content of lung right lobes of 28 day s.c. bleomycin model. 
Lung homogenate of WT SAL (n=6), WT BLM (n=7), KO SAL (n=5) and KO BLM (n=7) 
groups were assayed for hydroxyproline content which was calculated by interpolation 
on Graphpad Prism from an 8-point set of hydroxyproline standards. Absorption 
readings normalised to the weight of each lobe measured at harvest prior to acid 
hydrolysis with results represented as mean of duplicate wells in µg/g±SEM. Statistical 
significance determined by using a one-way analysis of variance (ANOVA); ns, p>0.05 
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Figure 5.33: TGF-β1 cytokine secretion in WT/KO BAL fluid with SC bleomycin 
administration. BAL perfused from WT SAL (n=6), WT BLM (n=7), KO SAL (n=5) and 
KO BLM (n=7) groups assayed by duoset ELISA. Results expressed as a mean of 
duplicate wells in pg/ml±SEM. All p values calculated using one-way analysis of 
variance (ANOVA); * p<0.05, ns p>0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
227 
 
5.7.6 Mediator levels in lung homogenate in WT and FPR KO mice ascertained 
via MSD multiplex ELISA 
Multiple pro-inflammatory cytokines were analysed via an MSD platform designed for 
IL-1β, MCP-1, IL-6 and KC analytes (Figure 5.34 a-d respectively). All showed 
increased levels following bleomycin treatment in both WT and KO mice. Basal level 
analyte measurement observed with saline groups was consistent with different 
markers. IL-1β was significantly elevated upon injury with BLM in WT mice, mean value 
of 7.07±1.519 pg/ml vs. 1.753±0.268 pg/ml in saline control (p<0.01). It is worth noting 
that the 7 mice within this group exhibit a high degree of variability with an outlier of 
14.1pg/ml. KO mice elicited a similar response with bleomycin treatment (p>0.05) with 
a lot less variability in cytokine level.                                                                                                   
MCP-1 cytokine levels demonstrated clear increases from control to BLM groups in 
lung homogenate. WT saline-treated mice produced 34.71±3.431pg/ml which was 
subsequently increased to 68.43±9.778pg/ml in a significant response (p<0.05). KO 
mice also demonstrated an increase in MCP-1 from 29.42±3.883pg/ml to 
72.87±5.87pg/ml in control and bleomycin groups respectively (p<0.01). The difference 
in the responses with regards to this cytokine may in fact be due to variable levels in 
the WT BLM group ranging from 28.19 to 112.2pg/ml.                                                                                   
KC, the mouse equivalent of human IL-8, was another analyte measured in lung 
homogenate which in fact displayed a significant response to SC bleomycin. WT mice 
secreted a mean value of 7.616±0.9812pg/ml in control group and increased to 
19.3±3.887pg/ml with BLM (p<0.05). KO mice elicited a similar response rising from 
7.358±1.663pg/ml to 18.52±1.34pg/ml in saline and bleomycin groups respectively 
(p<0.05).                                                           
IL-6 cytokine was significantly increased in WT with bleomycin repeated treatment with 
injury rising to 82.6±34.35 pg/ml (p<0.05) but did not increase significantly in KO 
groups (p>0.05). No apparent difference was observed between knockout and wild 
type bleomycin groups with any of the analytes.  
Bleomycin daily treatment does appear to be having an effect on cytokines in the lung 
environment even after 28 days possibly due to repeated dosing but the effect is 
distinct from acute lung injury response induced by a more targeted dosing.  
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Figure 5.34: Inflammatory cytokine mediators in SC bleomycin model. Lung 
homogenate from WT SAL (n=6), WT BLM (n=7), KO SAL (n=5) and KO BLM (n=7) 
groups assayed for pro-inflammatory cytokine levels pf (a) IL-1β, (b) MCP-1. (c) KC 
and (d) IL-6 was measured by MSD as a mean of duplicate wells in pg/ml ±SEM. All p 
values calculated using one-way analysis of variance (ANOVA); * p<0.05, ** p<0.01 
and ns p>0.05. 
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5.7.7 Conclusion of fpr1 deletion in subcutaneous bleomycin model 
 
Although this model was originally employed to investigate another method of 
bleomycin administration which would hypothetically induce fibrosis in two separate 
organs the data generated indicates that it at least partially failed. Skin fibrosis did not 
develop after 28 days of daily injections with no dermal thickening in bleomycin-treated 
mice irrespective of genotype. Indeed variable responses were observed in control 
groups potentially indicating an inflammatory reaction despite no stimulus, perhaps 
repeated injections triggered a wound-healing response of its own or injection sites 
were compromised by infection triggering an immune response. Due to these results 
the effect of FPR1 on skin fibrosis in vivo could not evaluated.  
From the systemic effects of bleomycin administration over the 28 days the lungs of 
WT and KO mice were subject to subtle changes in ECM proteins and fibrogenic 
triggers such a TGF-β. Despite not being an acute response-driven pathogenesis there 
is a definite effect after 28 days but with little difference between genotypes potentially 
indicating that FPR1 acts primarily on the wound-healing process via neutrophil-
mediated mechanisms. 
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5.8 Summary of fpr1 deletion in non-pulmonary fibrosis in vivo models 
 Carbon tetrachloride-induced liver injury and fibrosis model 
o Slightly reduced inflammatory response with ablation of fpr1 expression 
but fibrogenic mechanisms unaffected in acute CCl4 snapshot post-injury 
time points. 
o FPR1KO mice exhibit no effect on chronic CCl4 –mediated liver fibrosis 
with regards to ECM production. 
 
 Unilateral ureteral obstruction (UUO) renal fibrosis model 
o Infiltration (day 5 post-surgery) and fibrotic (day 12 post-surgery) phases 
exhibited no differences in histological features or IHC profile, fpr1 
deletion has no effect on the pathogenesis of this model. 
 
 Subcutaneous bleomycin systemic injury model 
o Daily treatment of bleomycin elicited a moderate response in the lungs 
of mice. FPR1KO animals did not respond differently to repeated injury 
with bleomycin.  
o Intratracheal bleomycin administration results in a pulmonary-specific 
injury and localised disease development unlike this model. 
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6 FPR expression profile in human/murine cells 
6.1 Hypothesis 
Regardless of whether cells are immune or architectural such as fibroblasts and 
epithelial cells the expression of the FPR family will be elevated with inflammatory 
stimuli.  
6.2 Aims 
Characterisation of the expression in multiple cell types is an important step in 
determining the role of the formyl peptide receptor in fibrogenic/fibrotic mechanisms. 
Through the use of multiple modalities FPR expression will be determined in cell lines 
and primary cells/tissue. In vivo effects of FPR1 have been observed in this present 
project and in other investigations, so it was logical to investigate FPRs expression 
profile. 
 
6.3 Human FPR1/2 expression in a variety of different cell types 
6.3.1 HEK transfectants overexpressing FPR1 and FPR2 
To evaluate human FPR1 and FPR2 gene expression human embryonic kidney (HEK) 
cells were stably transfected with control plasmids. Positive control cell lines HEK 
HFPR Ga16 Cl.1 and HEK Ga16 pGENIRES neo FPRL-1 Cl.5 overexpressed FPR1 
and FPR2 receptors respectively. Depending on the cell line different selection 
components supplemented the respective growth media. Human FPR1 expression in 
FPR1-HEK cells was elevated compared to FPR2-HEK cells (Figure 6.1(a)) with a 
mean fold change of 2.867±1.9 (p>0.05). In turn FPR2-HEK cells demonstrated high 
expression compared to basal, negligible levels in FPR1-HEK negative controls 
(Figure 6.1(b)) with a 4557.34 fold increase (p<0.0001).  
 
6.3.2 Immune cell FPR cell expression  
Due to the high amount of FPR1/FPR2 expression in these control cell lines they were 
ideal positive controls for gene and potentially protein expression. Neutrophils are 
typically well known for their abundancy of these membrane-bound chemoattractant 
receptors and may also be good controls for human FPR expression. In Figure 6.2 
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expression of the FPRs is clearly elevated in neutrophils over the other immune cells 
and the control cells lines (both positive and negative).  
 
 
  
Figure 6.1: Validation of human FPR1 and FPR2 in control cell lines via real-time PCR. 
Quantitative PCR determined mRNA levels of (a) FPR1 and (b) FPR2 in FPR1-/FPR2-
HEK transfected cells. Results calculated as mean relative fold change compared to 
respective control (normalised to GAPDH housekeeping gene). Data is representative 
of 3 independent experiments. All p values determined by an unpaired t-test, **** 
p<0.0001. 
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Both FPR2-HEK and T-cells had minimal FPR1 mRNA levels compared to that of 
FPR1-HEK (mean of 2.867±1.9), primary neutrophils (mean of 126.5±111.9) and 
macrophages (mean of 6.574±3.187). 
While changes in HFPR1 expression between different cell types were not significant, 
HFPR2 mRNA levels were significantly increased between positive and negative 
controls (FPR2-HEK and FPR1-HEK respectively, p<0.001). PMNs exhibited a high 
level of expression compared to FPR1-HEK negative control (p<0.0001), FPR2-HEK 
(p<0.001), primary macrophages (p<0.0001) and T-cells (p<0.0001).  
 
6.3.3 THP-1, monocytic cell line 
THP-1, a non-adherent monocyte cell line was activated with PMA (5ng/ml) to trigger 
expression of its adhesion molecules thereby differentiating the cells to an activated, 
adherent form. This cell line has been extensively utilised to investigate macrophage 
differentiation enabling FPR expression to be determined in pro-inflammatory and anti-
inflammatory phenotypes. Plated cells were treated accordingly to induce 
differentiation to an M1 (classically activated) or M2 (alternatively activated) phenotype 
via IFN-γ and IL-4/IL-13 treatments respectively. In PMA-activated THP-1 cells 
expression was significantly upregulated from 1.051±0.029 to 4.129±0.011 mean fold 
change with LPS (100ng/ml) treatment (p<0.0001). M1-activated THP-1 cells exhibited 
no such increase with stimulus but actually a significant decrease (p<0.05). M2-
activated THP-1 cells also had increased FPR1 expression from untreated controls to 
LPS-treated groups with a mean fold change from 1.151±0.017 to 3.824±0.047 
respectively (p<0.0001). M2 macrophages have been typically characterised as having 
a role in the wound-healing response (Wynn, 2004). 
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Figure.6.2: Human FPR1 and FPR2 mRNA levels in different immune cells. 
Quantitative PCR determined mRNA levels of (a) FPR1 and (b) FPR2 in FPR1-/FPR2-
HEK cells, PMNs, macrophages and T-cells. Results were calculated as mean relative 
fold change compared to respective control (normalised to GAPDH housekeeping 
gene). Data is representative of 3 independent experiments. All p values determined 
by using a one-way analysis of variance (ANOVA); **** p<0.00001; *** p<0.001. 
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Figure 6.3: Differentiated THP-1 cells and FPR expression. Quantitative PCR 
determined mRNA levels of respective FPR1 in THP-1 cells treated with polarising 
cytokines and LPS (100ng/ml). Results were calculated as mean relative fold change 
compared to respective control (normalised to GAPDH housekeeping gene). Data is 
representative of 3 independent experiments. All p values determined by using a one-
way analysis of variance (ANOVA); * p<0.05 and **** p<0.0001. 
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6.3.4 FPR expression in non-phagocyte pulmonary architectural cells  
While expression of the FPR1 and FPR2 is widely characterised in granulocytes such 
as neutrophils little is known of its expression in architectural cells such as fibroblasts 
and epithelial cells. Van Compernolle et al. (2003) determined that FPR expression in 
lung epithelium plays a role in wound-healing homeostatic mechanisms. Utilising 
positive and negative controls described previously FPR1 expression was investigated 
using RT-PCR (non-quantitative) to assess levels in different cultured cell types (Figure 
6.4).  
Evidently, there are high levels in FPR1-HEK as well as in PMN. FPR2-HEK have no 
detectable expression which is mirrored in primary lung fibroblasts, MRC5 cell line and 
primary bronchial epithelial cell (PBEC). The basal, untreated expression of HFPR1 is 
non-existent compared to levels in transfected controls and neutrophils.  
The next step was to determine if FPR1/2 expression changed in response to 
inflammatory stimuli such as LPS treatment (Figure 6.5) 100ng/ml for 24 hours. Human 
FPR1 expression remained low even after treatment in PBEC, HBEs (an immortalised 
PBEC cell line) and primary lung fibroblasts with no significant change (p>0.05). FPR2 
expression, however, was greatly increased in PBEC and to a smaller extent in HBE 
cells. Primary lung fibroblast expression remained low as with FPR1. Compared to 
FPR1, FPR2 is a more promiscuous receptor with the ability to bind a greater repertoire 
of ligands that the high-affinity receptor. One consideration of these results is that 
environment of cultured cells is entirely artificial with supplemented media and 
adherence to a plastic flask exerting unknown effects on the cells used to a specific 
microenvironment in the human body with multiple, coordinating cell types. 
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Figure 6.4: RT-PCR of human FPR1 expression in different cell types. FPR1 (FPR1-
HEK), FPR2 (FPR2-HEK), PMN (Neutrophil), PLF (Primary Lung Fibroblast), MRC5 
(fibroblast cell-line) and PBEC (Primary Bronchial Epithelial Cells). GAPDH used a 
loading control; PMN does not express GAPDH to the same level of other cells. 
Photograph taken of PCR samples obtained after 40 cycles and gel electrophoresis 
using a 2% agarose gel.  
 
 
 
Figure 6.5: Non-phagocyte expression of FPR1 and FPR2. PBEC (Primary Bronchial 
Epithelial Cells), HBE (Human Bronchial Epithelium) and PLF (Primary Lung 
Fibroblasts) were treated for 24 hours with LPS (100ng/ml). Results were calculated 
as mean relative fold change compared to respective control (normalised to GAPDH 
housekeeping gene). Data is representative of 3 independent experiments. All p values 
determined by using a one-way analysis of variance (ANOVA); p>0.05 and * p<0.05. 
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6.3.5 TLR expression levels in control transfectants overexpressing 
FPR1/FPR2 
Co-ordination of FPR signalling with other pathways has been demonstrated with 
regards to chemokines in particular CCR3 in human eosinophils (Svensson et al., 
2009). The role of TLRs was investigated as inflammatory stimulus LPS has been 
shown to increase expression of FPR1 in neutrophils and macrophages. Also another 
key mitochondrial DAMP that has been characterised is mtDNA. This CpG-island rich 
motif is bound by TLR9 (Zhang et al., 2010) and has been shown to activate p38 
MAPK. A disadvantage of these stable-transfected cells is that they were derived from 
clones. Different clones could have a different gene expression profiles due to the 
strength of the transfection. Perhaps by expanding with different constructs TLR 
expression data could be validated further. Figure 6.6 demonstrates an increase in 
TLR9 (p<0.0001) and TLR10 in FPR2-transfected HEK cells over THP-1, FPR1-
transfectants and HEK-293 cells. TLR10 is also upregulated in FPR1-HEK cells in 
comparison to un-transfected HEK 293 cells as well as THP-1 (PMA-activated) control 
template (p<0.01). 
 
6.4 Formyl peptide receptor mRNA levels in different murine organs  
Expression in a variety of different organs: spleen, kidney, brain, lung, liver and gut 
was analysed by real-time quantitative PCR of the three members of the FPR family 
(Figure 6.7). RNA isolated from primary neutrophils derived from bone marrow were 
utilised to synthesize cDNA which was used as positive control for chemoattractant 
receptor expression. In comparison with the different organs neutrophils have higher 
levels of mFPR1, mFPR2 and S100A9 mRNA. The high affinity receptor, mFPR1 
expression was undetectable in several of the different organs: kidney, lung, liver and 
gut with low levels determined in the spleen and brain (p>0.05). mFPR2 expression 
was clearly more abundant in the PMN controls compared to total organ DNA 
templates. Minimal levels were detected in spleen, kidney, brain, lung, liver and gut. 
S100A9 is a well characterised marker of myeloid cells such as neutrophils with 
expression elevated in this subset rather than in different organs.  
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Figure 6.6: Toll-like receptor (TLR) expression in THP-1, HEK-293, FPR1-HEK and 
FPR2-HEK cells. TLR1, 2, 4, 6, 7, 8, 9 and 10 were assayed. Results were calculated 
as mean relative fold change compared to respective control (normalised to GAPDH 
housekeeping gene). Data is representative of 3 independent experiments. All p values 
determined by using a one-way analysis of variance (ANOVA); ** p<0.01 and **** 
p<0.0001. 
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Figure 6.7: Murine FPR1, FPR2 and S100A9 gene expression in different organs. 
Results were calculated as mean relative fold change compared to respective control 
(normalised to GAPDH housekeeping gene). Data is representative of 3 independent 
experiments. All p values determined by using a one-way analysis of variance 
(ANOVA); p>0.05. 
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6.5 Priming of GPCR expression with inflammatory stimulus 
FPR expression is somewhat lower in non-immune cells according to data arising from 
recent studies. As with other receptors there is a potential rationale for up-regulation 
with inflammatory stimuli. Non-sterile injury and sepsis-related effects are related to 
bacterial release of N-formyl peptides. In bacterial infections other products are exuded 
in the form of PAMPs which bind pattern recognition receptors (PRRs). One such 
receptor is TLR4 which binds LPS as well the endogenous alarmin HMGB1. 
A hypothesis for stimulating cultured cells with inflammatory stimuli was that evidence 
has determined cross-talk between signalling pathways resulting in co-ordination of 
events. Recent research has highlighted co-ordination between uPA, EGFR and 
CXCR2 downstream signalling is not as simple in the cell as ligation of the receptor by 
formyl peptide molecules.  
 
6.5.1 Priming of expression in immune cells 
6.5.1.1 mFPR1 expression in neutrophils 
Expression of FPR1 is most abundant in PMNs (mouse and human) with a much higher 
baseline than in non-phagocyte cells. Even with high basal protein and mRNA levels, 
upon stimulation with LPS (TLR4 ligand) there was a non-significant increase after 3 
hours in mFPR1 expression (Figure 6.8) from 2.611±1.133 fold to 84.73±10.58 
(p>0.05) respectively. After 24 hours of LPS treatment there was a significant fold 
change of 141.7±57.66 relative untreated (U/T) controls (p<0.05). Essentially the 
inflammatory stimulus is inducing expression of receptor via a ‘priming’ mechanism. 
 
6.5.1.2 mFPR1 expression in macrophages 
Macrophages are susceptible to the formyl peptide chemoattractant properties with 
expression of the GPCR in question characterised. Compared to neutrophils, 
macrophages have significantly less expression. A time course of LPS treatments on 
primary macrophages isolated from murine bone marrow (Figure 6.9). In wild type mice 
bone marrow-derived macrophages elicited a significant increase in mFPR1 mRNA 
from a mean fold change to 0.7861±0.1059 to 1414±536.7 (p<0.01) in untreated and 
16 hours LPS respectively. After 24 hours mFPR1 expression was increased in a 
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significant manner (p<0.0001) with a mean fold change 3085±244.1 compared to 
untreated controls. Neutrophils are evidently more reactive to LPS stimulus than 
macrophages which fit with more abundant expression in this cell type. 
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Figure 6.8: Neutrophil stimulation of FPR1 expression by LPS. Cells were treated at 
respective time points with LPS (100ng/ml). Results were calculated as mean relative 
fold change compared to respective control (normalised to GAPDH housekeeping 
gene). Data is representative of 3 independent experiments. All p values were 
determined by using a one-way analysis of variance (ANOVA) * p<0.05. 
 
 
Figure 6.9: Macrophage stimulation of FPR1 expression by LPS. Cells were treated 
at respective time points with LPS (100ng/ml). Results were calculated as mean 
relative fold change compared to respective control (normalised to GAPDH 
housekeeping gene). Data is representative of 3 independent experiments. All p values 
were determined by using a one-way analysis of variance (ANOVA); ** p<0.01, **** 
p<0.0001. 
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6.5.1.3 Induction in non-phagocyte cells 
As with PMNs and macrophages non-phagocyte cells are capable of expressing 
mFPR1. Previously shown is the LPS induction of this GPCR in bone marrow-derived 
cells but murine hepatic stellate cells (mHSCs) and murine lung fibroblasts (MLFs) also 
increased their expression with inflammatory stimulus. MLFs (Figure 6.10) isolated by 
collagenase digestion of murine lung tissue significantly increased their expression 
from U/T control (mean fold change 1.334±0.2699) when treated with LPS for 24 hours 
(mean fold change 31.94±11.82; p<0.05).  
In a similar manner expression was elevated in HSCs (Figure 6.11) cultured and 
treated with different inflammatory stimuli. LPS treated cells had increased FPR1 
expression compared untreated controls exhibiting a significant mean fold change of 
10.44±0.6493 after 24 hour treatment (p<0.0001). Poly I:C treated cells also had a 
marked increase in FPR1 expression from a mean fold change of 0.6353±0.099 to 
3.646±0.5949 in U/T and treated groups respectively (p<0.001).  
In both immune cells and fibroblasts (liver and lung) FPR1 expression is increased by 
cells subjected to inflammatory stimuli suggesting a priming mechanism. This may 
indeed relate to models of acute injury where damaged epithelium initiate the 
development of a fibrotic phenotype. Damage response is potentially mimicked by 
inflammatory stimuli in vitro with increased FPR1 expression enabling increased ligand 
ligation of the receptors. 
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Figure 6.10: Murine lung fibroblast (MLF) expression of FPR1. Isolated cells were 
treated with LPS (100ng/ml) and poly I: C (HMW, 4µl/ml). Results were calculated as 
mean relative fold change compared to respective control (normalised to GAPDH 
housekeeping gene). Data is representative of 3 independent experiments. All p values 
determined by using a one-way analysis of variance (ANOVA); **** p<0.0001 and *** 
p<0.001. 
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Figure 6.11: Murine hepatic stellate cell (mHSC) expression of FPR1. Isolated cells 
were treated with LPS (100ng/ml), poly I:C (4µl/ml) and TNFα (50ng/ml) for 24 hours. 
Results were calculated as mean relative fold change compared to respective control 
(normalised to GAPDH housekeeping gene). Data is representative of 3 independent 
experiments. All p values determined by using a one-way analysis of variance 
(ANOVA); * p<0.05. 
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6.5.2 Protein expression of FPR1 in human tissue  
In order to validate expression of human FPR1 and FPR2 western blot analysis was 
performed. Protein expression was not forthcoming due to problems with commercial 
antibodies (Abcam and R&D systems respectively). Cross-reactivity with FPR2 was 
not tested by suppliers. Both antibodies display a lack of specificity to individual 
receptors: FPR1 and FPR2. Determination of a suitable negative control has as yet 
proved elusive. With regards to the FPRL1-antibody shows FPR2-expression in FPR2-
transfected HEK cells specifically but this result was not reproducible.  
Due to the lack of commercial antibodies that specifically detect members of the FPR 
family the evaluation of receptor expression proved difficult. From the industrial 
collaboration with MedImmune (Cambridge, UK) an in-house human FPR1 antibody 
became available for determining expression in vitro. This antibody was validated in-
house for specificity and enzyme kinetics (data not available; Douthwaite et al., 2014).  
 
6.5.2.1 Immunohistochemistry of human tissue sections for human FPR1 
expression 
The phage-display selected monoclonal antibody was directly linked to a horseradish-
peroxidase (HRP) conjugate (InnovaBiosciences) to enable selective staining of cells 
expressing FPR1. IHC staining of IPF human tissue sections showed areas of what 
appeared to be specific positive FPR1 expression in macrophage/monocyte cells. With 
this high expression in macrophage immune cells the antibody appeared to be suitable 
for determining protein expression (Figure 6.12). 
This immunostaining method yielded positive (brown) staining in different areas of 
diseased IPF lung tissue sections. In initial IHC tests of this antibody there was staining 
observed in macrophages, airway epithelium and serous mucosa glands (Figure 6.12 
(a)). The extent to which this staining is valid was hampered by extensive background 
staining. One problem encountered was the antigen retrieval method and blocking of 
the sections to eliminate non-specific binding as background was an issue. Following 
several protocol refinements using different blocking steps including pig and goat 
serum to eliminate non-specific binding, a Bovine serum albumin (BSA) block was 
chosen. The method demonstrated positivity in monocytes/macrophages and also 
epithelial serous mucosa (Figure 6.12 (b)). This may indeed be due to the monoclonal 
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antibody staining but the level of background is a concern so the validity of its specificity 
is in question. 
The BSA block method resulted in the least amount of background staining but due to 
widespread staining after the DAB step it appears that IHC may not be optimal method 
for this antibody. Direct linkage to an HRP-conjugate did not produce an expression 
profile that was believable; perhaps a dual-IHC method with multiple colours would 
have been ideal as cell types showing positivity could have been classified according 
to another cell surface marker’s expression. Human FPR1 expression in IPF cases 
(Figure 6.12 (c)) despite several optimisation protocols which demonstrated what 
appears to be specific expression in macrophage/monocyte cells, other cell types 
demonstrated non-specific staining. 
 
6.5.2.2 Immunocytochemistry of FFPE lung tissue 
Determining a method for visual confirmation of FPR1 expression was important to 
validate the same antibody used in a FACs based strategy (Douthwaite et al., 2014). 
Direct linkage to a fluorescent conjugate, allophycocyanin (APC, InnovaBiosciences) 
in a similar manner to the IHC method enabled intracellular staining of cells expressing 
human FPR1. The APC fluorophore is a phycobiliprotein isolated from red algae with 
excitation at 594-633nm and emission at 660nm. APC, a chemically cross-linked 
molecule, is ideally suited for highly sensitive fluorescence detection methods while 
distinct from the FITC excitation and emission wavelengths, 495nm and 519nm 
respectively. Due to the fact that APC is excited at a different wavelength to FITC 
and/or TRITC secondary antibodies there is no crossover between channels. This 
enabled the use of the labelled antibody in a triple staining method to determine co-
localisation (if any) of FPR1 with different cellular markers: immune or architectural 
(Figure 6.13). 
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Figure 6.12: Immunostaining of primary human IPF lung tissue sections. Human FPR1 
antibody was directly labelled to an HRP-conjugate and was used to stain FFPE tissue. 
Different optimisation runs shown in (a) and (b) utilising varying blocking methods and 
incubation periods. 
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Figure 6.12: Immunostaining of primary human IPF lung tissue sections. Human FPR1 
antibody was directly labelled to an HRP-conjugate and was used to stain FFPE tissue. 
Different optimisation runs shown in (c) demonstrate persistent background staining of 
fixed human tissue even with refined protocol. 
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6.5.2.3 Validation of hFPR1-APC antibody for immunofluorescence 
PMT gain and control settings were set on negative control slides, stained only with 
secondary antibodies. These included FITC, TRITC and IgG-APC isotype antibodies. 
These values determined by LSCM were applied to all subsequent immune-
fluorescently labelled tissue sections for the elimination of background auto-
fluorescence and non-specific binding. Normalising to these control slides ensures that 
any staining for the different cellular markers: CD45, CD68, E-CAD, VIM and FPR1 is 
true rather than artefact (Figure 6.14). 
As well as validation by flow cytometry-based methods the human FPR1 APC 
conjugated antibody was used for immunofluorescence. Transfected human 
embryonic kidney (HEK) cells were used as positive controls for FPR1 expression 
(Figure 6.15). These cells overexpress the two main receptors of this family of G-
protein coupled receptors. Staining of fixed cultured cells from both of these cell lines 
demonstrated high FPR1 localisation in the membrane/cytoplasmic compartments with 
intense expression. FPR1 expression was lower in HEK-FPR2 overexpressing cells as 
in these cells the GPCR is only present at basal level. In FPR2 HEK cells FPR1 is still 
localised to the membrane and also the cytoplasm. Localisation in methanol-fixed cells 
fits with the expression pattern of the receptor and internalisation via endocytosis. 
DAPI (4',6-diamidino-2-phenylindole) was used to counterstain nuclei by binding to A-
T rich DNA regions. DAPI staining determined that FPR1 staining was true and 
localised correctly. If more time had been available more cell types would have been 
tested for FPR1 expression in this manner particularly the THP-1 cell line which did 
show a minimal increase in gene expression with inflammatory stimuli and phenotype 
change. 
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Figure 6.13: Spectral overview of FITC, TRITC and APC excitation (dotted line) and 
emission (solid line) wavelengths. FITC (green), TRITC (yellow) and APC (red) peaks. 
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Figure 6.14: Control antibody staining of FFPE sections. (a) DAPI, (b) isotype (IgG-
APC), (c) FITC and (d) TRITC controls on FFPE sections. (e) Overlay composite of 
different fluorescent conjugates. Images are representative of 3 independent 
experiments. 
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Figure 6.15: Immunocytochemistry for FPR1 in cultured cells. (a) Unstained controls 
with DAPI nuclear stain, (b) FPR1-HEK transfectants and (c) FPR2-HEK transfectants. 
Images are representative of n=3 independent experiments.  
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6.5.2.4 Immunocytochemistry of FFPE diseased lung tissue  
6.5.2.4.1 Architectural cells: Fibroblasts and Epithelium 
Essentially the two panels of antibodies used on the primary human tissue allowed 
evaluation of architectural and immune cells localisation with respect to FPR1 
expression. E-Cadherin positive cells represented lung epithelium, vessel and lung 
airway walls with Vimentin positive expression in fibroblasts. Any co-localisation of the 
TRITC paired antibodies (Vimentin or CD45) with FPR1 resulted in a distinct magenta 
colourisation.  
As all cellular markers are present on the surface membrane EDTA antigen retrieval 
was employed to enable staining of epitopes. Different antibodies were evaluated in 
the architectural panel to determine which pair of epithelial and fibroblast markers 
worked in an optimal fashion. E-Cadherin showed highly specific localisation to 
epithelium through the diseased lung tissue with intense staining of airway walls and 
mucosa areas. Alpha-smooth muscle actin (α-SMA), fibronectin and vimentin were 
used as potential markers for the fibroblast population in human lung tissue as 
research has cited them all as key markers of fibroblasts and also cells were have 
undergone EMT. α-SMA and E-Cadherin used with TRITC (Red) and FITC (Green) 
secondary antibodies did not represent a usable pair for the architectural panel. Cells 
stained well for the epithelial marker but in terms of the fibroblast marker extensive 
auto-fluorescence and non-specific binding were clearly evident with high background 
levels in the TRITC channel. Both fibronectin and vimentin stained distinct populations 
in the tissue sections with localisation in the cellular cytoplasmic compartment as ECM 
components. Although specific staining was shown by fibronectin (Figure 6.16), 
vimentin was chosen due to its stronger profile in the same subset of cells in the tissue 
sections. 
Of antibodies tested to stain the fibroblast population in the fixed tissue vimentin 
exhibited the strongest specificity and signal. Alpha-SMA antibody (Abcam) revealed 
no strong pattern of expression coupled with TRITC secondary. Fibronectin, another 
extracellular matrix protein whose deposition is typically increased in fibrosis, did 
reveal specific staining in the cytoplasm of fibroblast populations. With vimentin a 
larger proportion of cells revealed positive expression which may be due to the fact 
256 
 
that this marker is increased in cells undergoing EMT as well as having stable 
expression in fibroblasts. 
 
 
 
Figure 6.16: Architectural staining of FFPE lung sections with fibronectin as fibroblast 
marker. (a) DAPI (nuclear stain), (b) FPR1-APC, (c) E-Cadherin (FITC), (d) Fibronectin 
(TRITC) and (e) overlay composite. Magnification at x20 (Images representative of n=3 
IPF cases). 
 
 
 
 
 
 
257 
 
Vimentin was selected as marker to selectively stain fibroblasts in the interstitium of 
IPF lung paraffin-embedded sections. Encoded by the VIM gene, this type III 
intermediate filament protein is an integral part of the cytoskeleton, the framework of 
the cell. For many years it has been characterised as a fibroblast marker along with 
other markers such as alpha-smooth muscle actin and fibronectin. In particular 
Vimentin is noted to be present in a majority of alveolar fibroblasts in ILDs (Fireman et 
al., 2001). 
Although it has been extensively used more markers should be used as vimentin is 
also a marker of cells undergoing epithelial-to-mesenchymal transdifferentiation 
(EMT). The passage to a mesenchymal phenotype results in a loss of epithelium 
marker expression such as cytokeratin 19/7 and an increase in vimentin expression 
(Strutz et al., 1995). The specificity of this marker was a concern as primary alveolar 
epithelial cells (AECs) demonstrate EMT-driven changes in gene expression and 
protein translation. The complexity of the cells making the architecture of lung tissue is 
a factor to be considered as fibroblasts provisionally identified through vimentin 
staining may be resident alveolar fibroblasts or mesenchymal EMT-derived cells 
displaying fibroblasts properties (Kim et al., 2006).  
 
6.5.2.5 IPF FFPE tissue sections 
In terms of the staining pattern observed in IPF tissue sections (Figure 6.17) there were 
different patterns exhibited. Epithelial cells with strong expression of E-Cadherin 
showed defined structures such as vessel and airway walls displayed no co-
localisation with human FPR1. Fibroblasts positive for vimentin expression were clearly 
distinct from epithelium populations but co-localisation did occur with E-Cadherin and 
Vimentin potentially indicating the process of EMT. Of particular note was that isolated 
fibroblasts (Vimentin positive) demonstrated clear expression of FPR1 resulting in a 
magenta stain from mixing of red (vimentin) and FPR1 (blue). This is fitting with recent 
literature where FPR1 expression was reported in lung fibroblasts (Van Compernolle 
et al., 2003). Higher magnification of immunostained sections shows localisation of 
FPR1 receptor in the cytoplasmic-membrane region of isolated cells which are 
vimentin positive fibroblasts (Figure 6.18).  
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6.5.2.6 Normal, COPD and bronchiectasis FFPE tissue sections 
Other chronic pulmonary disease conditions were subjected to immunocytochemistry 
using the same panel of antibodies on IPF tissue sections: DAPI, E-Cadherin, Vimentin 
and FPR1-APC. Normal lung tissue fixed in formalin was obtained from archived tissue 
sampled during ex vivo lung perfusions. A COPD case of fixed tissue exhibited a similar 
staining pattern to normal lung tissue with E-Cadherin and Vimentin localisation in the 
epithelium and fibroblasts respectively. Human FPR1 detected in tissue via the DAPI 
Cy7.7 channel distinct from FITC and TRITC emissions spectra (Figure 6.13) was not 
shown in normal or COPD cases stained (n=1 for each; COPD case shown in Figure 
6.19). Ideally if more time had been available more cases from each group would have 
been tested for each cellular marker. Bronchiectasis-sourced tissue stained as with the 
others cases expressed in a similar fashion E-Cadherin, Vimentin and FPR1. Patients 
exhibited co-localisation of human FPR1 and vimentin resulting in a magenta 
colourisation. As with IPF FFPE sections co-localisation occurred in isolated fibroblasts 
also expressing vimentin (Figure 6.20). Increased magnification (x1.77 zoom) of 
stained sections enabled zoomed-in imaging of co-localisation in fibroblast cells 
(Figure 6.21). 
259 
 
 
Figure 6.17: Architectural cell immunocytochemistry of IPF tissue sections using 
vimentin as fibroblast marker. FFPE sections were stained for (a) DAPI (cyan), (b) 
FPR1-APC (blue), (c) E-Cadherin (green), (d) Vimentin (red) and (e) overlap composite 
image with LCSM performed at x40 magnification. Image panel representative of n=3 
IPF cases. 
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Figure 6.18: Co-localisation of FPR1-APC and vimentin in IPF FFPE sections. FFPE 
sections were stained for DAPI (cyan), FPR1-APC (blue), E-Cadherin (green) and 
Vimentin (red). Overlap composite image in left panel with LCSM performed at x63 
magnification. Images representative of n=3 IPF cases. 
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Figure 6.19: COPD FFPE section staining pattern of architectural cellular markers. 
FFPE sections were stained for (a) DAPI (cyan), (b) FPR1-APC (blue), (c) E-Cadherin 
(green), (d) Vimentin (red) and (e) overlap composite image with LCSM performed at 
x20 magnification. Images representative of n=2 COPD cases. 
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Figure 6.20: Bronchiectasis lung FFPE section staining pattern of architectural cellular 
markers. FFPE sections were stained for (a) DAPI (cyan), (b) FPR1-APC (blue), (c) E-
Cadherin (green), (d) Vimentin (red). Co-localisation of FPR1 with vimentin resulted in 
magenta colourisation. (e) Overlap composite image in last panel with LCSM 
performed at x20 magnification. Images representative of n=3 cases. 
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Figure 6.21: Bronchiectasis lung FFPE section staining pattern of architectural cellular 
markers. FFPE sections were stained for DAPI (cyan), FPR1-APC (blue), E-Cadherin 
(green) and Vimentin (red). Co-localisation of vimentin and FPR1 resulted in magenta 
colourisation (highlighted by white dashed boxes). Overlap composite image 
generated with LCSM performed at x60 magnification (n=3 cases). 
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6.5.2.7 Immune cell staining in lung tissue sections 
Monocyte/macrophages localised in the tissue of the fixed lung sections were 
determined by Cluster of Differentiation 68 (CD68) glycoprotein immune-fluorescent 
staining. This 110 kilodalton (kD) transmembrane protein has long been characterised 
in this population (Wang et al., 2006). As a key immune cell in the lungs as either 
resident or infiltrating populations’ co-localisation with FPR1 is an important factor to 
be elucidated as well as co-localisation with other markers such as CD45, E-Cadherin 
and Vimentin.  
Leukocytes (white blood cells) are all CD45+ and CD68+ macrophages/monocytes are 
represented by FITC staining. As part of the immune cell markers used to stain lung 
sections CD45 was utilised to determine distribution of leukocytes. This includes 
lymphocytes, neutrophils and macrophages and as FPR1 is most abundant in 
neutrophils not all CD45 cells are expected to FPR1 positive. Firstly, a directly labelled 
CD45 (FITC) antibody was tested for its specificity for leukocytes. Unfortunately this 
antibody would not bind CD45+ cells and exhibited only non-specific staining in fixed 
lung tissue of artefact. This is clearly demonstrated by the absence of positivity in 
Figure 6.22 which is changed dramatically when the PMT gain is elevated past control 
settings showing a clear indiscriminate pattern.  
Obviously another antibody was sought to enable accurate visualisation of CD45+ 
leukocytes, a rabbit polyclonal (Abcam, UK) was chosen. Testing on human fixed 
tissue revealed specific staining of distinct cell populations in the lung. Indirect staining 
of tissue with the anti-CD45 primary and subsequently a TRITC secondary antibody 
demonstrated clear localisation of CD45 on the membrane/cytoplasm compartments. 
With the panels consisting of representative, functional markers FFPE-sections from 
normal, COPD, IPF and Bronchiectasis patients were subjected to 
immunocytochemistry to reveal co-localisation (if any) with human FPR1. As expected, 
a proportion of CD45+ cells (leukocytes) expressed FPR1 with this subpopulation most 
likely consisting of neutrophils. Correlating with previous data detailing lower 
expression in macrophages compared to PMNs, CD68+ cells did not co-localise with 
FPR1. 
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Figure 6.22: Immunocytochemistry with directly labelled CD45 antibody on FFPE 
sections. Sections counterstained with DAPI nuclear dye as well as CD45-FITC (x20 
magnification). With no specific staining the exposure was increased until signal was 
visible (above). 
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Figure 6.23: Immune cell staining of IPF FFPE tissue sections. FFPE sections were 
stained for (a) DAPI (cyan), (b) FPR1-APC (blue), (c) CD68 (green), (d) CD45 (red) 
and (e) overlap composite image generated with LCSM performed at x63 
magnification. Images representative of n=3 IPF cases. 
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Ideally increased numbers of patients from the different disease groups: IPF, COPD 
and normal would have been used but limited numbers of tissue blocks were available 
at the time. In the future more tissue sections from different patients should be stained 
for these markers to increase the power and validity of the expression profile that is 
demonstrated in the limited number of cases. 
 
6.6 Flow cytometry of cultured cells for human FPR1 protein expression 
Due to the lack of specific and good quality antibodies for western blotting an 
alternative strategy for evaluating protein expression of the formyl-peptide receptor 
was sought. A FACs-based method was investigated as MedImmune had recently 
generated an in-house antibody for human FPR1 along with a corresponding isotype 
control. Douthwaite et al. (2014) demonstrated abundant expression in neutrophils 
isolated from healthy volunteers. 
The direct linkage of the human FPR1 antibody (generated in-house by MedImmune, 
Cambridge) to an allophycocyanin (APC) fluorophore, according to lightning-linker 
protocol (InnovaBiosciences), enabled evaluation of FPR1 protein expression in a 
variety of different cell types. With the inclusion of an appropriate isotype control (IgG), 
unstained cells and viability dyes the median fluorescent intensity (MFI) is able to be 
calculated. 
Flow cytometry is a process by which dyes and fluorochromes absorb light and emit a 
higher wavelength. Dichroic mirrors are responsible for the reflection of light at specific 
wavelengths. These emissions are detected and converted to an electrical current with 
a proportional voltage relative to the amount of light resulting in a digital signal in form 
of median fluorescence intensity (MFI). 
Side and forward scatter equate to the two main measurements of the physicality of 
the cells being analysed. Forward scatter is the diffracted light from the laser is 
proportional to size. Side scatter is the refracted (plus reflected) light from the different 
lasers allowing intracellular complexity to be gauged.  
In the event of multi-parameter analysis when multiple antibodies are used to stain the 
same sample a variety of different channels are required. In the case of multiple 
fluorophore utilisation spectral overlap is a concern as conjugates with emission 
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ranges that are close together may result in false positive signals. Electronic 
compensation is required to correct signal ‘bleeding’ between different channels. 
Ideally fluorophores should be chosen with separate emission ranges such FITC and 
PerCp.  
Each experiment will have several different controls such as unstained cells, 
compensation controls and isotype controls. The latter control will define the non-
specific background. A threshold can be generated by defining a cut-off for negative 
and positive staining when using a multi-parameter panel.  
Following dissociation of cultured cells and staining in a 96-well format samples were 
run through the flow cytometry machine and analysed accordingly. Populations were 
gated to exclude cellular debris and doublets for live, single cells proportion. After 
live/dead exclusion following viability dye incubation cells were gated according to the 
signal for APC. For cultured cells appropriate controls were used including unstained, 
isotype APC antibody as well FPR1-APC antibody staining. The gating strategy 
employed for cultured cells was consistent with all cell types evaluated. 
 
6.6.1 HFPR1-APC antibody validation 
Firstly, the HFPR1-APC antibody was validated using the control transfectants 
overexpressing FPR1 and FPR2 respectively. As with gene expression ascertained by 
real-time PCR method FPR1 is abundant in FPR1-HEK cells while expression is 
dramatically reduced in FPR2-HEK cells. In FPR2-HEK cells expression drops to near 
basal levels showing little increase over unstained (U/S) and IgG isotype controls in 
terms of MFI (Figure 6.24). 
Validation of this antibody using control HEK HFPR Ga16 Cl.1 (MedImmune, UK) 
transfectants revealed strong expression in cells overexpressing FPR1. Cells had a 
mean MFI of 53.83±23.08 in unstained controls and 97.83±21.38 in the isotype APC 
control. FPR1-HEK cells showed high levels of FPR1 expression as indicated by a 
mean MFI of 452.5±24.62. There is a clear shift in signal between the negative controls 
and FPR1-APC stained cultured cells (p<0.0001). 
A different cell line, HEK Ga16 pGENIRES neo FPRL-1 Cl.5 (MedImmune) capable of 
overexpressing FPR2 (FPRL-1) exhibited a basal level of FPR1 expression. 
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Transfected to synthesise this FPR family member has normal expression of FPR1 
compared to FPR1-HEK cells with a clear reduction (p<0.01).     
Another way of validating the antibody was undertaken by testing neutrophils isolated 
from healthy human volunteers (carried out by John Simpson’s group). HFPR1 
expression is elevated in this cell type with significant signal shift compared to U/S and 
IgG controls (Figure 6.25). Cells had a mean MFI of 92.4±11.55 in unstained controls 
and 145.7±6.173 in the isotype APC control (p<0.05). PMNs showed high levels of 
FPR1 expression as indicated by a mean MFI of 340.3±9.433 rising significantly 
(p<0.0001) from unstained and isotype controls. This correlates with methodology in 
Douthwaite et al. (2014)’s paper where abundant expression of HFPR1 was reported 
as demonstrated by the quantitation of FPR receptors on the surface membrane. 
 
6.6.2 HFPR1 expression in primary human fibroblasts 
6.6.2.1 Normal lung fibroblasts 
Isolated from ex vivo perfused lungs these ‘normal’ phenotype lung fibroblasts were 
analysed for expression of FPR1 by flow cytometry. Cultured cells grown in 6-well 
plates were harvested for flow cytometry to evaluate FPR1 expression. Normal cells 
were treated with different inflammatory stimuli: lipopolysaccharide (LPS, a TLR4 
ligand); transforming growth factor-Beta (TGF-β1) and poly I:C (TLR3 ligand). TLR4 
expression is reported to be markedly low in lung fibroblasts compared to TLR3 
expression. Untreated normal fibroblasts exhibited no change in MFI between IgG and 
hFPR1-stained cells. Compared to unstained cells there was a significant increase in 
signal from both IgG and FPR1-stained cells (p<0.0001). With no difference between 
isotype and antibody stained cells in any of the treatments and certainly no increase in 
FPR1 MFI, the expression of human FPR1 is undetectable (Figure 6.26). 
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Figure 6.24: Validation of human FPR1-APC labelled antibody using control cell lines 
transfected with FPR1 and FPR2. U/S (unstained), IgG (isotype control) and FPR1 
(APC conjugate) antibody stained cells yielded a digital signal, median fluorescence 
intensity (MFI). Data is representative of 3 independent experiments. Results were 
calculated as mean MFI. All p values determined by using a one-way analysis of 
variance (ANOVA); **p<0.01, **** p<0.0001. 
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Figure 6.25: Human FPR1 levels in primary neutrophils. U/S (unstained), IgG (isotype 
control) and FPR1 (APC conjugate) antibody stained cells yielded a digital signal, 
median fluorescence intensity (MFI). Results were calculated as mean MFI. Data is 
representative of 3 independent experiments. All p values determined by using a one-
way analysis of variance (ANOVA) * p<0.05, **** p<0.001. 
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Figure 6.26: Normal human lung fibroblasts and their FPR1 levels following 
inflammatory stimuli. Isolated cells were treated with LPS (100ng/ml), poly I:C (4µl/ml) 
and TGFβ (10ng/ml). U/S (unstained), IgG (isotype control) and FPR1 (APC conjugate) 
antibody stained cells yielded a digital signal, median fluorescence intensity (MFI). 
Data is representative of 3 independent experiments. Results were calculated as mean 
MFI. All p values determined by using a one-way analysis of variance (ANOVA); *** 
p<0.001, **** p<0.0001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
273 
 
6.6.2.2 Diseased lung fibroblasts 
Fibroblasts derived from the lungs of diseased patients either IPF or COPD were 
analysed for hFPR1 expression at a basal, untreated state. Expression was compared 
between untreated controls and the two chronic diseases. As shown before NHL 
fibroblast there was no significant shift in MFI which indicated a barely detectable level 
of expression. In cells isolated from IPF lungs (n=3 patients) the MFI signal increased 
significantly from U/S negative controls (mean MFI of 136.8±28.73) to 284.7±33.05 
(IgG control; p<0.05) and 454±76.32 (hFPR1; p<0.0001). Human FPR1 expression 
was increased in IPF fibroblast significantly (p<0.05) comparing IgG and FPR1-stained 
cells. Compared to normal lung fibroblasts there is clear expression in cells isolated 
from fibrotic explant tissue (Figure 6.27). 
Fibroblasts derived from COPD patient fibroblasts (n=3) were also assayed for FPR1 
expression (Figure 6.28). From IgG-isotype stained controls and FPR1-stained cells 
increasing from mean MFIs of 250.4±25.59 to 335±16.52 respectively (p<0.05). In 
untreated cells human FPR1 expression was evident in fibroblasts sourced from 
diseased explant lungs potentially indicating a role for chronic lung conditions where 
repeated inflammation/damage is a common theme.   
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Figure 6.27: IPF and NHL fibroblast hFPR1 levels at a basal level. (a) Fluorescence 
histogram for NHL fibroblasts; (b) Fluorescence histogram for IPF fibroblasts. U/S 
(unstained, grey peak), IgG (isotype control, black peak) and FPR1 (APC conjugate, 
red peak) antibody stained cells yielded a digital signal; (c) median fluorescence 
intensity (MFI). Data is representative of 3 independent experiments. Results were 
calculated as mean MFI. All p values determined by using a one-way analysis of 
variance (ANOVA) * p<0.05, **** p<0.0001 
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Figure 6.28: COPD fibroblast hFPR1 levels at a basal level. U/S (unstained), IgG 
(isotype control) and FPR1 (APC conjugate) antibody stained cells yielded a digital 
signal, median fluorescence intensity (MFI). Data is representative of 3 independent 
experiments. Results were calculated as mean MFI. All p values determined by using 
a one-way analysis of variance (ANOVA) * p<0.05, *** p<0.001. 
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6.6.3 Conclusion of in vitro FPR profile  
Expression of the FPR family in different cell types was demonstrated in typical 
immune cells and non-phagocyte cells. Priming by inflammatory stimuli may indicate 
co-ordination of different signalling pathways perhaps involving the pattern recognition 
receptors, the TLRs. Analysis of protein expression proved difficult due to a lack of 
validated, commercial antibodies but from access to an in-house antibody 
(MedImmune, UK) as part of my industrial collaboration enabled preliminary 
experiments to be performed to determine protein expression in different cell types. 
Positive human FPR1 expression by flow cytometry was exhibited in IPF and COPD 
fibroblasts isolated from diseased tissue as well as in positive controls such as 
transfected cell line FPR1-HEK and neutrophils. By itself this is not definitive proof of 
expression in diseased fibroblasts hence determination of a FPR1 expression profile 
in FFPE lung tissue sections. Immunocytochemistry with the same antibody used in a 
FACs-based strategy showed that isolated fibroblasts in IPF sections and not in COPD 
sections were positive for FPR1 expression. Perhaps in culture the microenvironment 
of the cells changes to a non-physiologically relevant variant which is different in the 
FFPE sections.  
 
6.7 Summary of FPR expression profile 
 Inflammatory stimulus such as LPS ‘primed’ FPR expression at gene level in 
non-phagocytes and immune cells. 
 
 Expression was demonstrated in IPF lung sections and primary lung 
fibroblasts contrasting with normal human tissue. 
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7 Discussion 
7.1 Bleomycin-mediated fibrosis and FPR1 
The in vivo model for investigating pulmonary fibrosis is limited due to the nature of its 
pathogenesis (acute and fibrotic). Features observed during studies involving 
bleomycin are facets/caveats of the model itself not necessarily the disease it is 
purposed to mimic. The distinct phases of the bleomycin model: acute and fibrotic are 
unlike the pathogenesis of IPF presented in the literature. Lung fibrosis is not an acute 
process but in a way this an advantage of the in vivo model as fibrosis is able to develop 
in a matter of weeks not months or years as is typically the case in human patients. 
Some individuals are genetic predisposed to ILD development or some have moderate 
lung function then an exacerbating effect like a virus or opportunistic infection comes 
along and the conditions worsens. Human fibrotic disease is far more complicated than 
the pathogenesis of different in vivo models but the nature of these short-term 
manifestations of disease makes them ideal for therapeutic agent development in a 
high-throughput fashion. 
The bleomycin acute injury model is analogous to acute lung injury (ALI) in humans. 
Grommes and Soehnlein (2011) describe how an oedema forms with neutrophils as 
part of the innate immune response, migrating to injury site first to interstitial area in 
lung tissue as well as bronchoalveolar fluid. BAL is typically used to evaluate the 
inflammatory cellular infiltrate in the clinical setting and in vivo pulmonary fibrosis 
models. ILDs have an altered cytokine/chemokine level in BAL fluid (Vasakova et al., 
2008).   
Essentially the bleomycin in vivo is a combination of ALI and IPF due to the acute injury 
component which is not typical in the latter condition. The bithiazole ring side chain 
binds DNA resulting in thickening of the alveolar walls and epithelial/endothelial 
damage (Hay et al., 1990). FPR1 deletion provided protection against pulmonary 
fibrosis induced by bleomycin. TGFβ shown by Khalil et al (1989) to be elevated in 
BLM-induced fibrosis with a majority of cytokine production by alveolar macrophages 
which subsequently drives fibroblast proliferation. Transforming growth factor Beta-1 
was apparently not affected by ablation of FPR1 in my project’s bleomycin model. 
FPR1’s role in fibrosis is independent of this pro-fibrogenic mechanism inherently 
linked to the development of a fibrotic phenotype. As this cytokine is not affected by 
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the ablation of the fpr1 gene the adenoviral TGF-β1-overexpression model is an ideal 
candidate to evaluate the role of FPR1 in another pulmonary fibrosis 
mechanism/pathogenesis. Further investigation of FPR1 expression and its effect on 
TGFβ1 activity could potentially elucidate how this cytokine’s downstream signalling is 
affected in the non-functional mutants.  
 
7.1.1 Microenvironment of organ and FPR1’s role in fibrosis 
The role of neutrophils in chronic lung disease such as IPF is unclear, differential BAL 
counts and neutrophil elastase IHC increased counts in primary human tissue suggest 
a potential role for polymorphonuclear leukocyte (PMN) in this rare condition (Obayashi 
et al., 1997). Neutrophil properties include the production of cytokines, chemokines, 
proteases, reactive oxidants, prostaglandins, leukotrienes and presentation of Class II 
MHC on their cell surface membrane. These different products interact enabling multi-
functionality to be exhibited in terms of T-cell activation, adhesion molecules 
expression, chemoattraction and migration towards injury site. While it is apparent that 
neutrophils are certainly present in chronic disease in the lung, liver, kidney and other 
organs its function in the development of fibrosis is not as well defined. 
PMNs are a major part of the adaptive and innate immune response as clearly 
indicated at acute endpoints in the lung and the liver of mice dosed with bleomycin and 
carbon tetrachloride respectively where distinctive elevations of NIMP+ve cells were 
shown by IHC. Hepatic infiltration of the liver following CCl4 injury consists of migration 
into the parenchyma (Hasegawa, 2006). At 24 hours there were more PMNs present 
in the tissue than at 5 days post-bleomycin instillation which is in keeping with their 
short life span of approximately 12 hours in a non-activated state (Hu, 2012). With 
activation may live in the human body/culture for up to 48 hours so a peak neutrophilic 
response will be observed in this period.  
7.1.2 Liver fibrosis and the neutrophil 
The role of neutrophils in the liver is controversial with regards to fibrosis but in acute 
liver injury they are key players. Induction of PMNs and other immune cells with acute 
injury via CCl4 injections in the present project indicates a strong response to 
hepatotoxic injury. Acetaminophen (APAP), CCl4 and ischaemic reperfusion are all 
capable of triggering hepatocyte cell death in a sterile fashion which in turn leads to 
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the release of endogenous alarmins such as N-formylated peptides. Of particular note, 
recent research has highlighted that DAMPs released from damaged/dying 
hepatocytes may direct neutrophil homing to injury sites (Marques et al., 2013). Sterile 
inflammation may have more of an impact in the liver per say than the lung due to the 
nature of the organ microenvironment. Direct inhibition of neutrophil 
migration/activation with chemokine and FPR1 antagonists did indeed decrease PMN 
chemotaxis and ultimately liver injury. Blockage in vitro of neutrophils’ CXCR2 and 
FPR1 by antagonist correlated with in vivo work clearly demonstrating the well, 
characterised role for FPR1 in the chemotactic behaviour of neutrophils in the liver 
setting.  
Sterile inflammation in the liver as well as other organs is a relatively new concept with 
a multitude of different DAMPs released as a result cellular damage being present in 
the liver (Kubes and Mehal, 2012). In the liver DAMPs bind a variety of pattern 
recognition receptors including TLR2, TLR4, TLR9, RAGE, CD14, CD91, CD2 and 
formyl-peptide receptors, FPR1 and FPRL1. Certainly the range of diverse 
endogenous alarmins present due to injury, trauma and oxidative stress means that 
even without bacterial infection an inflammatory signal is able to be generated as a 
result of inflammasome activity (Moles et al., 2014) 
Sterile and non-sterile immune responses are important processes in the body as 
tissue injury is not necessarily associated with infection. Neutrophils, a key effector in 
the innate immune response are vital in any inflammatory events in the body especially 
since they respond to both endogenous and exogenous stimuli. tlr2-/- and s100a9-/- 
mice exhibited defective neutrophil recruitment to sites of injury induced by CCl4, a 
hepatotoxin. While neutrophils may not be as important in this model they are 
commonplace in liver disease such as acute alcoholic hepatitis (AAH), acetaminophen 
induced liver failure (APAP ALF), primary biliary cirrhosis (PBC), primary sclerosing 
cholangitis (PSC), alcoholic liver disease (ALD) and non-alcoholic steatohepatitis 
(NASH). The extent of neutrophil involvement in chronic fibrotic conditions such as 
cirrhosis is yet to be fully elucidated. Neutrophil recruitment with acute injury such as 
CCl4 toxin is triggered by the release of mediators from injured hepatocytes as well as 
Kupffer macrophage cell produced chemokines. These factors direct the neutrophils to 
the site of injury along a gradient enabling a rapid response in acute models/diseases 
(Moles et al., 2014).    
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N-formyl peptides are potent chemoattractant dictating the migration of immune cells 
towards sites of injury, damage and infection. NFPs and bacterial formyl-peptides elicit 
similar effects in neutrophils. Endogenous mechanisms play an inherent part in wound-
healing and fibrosis development (Ariel and Timor, 2013). Typically with neutrophils 
and macrophages this occurs along a gradient which cells follow. The role of 
neutrophils in the development of liver fibrosis or lack thereof is further supported by 
Saito et al. (2002) where they reported that depletion of PMNs demonstrated no effect 
on hepatic fibrogenesis in a bile duct ligation (BDL) cholestatic liver disease model. 
This model has different pathogenesis to the toxin-mediated models with ligation of the 
biliary structures leading to ductular inflammation, proliferation of bile ducts and 
development of portal fibrosis. Due to the high amount of infiltration in the BDL model 
of neutrophils to fibrotic areas and the fact that treatment with anti-neutrophil antiserum 
did not ECM deposition significantly, further cements the theory that neutrophils have 
little regulatory effect on liver fibrosis regardless of the model’s pathogenesis. The 
recent research of neutrophils in the liver with regards to acute injury, wound-healing, 
fibrosis development and hepatocellular carcinoma (HCC) highlights that neutrophils 
have a variety of pleiotropic functions depending on disease-specific mechanisms or 
‘redundancies’ in the case of liver fibrosis. If more time had been available another liver 
fibrosis model would have been utilised to confirm that FPR1+ve neutrophils do not 
have a major role.   
 
7.1.3 DAMPs in the liver 
7.1.3.1 FPR2, a better therapeutic target? 
Ablation of FPR1 and FPR2 expression in mice elicited downstream effects on the 
liver’s response to LPS, a bacterial membrane component. Without FPR1/2 the 
immune response is dysregulated leading uncontrolled inflammation and unchecked 
damage as indicated by serum transaminase levels, AST and ALT (Giebeler et al., 
2014). Key studies include: a murine model of hepatic (liver) necrosis induced by a 
targeted thermal injury. This model highlighted the importance of FPR1-mediated 
neutrophil accumulation at lesions (McDonald et al., 2010). With injury to the liver 
neutrophils are critical to the damage response. This clearly evident in my own project 
with neutrophil infiltration of the liver upon acute injury with carbon tetrachloride. The 
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controversy with liver fibrosis is whether neutrophils are key players in its development 
or redundant as recent studies suggest.  
Looking another member of the formyl-peptide receptor family, FPR2/FPRL1 appears 
to have a myriad of different roles in disease probably due to its large repertoire of 
ligands often with differing downstream signalling effects. Indeed the ALX/FPR2 has 
emerged recently as a potential therapeutic target in the treatment of chronic 
inflammation in COPD (Bozinovski et al., 2013). Opportunistic and persistent microbial 
insults provide a source of Serum Amyloid A (SAA) which induces downstream pro-
inflammatory effects. Interestingly, endogenous molecules and metabolites such as 
LXA4 have the opposite effect triggering pro-resolution events. FPR2 knockout mice 
were protected from OVA/alum-induced allergy model in lung with a reduced 
inflammatory response. This asthma in vivo model demonstrated a reduced CD11c+ 
dendritic cell infiltration in airways and lymphatic system along with lower levels of IL-
13, IL-4 and IL-5 Type II cytokines and allergy-mediator IgE (Chen et al 2010). The 
importance of FPR2 in airway inflammation was furthered by wild type BAL eliciting 
agonistic behaviour on bronchial embryonic epithelial cells. FPR2 is again associated 
with inflammation in the neurological setting with contributions to Alzheimer’s disease 
(AD) and other neurodegenerative disorders proven. Agonistic activity by Aβ42 plaque 
units, the causative agent behind the progressive neuronal loss, implicates FPR1 and 
FPR2 (Yazawa et al., 2001). One thing to consider in the FPR1 knockout mice is what 
is the deletion and loss of functionality doing to the activity of FPR2 in the different 
models of fibrosis. Are there compensatory mechanisms at play here that would 
perhaps explain why no effect is seen in the CCl4 and UUO models or is this purely 
due to the microenvironment/model-specific caveats?  
 
As for other immune cells heavily implicated in liver fibrosis, Kupffer macrophages, 
FPR1 appeared to have no effect on infiltration into CCl4-chronically injured livers. 
These resident liver macrophages act as TGFβ1 cytokine reservoirs thus are 
responsible for stellate cell activation and from human and mouse in vivo equivalents 
of liver fibrosis are key effectors of fibrogenesis (Kolios et al., 2006). Previously, data 
from the bleomycin-mediated pulmonary fibrosis model suggested a TGFβ1-
independent mechanism which may be consistent in the liver microenvironment. Since 
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a similar level of CD68 positive cells is observed in WT and KO injured livers there 
should be no change in TGFβ1 level between genotype. Hepatic Kupffer macrophages 
are also implicated in resolution of fibrosis as well as being a driving force behind 
fibrogenesis and stellate cell activation. Studies have shown that Kupffer cells have an 
indirect effect on re-balancing the ECM matrix equilibrium through neutrophil infiltration 
(Harty et al., 2008). Reparation of BDL-induced damage by biliary decompression of 
obstructed bile ducts is an ideal liver repair model. –evaluation of FPR1 deletion in 
this acute mechanical injury model would have been optimal.  
 
7.1.4 Renal fibrosis and FPR1 
To expand the work already completed with the UUO model in terms of histology and 
immunohistochemistry more aspects of this intriguing model should be considered 
before writing off the role of FPR in renal fibrosis. Gene expression levels of different 
renal injury and healing markers would be vital in fully determining the effect of FPR 
deletion in this novel microenvironment. One such specific biomarker is Kidney Injury 
Molecule-1 (KIM-1) a proximal tubular damage biomarker. This type 1 TM protein is 
well characterised in chronic kidney disease (human and in vivo) with defined 
diagnostic tests for urinary and serum outputs. Recent papers have highlighted this 
biomarker in the wider context of wound-healing rather than just an injury marker of 
proximal tubular epithelial cells (PTECs). Its expression on tubules and interstitial 
areas is an interesting avenue to consider due to the lack of knowledge in non-acute 
renal injury models such as the UUO model (Lim et al., 2013). Han et al.(2002) also 
highlight the importance of KIM-1 in proximal tubule injury processes and acute tubular 
necrosis (ATN) patients.  
Different endpoints are easily utilised in the UUO model to represent the infiltration and 
renal fibrotic phases. Tubular damage was assessed in a MMP-12 -/- based model 
with KIM-1 by Abraham et al. (2012). The ability to assess injury at a molecular level 
will strengthen histological scoring of the PAS-stained tissue sections which 
determines the extent of tubular dilatation and interstitial expansion, two key measures 
of the progressive injury in this renal setting. The UUO model involves a different type 
of injury compared to bleomycin acute model and CCl4-chronic model. Ischaemia-
reperfusion (I/R) injury models of kidney chronic disease may be more suitable for 
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investigation of formyl peptide receptor in this setting. One of the features of this model 
in the kidney and other organs is major leukocyte migration (Gavins, 2010). 
 
7.1.5 Induction of FPR expression  
A common theme determined in cells cultured in vitro, whether they be immune or non-
phagocyte, is that FPR expression is ‘primed’ or up-regulated by inflammatory stimulus 
lipopolysaccharide (LPS) treatment. This suggests a co-ordination of signalling 
pathways such a TLR2/4 which LPS binds. LPS significantly heightens expression of 
FPR in macrophages, neutrophils and fibroblasts which would theoretically increase 
FMLF activity in those cells due to increased ligand-receptor interaction. Synergy of 
LPS and FMLF functionality in cultured has been shown to demonstrate coordinated 
cytokine inflammatory responses (Chen et al., 2009). In non-sterile microenvironments 
in the body endogenous N-formylated peptides are released from necrotic/dead cells 
which in conjunction with underlying conditions such as opportunistic infections 
(bacterial/viral) exacerbate inflammation and potentially the subsequent wound-
healing response. Contrary to this coordinated affair, earlier research by Vulcano et al. 
(1998) elucidated a tolerising effect of FMLF pre-treatment on human neutrophil 
resulting in a dampened pro-inflammatory TNFα response. It is worth considering that 
different ligands interacting with the different FPRs have a plethora of effects and co-
ordination with a myriad of signalling pathways including CXCR2, uPA and EGFR. 
FPR2 does not bind high affinity ligands such as FMLF but a more promiscuous role 
in the body not restricted to inflammation and immune cell migration.  
TLR4 has reportedly very low expression in human fibroblasts unlike mouse 
equivalents hence responsiveness may be affected between species. 
 
7.2 Future work 
7.2.1 FMLF activity 
Due to the effect determined in the lungs of bleomycin-injured mice depleted of FPR1 
expression further work is required to elucidate the mechanism behind N-formyl 
peptide involvement in pulmonary fibrosis. A key experiment that would have added to 
existing data regarding the acute injury model would be to ascertain if formyl peptides 
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are located in diseased human lung of IPF patients. Although no antibodies are 
commercially available, some immunoglobulins have been generated that select for N-
formyl peptides. Antibody FTD6G5 and other selective N-formyl peptide antibodies 
may indeed be further developed for therapeutic interventions for use in a myriad of 
different diseases (Tanaka et al., 2007). Another potential strategy for detection of 
these peptides in diseased lung whether from injured mice or chronic human cases 
could be the utilisation of mass spectroscopy. Breitung et al. (2008) describe a method 
for generating labelled N-formylated peptide: N-formyl-Met-Leu-Phe-OH (1) in a mild 
synthetic manner consisting of solid phase amino acid polymerisation, N-formylation 
and purification via high-performance liquid chromatography (HPLC). For validation of 
the produced peptide f-MLF-OH was radiolabelled and analysed for its mass spectrum 
yielded a value of 460.3. The detection of this labelled tri-amino acid chain via solid 
state NMR may indicate a novel method for determining formyl peptide release in the 
injured lung microenvironment (Breitung et al., 2008).  
 
In order to build upon the nature of formyl peptide involvement in lung fibrosis a 
mechanistic, more ligand-driven approach is required. The use of knockout mice with 
ablated FPR1 expression was a useful tool to investigate how ligation of this receptor 
affected fibrosis in the lung and other organs but the effect of formyl peptides to the 
pulmonary environment needs to be elucidated. Since a significant reduction in the 
bleomycin-injury model was determined via a drop in a variety of different fibrotic 
markers in knockout mice, the activation of this receptor by formyl peptides may 
potentially have an effect on the development of pulmonary fibrosis. One point to 
consider is on the main caveats of bleomycin’s pathogenesis: the dependence of the 
latter fibrosis stage on the acute inflammatory phase. This complicates any findings 
from the bleomycin model as it any protective effects in FPR1 null mice may be due to 
inflammation-dependent fibrosis. A key point worth investigating is whether FMLF 
administration before/after bleomycin-injury would augment the fibrosis development 
in the latter phase. The groups of such an experiment would be as follows: 1) WT - 
Bleomycin IT - Twice weekly saline IN; 2) WT - Bleomycin IT - Twice weekly FMLF IN; 
3) fpr-/- - Bleomycin IT - Twice weekly saline IN; 4) fpr-/- - Bleomycin IT - Twice weekly 
FMLF IN; 5) WT - Saline IT; 6)  fpr-/- - Saline IT with harvesting after 21 days. 
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Regardless, FMLF ligand downstream effects in the lung need to be addressed apart 
from the bleomycin model. As well allowing determination of high formyl peptide 
involvement in lung fibrosis this will enhance the data obtained by the preliminary 
investigation into the role of FPR+ve neutrophils in pulmonary fibrosis. If time and 
resource constraints had not been a problem dosing of wild type and knockout mice 
repeatedly with formyl peptide intranasally would have been undertaken. This would’ve 
answered the question of whether FMLF drives persistent neutrophil and other immune 
cell recruitment in the lung. The repeated dosing of the ligand is equivalent to 
successive damage to cells which has demonstrated to release endogenous sources 
of this DAMP.  As with other inflammatory events in the bleomycin model: cell 
infiltration and pro-inflammatory cytokine release the response would be more than 
likely reduced in fpr1-/- mice. Ideally this experiment will consist of 4 groups: 1- WT 
saline; 2- WT FMLF; 3- fpr-/- saline; 4- fpr-/- FMLF with saline as the control treatment 
for each genotype. The lung showed how fast it reacts to acute stimuli in the bleomycin 
model when mice were sacrificed a day after dosing, neutrophils are rapidly localised 
to sites of injury as indicated by increased NIMP counts. IHC of tissue harvested 24 
hours post-FMLF administration will enable measurement of neutrophil recruitment 
when the level of chemoattractant is artificially elevated. The expected outcome of this 
experiment will be vastly increased migration of neutrophils in lungs of FMLF-dosed 
mice in acute model. 
This approach is a tantalising route to assess the role of formyl peptide activity in the 
lung microenvironment but several things must be considered. FMLF treatments in vivo 
should be undertaken with the knowledge that FMLF has a transient stability in the 
mouse lung due to rapid metabolism. Potential adverse effects also present a problem 
as FMLF causes direct bronchoconstriction with high doses triggering pulmonary 
toxicity. Corteling et al. (2002) present a novel method of lung neutrophil activation in 
different strains of mice and hamsters but the practicalities of such the intranasal 
method are a major consideration. BAL differential cell counts for neutrophils, 
lymphocytes and eosinophils all showed significant increases in different strains of 
mice (BALB/c and C57BL/6) with inflammatory stimulus, lipopolysaccharide (LPS). Of 
particular note for the work undertaken previously in my project is that C57BL/6 mice 
display neutrophil infiltration with LPS and FMLF treatment. Essentially, a priming 
mechanism is in effect due to FMLF alone having no effect on neutrophilic response. 
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Myeloperoxidase (MPO) and elastase activity was drastically increased in dual-treated 
mice compared to that of vehicle and single-treatments also suggesting a priming 
mechanism based on co-ordination of different pathways. 
Reproducibility of the FMLF response coupled with the similar effects of LPS on 
neutrophils in the lung are key factors to take into account for this method. Utilisation 
of a high-grade purity source of FMLF with no LPS contamination would eliminate any 
doubt over responses elicited following treatment which is a concern due to reported 
synergy of the LPS-driven pathways and FMLF activity (Chen et al., 2009). In-house 
experiments conducted at MedImmune (Cambridge, UK) determined that combined 
treatments of LPS and FMLF triggered variable responses with little reproducibility. 
The activity of FMLF in the lung is a key area with many unknowns and due to 
optimisation issues in terms of its stability and adverse effects this may prove a difficult 
task to elucidate. Determining whether FMLF exacerbates lung injury is not a simple 
experiment due to the fact that FMLF causes direct bronchoconstriction. This may be 
related to its contractile effects on smooth muscle directly induced by FMLF-driven 
calcium ion influx (Arreto et al., 1993; Kawata et al., 2005). Airway smooth muscle 
studies in guinea pig T. coli tissue have demonstrated clear increases in insuflation 
pressure (cmH2O) which presents a problem for acute lung injury bleomycin mice 
models. A double insult with FMLF and bleomycin may be too severe for the animals 
for treatments to be performed. The bronchoconstriction function of the high affinity 
FPR ligand is not restricted to mice, hamsters or guinea pigs, preliminary investigations 
in non-asthmatic human patients indicated contraction of primary airway cells in vitro 
and a response to nebulised FMLF on airway function (Berend et al., 1987).  
 
As previously stated other models of inducing fibrosis and airway remodelling are 
required to determine if FPR ligation is playing a key role in this disease. One of many 
well-characterised in vivo methods is the chronic house-dust mite (HDM) model, a type 
II allergy-driven response. The inclusion of a FMLF ligands/saline regimen into the 
model will enable the role the ligand in airway remodelling to be elucidated. The groups 
for this experiment if performed in the future would be as follows: 1) WT - biweekly 
saline IN for 8 weeks; 2) WT - biweekly FMLF IN for 8 weeks; 3) fpr-/- - biweekly saline 
IN for 8 weeks; 4) fpr-/- - biweekly FMLF IN for 8 weeks. As with assessment of fibrosis 
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3 weeks post-bleomycin i.t. data from the 8 week endpoint would include 
hydroxyproline content, PSR and α-SMA IHC and ECM marker gene expression.  
 
7.2.2 Formyl-peptide levels in the lung 
The issue of assessing levels of formyl peptides in diseased tissue is a complicated 
one. In terms of human disease (Idiopathic pulmonary fibrosis) a potential method of 
assessing FP activity could be to digest explant tissue (probably via collagenase) to 
release peptides. The mixture would then be applied to human neutrophils (isolated 
from blood) for use in chemotaxis assay. Negative controls would consist of blank 
media and anti-FPR1 blocked neutrophils. The latter control is important as this will 
block any ligation of the high affinity receptor. This experiment plan is actually similar 
to a study conducted by Hauser et al. (2010) where mitochondrial-derived N-formyl 
peptides and DNA triggered rapid Ca2+ production, MAPK activation, IL-8 and MMP-9 
secretion in neutrophils. Such responses were blocked by antagonist action of CsH or 
anti-formyl peptide receptor-1. Another potential way of determining formyl peptide 
activity in diseased human/mouse tissue may to utilise the bronchoalveolar lavage 
(BAL) fluid. Application of the supernatant to human/mouse neutrophils in vitro could 
then be assessed for chemotactic effects, cytokine secretion and MAPK activation. 
From these tests the functionality of the BAL with regards to formyl peptide activity 
through ligation of FPR1/2 would be determined.  
Mass spectrometry of the BAL samples would be needed to confirm the presence of 
formyl peptides in the extracellular fluid, to be performed in a similar manner to Breitung 
et al. (2008). Mass spectrometry is an ideal method to the lack of available antibodies 
for formyl-peptides and the separation by mass (Daltons, Da) and electrical charge 
(MacGregor et al., 2008). Other studies have applied surface enhanced laser 
desorption ionisation time of flight (SELDI-TOF) mass spectrometry to BAL fluid for 
assessing cystic fibrosis biomarkers. An advantage of this protocol is the avoidance of 
biased protein identification by fingerprinting of trypsin digests as well as the low 
volumes required for analysis (MacGregor et al., 2008).  
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7.3 Conclusions 
This project has yielded interesting data regarding the role of the formyl-peptide 
receptor in the development of pulmonary fibrosis. The abundance of this 
chemoattractant receptor on neutrophils and to a lesser extent macrophages is 
perhaps highlighted in the animal models utilised to investigate its role in fibrosis in 
different organs. The pathogenesis of the fibrotic mechanism and the degree of 
neutrophil involvement varies between the lung, liver and kidney due to their specific 
microenvironments and cellular interactions. These observations may be purely 
bleomycin-model caveats but the aetiology of IPF is complicated which in turn could 
indicate a potential therapeutic target perhaps in the form of monoclonal antibody 
therapy. Immunofluorescent staining revealed expression of human FPR1 in CD45+ve 
neutrophils as well as in isolated vimentin positive fibroblasts. The same fluorescent 
antibody conjugate validated this localisation in cultured IPF fibroblasts indicated a 
possible role for FPR1 architecture. Bacterial and endogenous N-formylated peptides 
could in effect bind both immune cells and these FPR1+ve fibroblasts in the event of 
opportunistic infection, sepsis or trauma/tissue damage leading to release of cellular 
contents.  
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10 Appendix 
A (i) Gating strategy for FACs panel 1 for neutrophil activation markers: CD11b and 
CD66a following bleomycin injury. 
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A (ii) Gating strategy for FACs panel 2 for neutrophils (Ly6G) versus eosinophils 
(SigLecF) populations following bleomycin injury. 
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A (iii) Gating strategy for FACs panel 3 for lymphocytes: CD3+CD4+/CD8+, B220+ B-
cells and NK1.1 CD49b natural killer cells following bleomycin injury. 
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A (iv) Gating strategy for FACs panel 4 for macrophage phenotype following bleomycin 
injury. CCR7 (M1) and CD206 (M2) expression gated accordingly. 
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A (v) Gating strategy for FACs panel 5 for macrophage phenotype M1/M2 populations 
following bleomycin injury. iNOS (M1) and FIZZ-1 (M2) markers gated accordingly. 
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B (i) Immunohistochemistry relative photographs of bone marrow chimera lungs 
stained for PicroSiriusRed (PSR). Group 1 – WT-WT, Group 2 – WT-KO, Group 3 – 
KO-WT and Group 4 – KO-KO (Recipient-Donor bone marrow groups), x10 
magnification with scale bars representing 100µm. 
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B (ii) Immunohistochemistry relative photographs of bone marrow chimera lungs 
stained for α-SMA+ve myofibroblasts. Group 1 – WT-WT, Group 2 – WT-KO, Group 3 
– KO-WT and Group 4 – KO-KO (Recipient-Donor bone marrow groups), x10 
magnification with scale bars representing 100µm. 
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B (iii) Immunohistochemistry relative photographs of bone marrow chimera lungs 
stained for NIMP+ve neutrophils. Group 1 – WT-WT, Group 2 – WT-KO, Group 3 – 
KO-WT and Group 4 – KO-KO (Recipient-Donor bone marrow groups), x20 
magnification with scale bars representing 100µm. 
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B (iv) Immunohistochemistry relative photographs of bone marrow chimera lungs 
stained for CD68+ve macrophages. Group 1 – WT-WT, Group 2 – WT-KO, Group 3 – 
KO-WT and Group 4 – KO-KO (Recipient-Donor bone marrow groups), x20 
magnification with scale bars representing 100µm. 
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C (i) Relative photographs at x10 magnification of α-SMA levels in livers injured acutely 
with CCl4 / olive oil (vehicle), assayed at 24, 48 and 72 hours post-injury. Scale bars 
represent 100µm,  
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C (ii) Relative photographs at x20 magnification of NIMP+ve neutrophils in livers 
injured acutely with CCl4 / olive oil (vehicle), assayed at 24, 48 and 72 hours post-
injury. Scale bars represent 100µm,  
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C (iii) Relative photographs at x20magnification of CD68+ve macrophages in livers 
injured acutely with CCl4 / olive oil (vehicle), assayed at 24, 48 and 72 hours post-
injury. Scale bars represent 100µm, 
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C (iv) Relative photographs at x20magnification of CD3+ve lymphocytes in livers 
injured acutely with CCl4 / olive oil (vehicle), assayed at 24, 48 and 72 hours post-
injury. Scale bars represent 100µm,  
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C (iv) Relative photographs at x20 magnification of PCNA+ve proliferating hepatocytes 
in livers injured acutely with CCl4 / olive oil (vehicle), assayed at 24, 48 and 72 hours 
post-injury. Scale bars represent 100µm,  
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D (i) Relative photographs of negative no primary antibody controls for 
immunohistochemistry staining in mouse lung tissue for (A) alpha-smooth muscle actin 
(x10 magnification), (B) NIMP, (C) CD68 and (D) CD3 (x20 magnification). 
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D (ii) Relative photographs of negative  no primary antibody controls for 
immunohistochemistry staining in mouse liver tissue for (A) alpha-smooth muscle actin 
(x10 magnification), (B) NIMP, (C) CD68 and (D) CD3 and (E) PCNA (x20 
magnification). 
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D (iii) Relative photographs of negative no primary antibody controls for 
immunohistochemistry staining in mouse kidney tissue for (A) alpha-smooth muscle 
actin (x10 magnification), (B) NIMP, (C) CD68 and (D) CD3 (x20 magnification). 
 
